Document:

EX-10.13

 Exhibit 10.13 

LOAN AND SECURITY AGREEMENT 

THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this
“Agreement”) dated as of September 9, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314
(“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a
Lender and SQUARE 1 BANK, a North Carolina banking corporation with an office located at 406 Blackwell Street, Suite 240, Durham, NC 27701 (“Bank” or “Square 1”) (each a “Lender” and collectively,
the “Lenders”), and VISTERRA, Inc., a Delaware corporation with offices located at One Kendall Square, Suite B3301, Cambridge, MA 02139 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower
and Borrower shall repay the Lenders. The parties agree as follows: 
  

	1.	ACCOUNTING AND OTHER TERMS 

 1.1 Accounting terms not defined in this
Agreement shall be construed in accordance with GAAP. Calculations and determinations must be made in accordance with GAAP. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13. All other
terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein. All references to “Dollars” or “$” are United States Dollars,
unless otherwise noted. 
  

	2.	LOANS AND TERMS OF PAYMENT 

 2.1 Promise to Pay. Borrower hereby
unconditionally promises to pay each Lender, the outstanding principal amount of all Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this
Agreement. 
 2.2 Term Loans. 

(a) Availability. (i) Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make
term loans to Borrower on the Effective Date in an aggregate amount of Five Million Dollars ($5,000,000) according to each Lender’s Term A Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter
referred to singly as a “Term A Loan”, and collectively as the “Term A Loans”). After repayment, no Term A Loan may be re-borrowed. 

(ii) Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to
make term loans to Borrower in an aggregate amount up to Five Million Dollars ($5,000,000) according to each Lender’s Term B Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to
singly as a “Term B Loan”, and collectively as the “Term B Loans”; each Term A Loan or Term B Loan is hereinafter referred to singly as a “Term Loan” and the Term A Loans
and the Term B Loans are hereinafter referred to collectively as the “Term Loans”). After repayment, no Term B Loan may be re-borrowed. 

(b) Repayment. Borrower shall make monthly payments of interest only in arrears commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding
the Amortization Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments (which payments shall be of both principal and interest as set forth in
the amortization tables attached to the applicable Disbursement Letter), in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such
Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to thirty-six (36) months. All unpaid principal and accrued and unpaid interest with respect to
each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d). 

 (c) Mandatory Prepayments. If the Term Loans are accelerated following the occurrence of
an Event of Default, Borrower shall immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Loans plus accrued and unpaid
interest thereon through the prepayment date, (ii) the Final Payment, (iii) the Prepayment Fee, plus (iv) all other Obligations that are due and payable, including Lenders’ Expenses and interest at the Default Rate with respect
to any past due amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall pay to
Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the Final Payment in respect of the Term Loan(s). 

(d) Permitted Prepayment of Term Loans. Borrower shall have the option to prepay all, but not less than all, of the Term Loans advanced
by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, and (ii) pays to the Lenders on the date
of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date,
(B) the Final Payment, (C) the Prepayment Fee, plus (D) all other Obligations that are due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. 

2.3 Payment of Interest on the Credit Extensions. 

(a) Interest Rate. Subject to Section 2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a
fixed per annum rate (which rate shall be fixed for the duration of the applicable Term Loan) equal to the Basic Rate, determined by Collateral Agent on the Funding Date of the applicable Term Loan, which interest shall be payable monthly in arrears
in accordance with Sections 2.2(b) and 2.3(e). Interest shall accrue on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the principal amount outstanding under such Term Loan through and
including the day on which such Term Loan is paid in full. 
 (b) Default Rate. Immediately upon the occurrence and during the
continuance of an Event of Default, Obligations shall accrue interest at a fixed per annum rate equal to the rate that is otherwise applicable thereto plus five percentage points (5.00%) (the “Default Rate”). Payment or
acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of
Collateral Agent. 
 (c) 360-Day Year. Interest shall be computed on the basis of a three
hundred sixty (360) day year consisting of twelve (12) months of thirty (30) days. 
 (d) Debit of Accounts.
Collateral Agent and each Lender may debit (or ACH) any deposit accounts, maintained by Borrower or any of its Subsidiaries, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrower owes the Lenders
under the Loan Documents when due. Any such debits (or ACH activity) shall not constitute a set-off. Without limiting the foregoing, Collateral Agent and each Lender shall use commercially reasonable efforts
to promptly notify Borrower for the reasons of debiting of any amounts (other than principal and interest payments) debited from Borrower’s deposit accounts in respect of this Agreement after such debit has been made; provided, however, failure
to provide such notice shall not be considered a breach of any provision hereof by Collateral Agent or any Lender. 
 (e) Payments.
Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective Lender to which such payments are owed, at such Lender’s office in immediately available funds on the date
specified herein. Unless otherwise provided, interest is payable monthly in arrears on the Payment Date of each month. Payments of principal and/or interest received after 2:00 p.m. Eastern time are considered received at the opening of business on
the next Business Day. When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower
hereunder or under any other Loan Document, including payments of principal and interest, and all fees, expenses, indemnities and 

  
 2 

 
reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds. 

2.4 Secured Promissory Notes. The Term Loans shall be evidenced by a Secured Promissory Note or Notes in the form attached as
Exhibit D hereto (each a “Secured Promissory Note”), and shall be repayable as set forth in this Agreement. Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding Date of any
Term Loan or at the time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may
be) the receipt of such payment. The outstanding amount of each Term Loan set forth on such Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure
to record, or any error in so recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document to make
payments of principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note (and including customary lost note
indemnification provisions that are reasonably acceptable to such Lender), Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor. 

2.5 Fees. Borrower shall pay to Collateral Agent: 

(a) Facility Fee. A fully earned, non-refundable facility fee of Fifty Thousand Dollars
($50,000) to be shared between the Lenders pursuant to their respective Commitment Percentages, which has already been paid by Borrower; 

(b) Final Payment. The Final Payment, when due hereunder, to be paid to Oxford; 

(c) Prepayment Fee. The Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro
Rata Shares; and 
 (d) Lenders’ Expenses. All Lenders’ Expenses (including reasonable attorneys’ fees and expenses
for documentation and negotiation of this Agreement) incurred through and after the Effective Date, when due. 
 2.6 Withholding.
Payments received by the Lenders from Borrower hereunder will be made free and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by
any governmental authority (including any interest, additions to tax or penalties applicable thereto). Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement requires Borrower to make
any withholding or deduction from any such payment or other sum payable hereunder to the Lenders, Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable hereunder will be increased to
the extent necessary to ensure that, after the making of such required withholding or deduction, each Lender receives a net sum equal to the sum which it would have received had no withholding or deduction been required and Borrower shall pay the
full amount withheld or deducted to the relevant Governmental Authority; provided, that a Lender that shall have become a Lender pursuant to a Lender Transfer shall be entitled to receive only such additional amounts as such Lender’s assignor
would have been entitled to receive pursuant to this Section 2.6. Borrower will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower has made such withholding payment; provided, however,
that Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower. The
agreements and obligations of Borrower contained in this Section 2.6 shall survive the termination of this Agreement. 
  

	3.	CONDITIONS OF LOANS 

 3.1 Conditions Precedent to Initial Credit Extension.
Each Lender’s obligation to make a Term A Loan is subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have 

  
 3 

 
received, in form and substance satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem
necessary or appropriate, including, without limitation: 
 (a) original Loan Documents, each duly executed by Borrower; 

(b) duly executed original Control Agreements with respect to any Collateral Accounts maintained by Borrower; 

(c) duly executed original Secured Promissory Notes in favor of each Lender according to its Term A Loan Commitment Percentage; 

(d) the Operating Documents and good standing certificates of Borrower certified by the Secretary of State (or equivalent agency) of
Borrower’s jurisdiction of organization or formation and each jurisdiction in which Borrower is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date; 

(e) a completed Perfection Certificate for Borrower; 

(f) the Annual Projections, for the current calendar year; 

(g) duly executed original officer’s certificate for Borrower, in a form acceptable to Collateral Agent and the Lenders; 

(h) certified copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, as
Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial
Credit Extension, will be terminated or released; 
 (i) a landlord’s consent executed in favor of Collateral Agent in respect of all
of Borrower’s leased locations; 
 (j) a bailee waiver executed in favor of Collateral Agent in respect of each third party bailee
where Borrower or any Subsidiary maintains Collateral having a book value in excess of Two Hundred Fifty Thousand Dollars ($250,000.00); 

(k) the financial statements referenced in Section 6.2(a)(i) for the month ending July 31, 2014; 

(l) a duly executed legal opinion of counsel to Borrower dated as of the Effective Date; 

(m) evidence satisfactory to Collateral Agent and the Lenders that the insurance policies required by Section 6.5 hereof are in full
force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent, for the ratable benefit of the Lenders; 

(n) a copy of any applicable Registration Rights Agreement or Investors’ Rights Agreement and any amendments thereto; 

(o) a payoff letter from Lighthouse Capital Partners in respect of the Existing Indebtedness that shall evidence Lighthouse Capital
Partners’ agreement that (i) the Liens securing the Existing Indebtedness will be terminated and (ii) the documents and/or filings evidencing the perfection of such Liens, including without limitation any financing statements and/or
control agreements, have or will, concurrently with the initial Credit Extension, be terminated; and 
 (p) payment of the fees and
Lenders’ Expenses then due as specified in Section 2.5 hereof. 

  
 4 

 3.2 Conditions Precedent to all Credit Extensions. The obligation of each Lender to make
each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent: 
 (a) receipt by
(i) the Lenders of an executed Disbursement Letter in the form of Exhibit B-1 attached hereto; and (ii) Square 1 of an executed Loan Payment/Advance Request Form in the form of Exhibit B-2 attached hereto; 
 (b) the representations and warranties in Section 5 hereof
shall be true, accurate and complete in all material respects on the date of the Disbursement Letter (and the Loan Payment/Advance Request Form) and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier
shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be
true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit Extension. Each Credit Extension is Borrower’s representation and warranty on that
date that the representations and warranties in Section 5 hereof are true, accurate and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that
already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such
date; 
 (c) in such Lender’s good faith discretion, there has not been any Material Adverse Change; 

(d) to the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes in substantially the forms of Exhibits
D and Warrants substantially in the form of the Warrants delivered on the Effective Date, in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension made by such Lender after the Effective Date; and 

(e) payment of the fees and Lenders’ Expenses then due as specified in Section 2.5 hereof. 

3.3 Covenant to Deliver. Borrower agrees to deliver to Collateral Agent and the Lenders each item required to be delivered to
Collateral Agent under this Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that a Credit Extension made prior to the receipt by Collateral Agent or any Lender of any such item shall not constitute a waiver by
Collateral Agent or any Lender of Borrower’s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in each Lender’s sole discretion. 

3.4 Procedures for Borrowing. Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set
forth in this Agreement, to obtain a Term Loan (other than Term A Loan on the Effective Date), Borrower shall notify the Lenders (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 noon Eastern time three
(3) Business Days prior to the date the Term Loan is to be made. Together with any such electronic, facsimile or telephonic notification, Borrower shall deliver to the Lenders by electronic mail or facsimile a completed Disbursement Letter (and
the Loan Payment/Advance Request Form, with respect to Square 1) executed by a Responsible Officer or his or her designee. The Lenders may rely on any telephone notice given by a person whom a Lender reasonably believes is a Responsible Officer or
designee. On the Funding Date, each Lender shall credit and/or transfer (as applicable) to the Designated Deposit Account, an amount equal to its Term Loan Commitment. 
  

	4.	CREATION OF SECURITY INTEREST 

 4.1 Grant of Security Interest. Borrower
hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the
Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times
continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement  

  
 5 

 
to have priority to Collateral Agent’s Lien. If Borrower shall acquire a commercial tort claim (as defined in the Code), Borrower shall promptly notify Collateral Agent in a writing signed
by Borrower, as the case may be, of the general details thereof (and further details as may be required by Collateral Agent) and grant to Collateral Agent, for the ratable benefit of the Lenders, in such writing a security interest therein and in
the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral Agent. 

If this Agreement is terminated, Collateral Agent’s Lien in the Collateral shall continue until the Obligations (other than inchoate
indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders’ obligation to make Credit Extensions has terminated, Collateral
Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower. 

4.2 Authorization to File Financing Statements. Borrower hereby authorizes Collateral Agent to file financing statements or take any
other action required to perfect Collateral Agent’s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s interest or rights under the Loan Documents,
including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code. 

 

	5.	REPRESENTATIONS AND WARRANTIES 

 Borrower represents and warrants to Collateral
Agent and the Lenders as follows: 
 5.1 Due Organization, Authorization: Power and Authority. Borrower and each of its Subsidiaries
is duly existing and in good standing as a Registered Organization or equivalents in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed to do business and is in good standing in any
jurisdiction in which the conduct of its businesses or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change. In connection with this Agreement,
Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate signed by an officer of Borrower or such Subsidiary (each a “Perfection Certificate” and collectively, the
“Perfection Certificates”). Borrower represents and warrants that (a) Borrower and each of its Subsidiaries’ exact legal name is that which is indicated on its respective Perfection Certificate and on the signature page of
each Loan Document to which it is a party; (b) Borrower and each of its Subsidiaries is an organization of the type and is organized in the jurisdiction set forth on its respective Perfection Certificate; (c) each Perfection Certificate
accurately sets forth each of Borrower’s and its Subsidiaries’ organizational identification number or accurately states that Borrower or such Subsidiary has none; (d) each Perfection Certificate accurately sets forth Borrower’s
and each of its Subsidiaries’ place of business, or, if more than one, its chief executive office as well as Borrower’s and each of its Subsidiaries’ mailing address (if different than its chief executive office); (e) except as
disclosed in the Perfection Certificate, Borrower and each of its Subsidiaries (and each of its respective predecessors) have not, in the past five (5) years, changed its jurisdiction of organization, organizational structure or type, or any
organizational number assigned by its jurisdiction; and (f) all other information set forth on the Perfection Certificates pertaining to Borrower and each of its Subsidiaries is accurate and complete (it being understood and agreed that
Borrower and each of its Subsidiaries may from time to time update certain information in the Perfection Certificates (including the information set forth in clause (d) above) after the Effective Date to the extent permitted by one or more
specific provisions in this Agreement which updates may be provided by Borrower to Collateral Agent contemporaneously with the delivery of the Compliance Certificate delivered by Borrower pursuant to Section 6.2(b) relating to the last month of
each fiscal quarter of Borrower in which such change(s) occurs; the Lenders acknowledge that until the Perfection Certificates are so updated (and provided the Perfection Certificates are so updated as required pursuant to this clause) the
Perfection Certificates shall not be deemed inaccurate or incomplete); such updated Perfection Certificates subject to the review and approval of Collateral Agent in all cases. If Borrower or any of its Subsidiaries is not now a Registered
Organization but later becomes one, Borrower shall notify Collateral Agent of such occurrence and provide Collateral Agent with such Person’s organizational identification number within five (5) Business Days of receiving such
organizational identification number. 

  
 6 

 The execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan
Documents to which it is a party have been duly authorized, and do not (i) conflict with any of Borrower’s or such Subsidiaries’ organizational documents, including its respective Operating Documents, (ii) contravene, conflict
with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority
by which Borrower or such Subsidiary, or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such
Governmental Approvals which have already been obtained and are in full force and effect or are being obtained pursuant to Section 6.1(b)), or (v) constitute an event of default under any material agreement by which Borrower or any of such
Subsidiaries, or their respective properties, is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be
expected to have a Material Adverse Change. 
 5.2 Collateral. 

(a) Borrower and each its Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which it
purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and neither Borrower nor any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment
accounts other than the Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral Agent in connection herewith with respect of which Borrower or such Subsidiary has given
Collateral Agent notice and taken such actions as are necessary to give Collateral Agent a perfected security interest therein (to the extent required pursuant to Section 6.6 hereof). The Accounts are bona fide, existing obligations of the
Account Debtors. 
 (b) On the Effective Date, and except as disclosed on the Perfection Certificate (i) the Collateral is not in the
possession of any third party bailee (such as a warehouse), and (ii) no such third party bailee possesses components of the Collateral in excess of Two Hundred Fifty Thousand Dollars ($250,000.00). None of the components of the Collateral shall
be maintained at locations other than as disclosed in the Perfection Certificates on the Effective Date or as permitted pursuant to Section 6.11. 

(c) All Inventory is in all material respects of good and marketable quality, free from material defects. 

(d) Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of
all Liens other than Permitted Liens. Except as noted on the Perfection Certificate, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement (other than open source,
over-the-counter software, prepackaged software and other software that is commercially available to the public) with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts Borrower or its
Subsidiaries from granting a security interest in Borrower’s or such Subsidiaries’ interest in such material license or material agreement or any other property, or (ii) for which a default under or termination of could interfere with
Collateral Agent’s or any Lender’s right to sell any Collateral. 
 5.3 Litigation. Except as disclosed (i) on the
Perfection Certificates, or (ii) in accordance with Section 6.9 hereof, there are no actions, suits, investigations, or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or
any of its Subsidiaries involving more than Two Hundred Fifty Thousand Dollars ($250,000.00). 
 5.4 No Material Deterioration in
Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent fairly present, in conformity with GAAP, in all material respects the consolidated financial
condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries (except (i) financial statements provided for periods prior to 2015 are not prepared in conformity with GAAP, and
(ii) unaudited financial statements for periods from and after 2015 will not contain GAAP footnotes and will be subject to year-end adjustments; however such financial statements do fairly and accurately state all information regarding cash in
accordance with GAAP). There  

  
 7 

 
has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender.

 5.5 Solvency. Borrower and each of its Subsidiaries is Solvent. 

5.6 Regulatory Compliance. Neither Borrower nor any of its Subsidiaries is an “investment company” or a company
“controlled” by an “investment company” under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under
Regulations X, T and U of the Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a “holding
company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company” as each term is defined and used in the Public Utility Holding Company Act of 2005. Neither Borrower nor
any of its Subsidiaries has violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change. Neither Borrower’s nor any of its Subsidiaries’ properties or assets has been used
by Borrower or such Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower and each of
its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently
conducted. 
 None of Borrower, any of its Subsidiaries, or any of Borrower’s or its Subsidiaries’ Affiliates or any of
their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or
conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a
Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement,
(x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or
interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law. 

5.7 Investments. Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership interests or other equity securities
except for Permitted Investments. 
 5.8 Tax Returns and Payments; Pension Contributions. Borrower and each of its
Subsidiaries has timely filed all required tax returns and reports, and Borrower and each of its Subsidiaries, has timely paid all foreign and federal taxes, assessments, deposits and contributions (and all material state and local taxes,
assessments, deposits and contributions owed by Borrower and such Subsidiaries, in all jurisdictions in which Borrower or any such Subsidiary is subject to taxes i.e. all state and local taxes, assessments, deposits and contributions in an aggregate
amount of $50,000 or more for Borrower and all Subsidiaries together), unless such taxes are being contested in accordance with the following sentence. Borrower and each of its Subsidiaries, may defer payment of any contested taxes, provided that
Borrower or such Subsidiary, (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted, (b) notifies Collateral Agent in writing of the commencement of, and any
material development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the Governmental Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a
“Permitted Lien.” Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower’s or such Subsidiaries’, prior tax years which could result in material additional taxes
becoming due and payable by Borrower or its Subsidiaries. Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither
Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan, in each case, which could
reasonably be expected to result in any material liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority. 

5.9 Intentionally Omitted 

  
 8 

 5.10 Full Disclosure. No written representation, warranty or other statement of Borrower
or any of its Subsidiaries in any certificate or written statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written
statements given to Collateral Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized
that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the
projected or forecasted results).  
 5.11 Definition of “Knowledge.” For purposes of the Loan Documents,
whenever a representation or warranty is made to Borrower’s knowledge or awareness, to the “best of” Borrower’s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable
investigation, of the Responsible Officers. 
  

	6.	AFFIRMATIVE COVENANTS 

 Borrower shall, and shall cause each of its Subsidiaries
to, do all of the following: 
 6.1 Government Compliance. 

(a) Maintain its and all its Subsidiaries’ legal existence and good standing in their respective jurisdictions of organization and
maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change. Comply with all laws, ordinances and regulations to which Borrower or any of its Subsidiaries is subject,
the noncompliance with which could reasonably be expected to have a Material Adverse Change. 
 (b) Obtain and keep in full force and
effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for
the ratable benefit of the Lenders, in all of the Collateral. Borrower shall promptly provide notice to Collateral Agent of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries and if requested by Collateral Agent,
also provide copies of such Governmental Approvals. 
 6.2 Financial Statements, Reports, Certificates. 

(a) Deliver to each Lender: 

(i) as soon as available, but no later than thirty (30) days after the last day of each month, a company prepared consolidated and
consolidating balance sheet, income statement and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries for such month certified by a Responsible Officer as fairly presenting in all material respects the financial
condition, results of operations, shareholders’ equity and cash flows of the Borrower and its Subsidiaries in accordance with GAAP (except (i) that financial statements provided for periods prior to 2015 are not prepared in conformity with
GAAP, and (ii) unaudited financial statements for periods from and after 2015 will not contain GAAP footnotes and will be subject to year-end adjustments; however such financial statements do fairly and accurately state all information
regarding cash in accordance with GAAP), and in a form reasonably acceptable to Collateral Agent and each Lender; 
 (ii) as soon as
available, but no later than one hundred eighty (180) days after the last day of Borrower’s fiscal year or within five (5) days of filing with the SEC, audited consolidated financial statements prepared under GAAP, consistently
applied, together with an unqualified opinion on the financial statements from an independent certified public accounting firm reasonably acceptable to Collateral Agent and each Lender in its reasonable discretion; provided, however, that
notwithstanding the foregoing, audited consolidated financial statements for Borrower’s fiscal year ended December 31, 2013 may be delivered by, but no later than, March 31, 2015; 

  
 9 

 (iii) within seven (7) days after approval thereof by Borrower’s Board of Directors,
but no later than sixty (60) days after the last day of each of Borrower’s fiscal years, Borrower’s annual financial projections for the entire current fiscal year as approved by Borrower’s Board of Directors, which such
annual financial projections shall be set forth in a quarterly format (such annual financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the “Annual Projections”; provided that,
any revisions of the Annual Projections approved by Borrower’s Board of Directors shall be delivered to Collateral Agent and the Lenders no later than seven (7) days after such approval); 

(iv) within five (5) days of delivery, copies of all statements, reports and notices made available generally to Borrower’s
security holders or holders of Subordinated Debt; 
 (v) in the event that Borrower becomes subject to the reporting requirements under the
Securities Exchange Act of 1934, as amended, within five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed
with the Securities and Exchange Commission, 
 (vi) prompt notice (i) of any amendments of the Operating Documents of Borrower or any
of its Subsidiaries and (ii) any material amendments or other material changes to the capitalization table of Borrower or any of its Subsidiaries, together with any copies reflecting such amendments or changes with respect thereto; 

(vii) prompt notice of any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;

 (viii) written notice to Collateral Agent and each Lender within ten (10) Business Days of Borrower or any of its Subsidiaries
entering into or becoming bound by any material license or material agreement with respect to which Borrower or any Subsidiary is the licensee of Intellectual Property (other than open source, over-the-counter software, prepackaged software and
other software that is commercially available to the public); 
 (ix) as soon as available, but no later than thirty (30) days after
the last day of each month, copies of the month-end account statements for each Collateral Account maintained by Borrower or its Subsidiaries, which statements may be provided to Collateral Agent and each
Lender by Borrower or directly from the applicable institution(s); and 
 (x) other information as reasonably requested by Collateral Agent
or any Lender. 
 Notwithstanding the foregoing, documents required to be delivered pursuant to the terms hereof (to the extent any such documents are
included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower’s
website on the internet at Borrower’s website address. 
 (b) Concurrently with the delivery of the financial statements specified in
Section 6.2(a)(i) above but no later than thirty (30) days after the last day of each month, deliver to each Lender, a duly completed Compliance Certificate signed by a Responsible Officer, and, upon request of any Lender, aged
listings by invoice date of accounts receivable and accounts payable. 
 (c) Keep proper books of record and account in accordance with GAAP
in all material respects (except books of record and account for periods prior to 2015 may not be prepared in conformity with GAAP in all respects; however such records and accounts will fairly and accurately state all information regarding cash in
accordance with GAAP), in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities. Borrower shall, and shall cause each of its Subsidiaries to, allow Collateral Agent or any
Lender, at the sole cost of Borrower, during regular business hours upon reasonable prior notice (provided that no notice shall be required when an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to
examine and make abstracts or copies from any of its books and records, and to 

  
 10 

 
conduct a collateral audit and analysis of its operations and the Collateral. Such audits shall be conducted no more often than once every year unless (and more frequently if) an Event of Default
has occurred and is continuing. 
 6.3 Inventory; Returns. Keep all Inventory in good and marketable condition, free from material
defects. Returns and allowances between Borrower, or any of its Subsidiaries, and their respective Account Debtors shall follow Borrower’s, or such Subsidiary’s, customary practices as they exist at the Effective Date. Borrower must
promptly notify Collateral Agent and the Lenders of all returns, recoveries, written disputes and written claims with respect to Borrower’s Inventory that involve more than Two Hundred Fifty Thousand Dollars ($250,000.00) individually or in the
aggregate in any calendar year. 
 6.4 Taxes; Pensions. Timely file and require each of its Subsidiaries to timely file, all
required tax returns and reports and timely pay, and require each of its Subsidiaries to timely file, all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower or its Subsidiaries, except for deferred
payment of any taxes contested pursuant to the terms of Section 5.8 hereof, and shall deliver to Lenders, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all material liabilities under any
present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans. 
 6.5 Insurance.
Keep Borrower’s and its Subsidiaries’ business and the Collateral insured for risks and in amounts standard for companies in Borrower’s and its Subsidiaries’ industry and location and as Collateral Agent may reasonably request.
Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent and Lenders. All property policies shall have a lender’s loss payable endorsement showing Collateral Agent as lender loss
payee and waive subrogation against Collateral Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent, as additional insured. The Collateral Agent shall be named as lender loss payee and/or additional insured
with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the
Collateral Agent, that it will give the Collateral Agent thirty (30) days prior written notice before any such policy or policies shall be canceled (it being understood and agreed that Borrower shall provide Collateral Agent thirty
(30) days prior written notice before any such policy or policies are materially altered). At Collateral Agent’s request, Borrower shall deliver certified copies of policies and evidence of all premium payments. Proceeds payable under any
property policy shall, at Collateral Agent’s option, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and
is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to Two Hundred Fifty Thousand Dollars ($250,000.00) with respect to any loss, but not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00), in the
aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal, like or greater value as the
replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds
payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations. If Borrower or any of its Subsidiaries fails to obtain insurance as
required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent and/or any Lender may make, at Borrower’s expense, all or part of such payment or obtain such insurance
policies required in this Section 6.5, and take any action under the policies Collateral Agent or such Lender deems prudent. 

6.6 Operating Accounts. 

(a) Maintain all of Borrower’s and its Subsidiaries’ Collateral Accounts in accounts which are subject to a Control Agreement in
favor of Collateral Agent and if such accounts are in the U.S. or any other jurisdiction in which Bank or one of its Affiliates operates, maintain such accounts with the Bank or one of its Affiliates; provided, however, Borrower’s operating
account with Silicon Valley Bank must be closed within 45 days after the Effective Date and the evidence of its closure reasonably satisfactory to the Collateral Agent provided thereto (provided further that the only funds that Borrower may keep in
such operating account during such period would be such as would be necessary to meet Borrower’s payment obligations under checks already issued by Borrower and funds in excess of such aggregate amount must be transferred to one of
Borrower’s Collateral 

  
 11 

 
Accounts maintained with the Bank or one of its affiliates). The provisions of the previous sentence shall not apply to: (i) (A) an account of cash or cash equivalents maintained with
Silicon Valley Bank solely to secure the letter of credit issued by Silicon Valley Bank for the benefit of the Borrower’s landlord, provided, however the balance in such account shall not exceed $120,000 and to the extent it does, the excess
amount shall be swept to a Collateral Account which is subject to a Control Agreement in favor of Collateral Agent within two (2) Business Days, and provided further that such letter of credit shall be cancelled or terminated not later than the
first renewal date of such letter of credit occurring after the Effective Date or (B) after the closure of such account maintained with Silicon Valley Bank and the termination or cancellation of such letter of credit, an account of cash or cash
equivalents maintained with the Bank, solely to secure the letter of credit issued by Bank for the benefit of the Borrower’s landlord, provided, however the balance in such account shall not exceed $120,000 and to the extent it does, the excess
amount shall be swept to a Collateral Account which is subject to a Control Agreement in favor of Collateral Agent within two (2) Business Days, (each of the accounts referred to in this clause (i), a “LC Account”), and
(ii) (A) an account of cash or cash equivalents maintained with Silicon Valley Bank solely to secure credit cards issued by Silicon Valley Bank or its affiliates for a period of 90 days after the Effective Date, provided, however, the
balance in such account shall not exceed $10,000 (and to the extent it does, the excess amount shall be swept to a Collateral Account which is subject to a Control Agreement in favor of Collateral Agent within two (2) Business Days) or
(B) after the closure such account maintained with Silicon Valley Bank, an account of cash or cash equivalents maintained with the Bank solely to secure ancillary banking services provided by the Bank, provided, however, the balance in such
account shall not exceed $75,000 (and to the extent it does, the excess amount shall be swept to a Collateral Account which is subject to a Control Agreement in favor of Collateral Agent within two (2) Business Days) (each of the accounts
referred to in this clause (ii), an “Ancillary Services Account”). 
 (b) Borrower shall provide Collateral Agent five
(5) days’ prior written notice before Borrower or any of its Subsidiaries establishes any Collateral Account at or with any Person other than Bank or its Affiliates. In addition, for each Collateral Account that Borrower or any of its
Subsidiaries at any time maintains (except for any Excepted Account), Borrower or such Subsidiary shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control
Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral Agent’s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral Account, which
Control Agreement may not be terminated without prior written consent of Collateral Agent. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit
payments to or for the benefit of Borrower’s, or any of its Subsidiaries’, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificates. 

(c) Neither Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance
with Sections 6.6(a) and (b). 
 6.7 Protection of Intellectual Property Rights. Borrower and each of its Subsidiaries shall:
(a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to Borrower’s business; (b) promptly advise Collateral Agent in writing of material
infringement of which it is aware by a third party of its Intellectual Property; and (c) not allow any Intellectual Property material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Collateral
Agent’s prior written consent. 
 6.8 Litigation Cooperation. Commencing on the Effective Date and continuing through the
termination of this Agreement, make available to Collateral Agent and the Lenders, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower’s officers, employees and agents and Borrower’s Books, at reasonable times
and at reasonable intervals (unless an Event of Default has occurred and is continuing) to the extent that Collateral Agent or any Lender may reasonably deem them necessary to prosecute or defend any
third-party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to any Collateral or relating to Borrower. 

6.9 Notices of Litigation and Default. Borrower will give prompt written notice to Collateral Agent and the Lenders of any litigation
or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of Two Hundred Fifty Thousand Dollars
($250,000.00) or more or which could reasonably be expected  

  
 12 

 
to have a Material Adverse Change. Without limiting or contradicting any other more specific provision of this Agreement, promptly (and in any event within three (3) Business Days) upon
Borrower becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower shall give written notice to Collateral Agent and the Lenders of
such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default. 

6.10 Use of Proceeds. Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general
business requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes. A portion of the proceeds of the Term A Loans shall be used by Borrower to repay the Existing
Indebtedness in full on the Effective Date. 
 6.11 Landlord Waivers; Bailee Waivers. In the event that Borrower or any of its U.S.
Subsidiaries, after the Effective Date, intends to add any new offices or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the Collateral to, a bailee, in each case pursuant
to Section 7.2, then Borrower or such Subsidiary will first notify Collateral Agent and, in the event that the Collateral at any new location is valued in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate, such bailee
or landlord, as applicable, must execute and deliver a bailee waiver or landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent and each Lender prior to the addition of any new offices or business locations,
or any such storage with or delivery to any such bailee, as the case may be. 
 6.12 Creation/Acquisition of Subsidiaries. In the
event Borrower, or any of its Subsidiaries creates or acquires any Subsidiary, Borrower shall provide prior written notice to Collateral Agent and each Lender of the creation or acquisition of such new Subsidiary and take all such action as may be
reasonably required by Collateral Agent or any Lender to cause each such Subsidiary to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents and, in each case,
grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on Exhibit A hereto); and Borrower (or its Subsidiary, as applicable) shall grant and pledge to Collateral Agent, for the
ratable benefit of the Lenders, a perfected security interest in the stock, units or other evidence of ownership of each such newly created Subsidiary; provided, however, that solely in the circumstance in which Borrower or any Subsidiary creates or
acquires a Foreign Subsidiary in an acquisition permitted under this Agreement or otherwise approved by the Required Lenders, (i) such Foreign Subsidiary shall not be required to guarantee the Obligations of Borrower under the Loan Documents
and grant a continuing pledge and security interest in and to the assets of such Foreign Subsidiary, and (ii) Borrower shall not be required to grant and pledge to Collateral Agent, for the ratable benefit of Lenders, a perfected security
interest in more than sixty-five percent (65%) of the stock, units or other evidence of ownership of such Foreign Subsidiary, if Borrower demonstrates to the reasonable satisfaction of Collateral Agent
that such Foreign Subsidiary providing such guarantee or pledge and security interest or Borrower providing a perfected security interest in more than sixty-five percent (65%) of the stock, units or other
evidence of ownership would create a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code (it being agreed that Borrower does not need make such demonstration with respect to the stock of the Singapore
Subsidiary and that, notwithstanding any provision of this Agreement (including the definition of “Collateral”), no more than sixty-five percent (65%) of the stock, units or other evidence of
ownership of the Singapore Subsidiary shall be subject to a pledge and security interest in favor of the Agent and the Lenders). 
 6.13
Further Assurances. 
 (a) Execute any further instruments and take further action as Collateral Agent or any Lender reasonably requests
to perfect or continue Collateral Agent’s Lien in the Collateral or to effect the purposes of this Agreement. 
 (b) Deliver to
Collateral Agent and Lenders, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a
material adverse effect on any of the Governmental Approvals material to Borrower’s business or otherwise could reasonably be expected to have a Material Adverse Change. 

  
 13 

 6.14 Right to Invest. Borrower shall grant to Oxford and its Affiliates a right to invest
in Borrower’s future private equity rounds on the terms and conditions as more fully set forth in the Investment Letter. 
  

	7.	NEGATIVE COVENANTS 

 Borrower shall not, and shall not permit any of its
Subsidiaries to, do any of the following without the prior written consent of the Required Lenders: 
 7.1 Dispositions. Convey,
sell, lease, transfer, assign, or otherwise dispose of (collectively, “Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the
ordinary course of business; (b) of worn out, surplus or obsolete Equipment; and (c) in connection with Permitted Liens, Permitted Investments and Permitted Licenses. 

7.2 Changes in Business, Management, Ownership, or Business Locations. (a) Engage in or permit any of its Subsidiaries to engage
in any business other than the businesses engaged in by Borrower as of the Effective Date or reasonably related thereto; (b) liquidate or dissolve; (c) (i) any Key Person shall cease to be actively engaged in the management of
Borrower unless written notice thereof is provided to Collateral Agent within Seven (7) Business Days of such change, or (ii) enter into any transaction or series of related transactions in which the stockholders of Borrower who were not
stockholders immediately prior to the first such transaction own more than forty nine percent (49%) of the voting stock of Borrower immediately after giving effect to such transaction or related series of such transactions (other than by the
sale of Borrower’s equity securities in a public offering, a private placement of public equity or to any of Borrower’s existing venture capital investors as of the Effective Date); (d) suffer a change on its board of directors that
results in the failure of at least one partner of each of Flagship Ventures and Polaris Venture Partners or their respective Affiliates to serve as a voting member; or (e) suffer the resignation of one or more directors from its board of
directors in anticipation of Borrower’s insolvency. Borrower shall not, without at least thirty (30) days’ prior written notice to Collateral Agent: (A) add any new offices or business locations, including warehouses (unless such
new offices or business locations contain less than Two Hundred Fifty Thousand Dollars ($250,000.00) in assets or property of Borrower or any of its Subsidiaries); (B) change its jurisdiction of organization, (C) change its organizational
structure or type, (D) change its legal name, or (E) change any organizational number (if any) assigned by its jurisdiction of organization.  

7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or
acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person. A Subsidiary may merge or consolidate into another Subsidiary (provided such surviving Subsidiary is a “co-Borrower” hereunder or has provided a secured Guaranty of Borrower’s Obligations hereunder) or with (or into) Borrower provided Borrower is the surviving legal entity, and as long as no Event of
Default is occurring prior thereto or arises as a result therefrom. Without limiting the foregoing, Borrower shall not, without Collateral Agent’s prior written consent, enter into any binding contractual arrangement with any Person to attempt
to facilitate a merger or acquisition of Borrower, unless (i) no Event of Default exists when such agreement is entered into by Borrower, (ii) such agreement does not give such Person the right to claim any fees or similar payments from
Borrower in excess of Five Hundred Thousand Dollars ($500,000.00), and (iii) Borrower notifies Collateral Agent in advance of entering into such an agreement. 

7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted
Indebtedness. 
 7.5 Encumbrance. Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any
right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest granted herein (except for
Permitted Liens that are permitted by the terms of this Agreement to have priority over Collateral Agent’s Lien), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral Agent, for the
ratable benefit of the Lenders) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging, granting a security interest in or upon, or
encumbering any of Borrower’s or such Subsidiary’s Intellectual Property, except for agreements, documents, instruments or other arrangements permitted in Section 7.1 hereof, or, in the definition of “Permitted Liens”
herein. 

  
 14 

 7.6 Maintenance of Collateral Accounts. Maintain any Collateral Account except pursuant to
the terms of Section 6.6 hereof. 
 7.7 Distributions; Investments. (a) Pay any dividends (other than dividends
payable solely in capital stock or dividends to the Borrower) or make any distribution or payment in respect of or redeem, retire or repurchase any capital stock (other than (i) repurchases pursuant to the terms of employee stock purchase
plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, or similar plans, provided such repurchases do not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate per fiscal
year and (ii) repurchases pursuant to the terms of that certain Amended and Restated Letter Agreement, dated November 7, 2013, between Borrower and the Bill & Melinda Gates Foundation, as amended on September 4, 2014, and as
further amended from time to time, in the event of a Charitability Default (as defined therein), provided that such repurchases are funded by Borrower or any of its Subsidiaries solely through the incurrence of indebtedness to the Bill &
Melinda Gates Foundation (“Gates Repurchase Indebtedness”), and provided further that such indebtedness is subordinated to all Indebtedness of Borrower and/or its Subsidiaries to the Lenders (pursuant to a subordination agreement
entered into between Collateral Agent, Lenders, Borrower, and/or any of its Subsidiaries, and the Bill & Melinda Gates Foundation, which subordination agreement shall substantially be in the form agreed upon by the Collateral Agent, Lenders
and Bill & Melinda Gates Foundation on or prior to the Effective Date), on terms reasonably acceptable to Collateral Agent and the Lenders or (b) directly or indirectly make any Investment other than Permitted Investments, or permit
any of its Subsidiaries to do so. 
 7.8 Transactions with Affiliates. Directly or indirectly enter into or permit to exist any
material transaction with any Affiliate of Borrower or any of its Subsidiaries, except for (a) transactions that are in the ordinary course of Borrower’s or such Subsidiary’s business, upon fair and reasonable terms that are no less
favorable to Borrower or such Subsidiary than would be obtained in an arm’s length transaction with a non-affiliated Person, and (b) Subordinated Debt or equity investments by Borrower’s
investors in Borrower or its Subsidiaries. 
 7.9 Subordinated Debt. (a) Make or permit any payment on any Subordinated
Debt, except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the
amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders. 
 7.10 Compliance. Become an
“investment company” or a company controlled by an “investment company”, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as
defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited
Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change, or permit any of its
Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred
compensation plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries, including any material liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental
Authority. 
 7.11 Compliance with Anti-Terrorism Laws. Collateral Agent hereby
notifies Borrower and each of its Subsidiaries that pursuant to the requirements of Anti-Terrorism Laws, and Collateral Agent’s policies and practices, Collateral Agent is required to obtain, verify and
record certain information and documentation that identifies Borrower and each of its Subsidiaries and their principals, which information includes the name and address of Borrower and each of its Subsidiaries and their principals and such other
information that will allow Collateral Agent to identify such party in accordance with Anti-Terrorism Laws. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries
permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Borrower and each of its Subsidiaries shall immediately notify Collateral Agent if
Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or
(d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. Neither Borrower nor any of its Subsidiaries  

  
 15 

 
shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked
Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or
interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades
or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law. 

 

	8.	EVENTS OF DEFAULT 

 Any one of the following shall constitute an event of
default (an “Event of Default”) under this Agreement: 
 8.1 Payment Default. Borrower fails to (a) make
any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall
not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section 9.1 (a) hereof). During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be
made during the cure period); 
 8.2 Covenant Default. 

(a) Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports,
Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and Default), 6.11 (Landlord Waivers; Bailee Waivers), 6.12 (Creation/Acquisition of Subsidiaries) or
6.13 (Further Assurances) or Borrower violates any covenant in Section 7; or 
 (b) Borrower, or any of its Subsidiaries, fails or
neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term,
provision, condition, covenant or agreement that can be cured, has failed to cure the default within ten (10) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10) day
period or cannot after diligent attempts by Borrower be cured within such ten (10) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed
thirty (30) days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Grace periods
provided under this Section shall not apply, among other things, to financial covenants or any other covenants set forth in subsection (a) above; 

8.3 Material Adverse Change. A Material Adverse Change occurs; 

8.4 Attachment; Levy; Restraint on Business. 

(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of
any entity under control of Borrower or its Subsidiaries on deposit with any Lender or any Lender’s Affiliate or any bank or other institution at which Borrower or any of its Subsidiaries maintains a Collateral Account, or (ii) a notice of
lien, levy, or assessment is filed against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence
thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10) day cure period; and 

(b) (i) any material portion of Borrower’s or any of its Subsidiaries’ assets is attached, seized, levied on, or comes into
possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting any part of its business; 

  
 16 

 8.5 Insolvency. (a) Borrower or any of its Subsidiaries is or becomes Insolvent;
(b) Borrower or any of its Subsidiaries begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and not dismissed or stayed within
forty-five (45) days (but no Credit Extensions shall be made while Borrower or any Subsidiary is Insolvent and/or until any Insolvency Proceeding is dismissed); 

8.6 Other Agreements. There is a default in any agreement to which Borrower or any of its Subsidiaries is a party with a third party or
parties (a) resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Two Hundred Fifty Thousand Dollars ($250,000.00), (b) in connection with
any lease of real property material to the conduct of Borrower’s business, if such default or failure to perform results in the right of another party to terminate such lease, or (c) that could reasonably be expected to have a Material
Adverse Change; 
 8.7 Judgments. One or more judgments, orders, or decrees for the payment of money in an amount,
individually or in the aggregate, of at least Two Hundred Fifty Thousand Dollars ($250,000.00) (not covered by independent third-party insurance as to which liability has been accepted by such insurance
carrier) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied, unvacated, or unstayed for a period of ten (10) days after the entry thereof (provided that no Credit Extensions will be made prior to the
satisfaction, vacation, or stay of such judgment, order or decree); 
 8.8 Misrepresentations. Borrower or any of its
Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and/or Lenders or to
induce Collateral Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made; 

8.9 Subordinated Debt. A default or breach occurs under any agreement between Borrower or any of its Subsidiaries and any creditor of
Borrower or any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders, or any creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any
terms of such agreement;  
 8.10 Guaranty. (a) Any Guaranty terminates or ceases for any reason to be in full force and
effect; (b) any Guarantor does not perform any obligation or covenant under any Guaranty; (c) any circumstance described in Sections 8.3, 8.4, 8.5, 8.7, or 8.8 occurs with respect to any Guarantor, or (d) the death (in case of a
Guarantor who is an individual) or liquidation, winding up, or termination of existence of any Guarantor that is an entity; or: (e) a Material Adverse Change with respect to any Guarantor; 

8.11 Governmental Approvals. Any Governmental Approval shall have been revoked, rescinded, suspended, modified in an adverse manner, or
not renewed in the ordinary course for a full term and such revocation, rescission, suspension, modification or non-renewal has resulted in or could reasonably be expected to result in a
Material Adverse Change; or  
 8.12 Lien Priority. Any Lien created hereunder or by any other Loan Document shall at any time
fail to constitute a valid and perfected Lien on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens which are permitted to have priority in accordance with the terms of this
Agreement. 
  

	9.	RIGHTS AND REMEDIES 

 9.1 Rights and Remedies. 

(a) Upon the occurrence and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of Required
Lenders shall, without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default
described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii) by notice to Borrower 

  
 17 

 
suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and
Collateral Agent and/or the Lenders (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other
agreement between Borrower and Collateral Agent and/or the Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders). 

(b) Without limiting the rights of Collateral Agent and the Lenders set forth in Section 9.1(a) above, upon the occurrence and
during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following: 

(i) foreclose upon and/or sell or otherwise liquidate, the Collateral; 

(ii) apply to the Obligations any (a) balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, or
(b) any amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower; and/or 

(iii) commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding. 

(c) Without limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence
and during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following: 

(i) settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers
advisable, notify any Person owing Borrower money of Collateral Agent’s security interest in such funds, and verify the amount of such account; 

(ii) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the
Collateral. Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably designates. Collateral Agent may enter premises where the Collateral is located, take and maintain
possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Collateral Agent a license to enter and occupy
any of its premises, without charge, to exercise any of Collateral Agent’s rights or remedies; 
 (iii) ship, reclaim, recover, store,
finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral. Collateral Agent is hereby granted a non-exclusive, royalty-free license or other
right to use, without charge, Borrower’s and each of its Subsidiaries’ labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar
property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent’s exercise of its rights under this Section 9.1, Borrower’s and each of
its Subsidiaries’ rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of the Lenders; 

(iv) place a “hold” on any account maintained with Collateral Agent or the Lenders and/or deliver a notice of exclusive control,
any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; 

(v) demand and receive possession of Borrower’s Books; 

(vi) appoint a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any
competent court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower or any of its Subsidiaries; 

  
 18 

 (vii) subject to clauses 9.1(a) and (b), exercise all rights and remedies available to
Collateral Agent and each Lender under the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof); and 

(viii) demand that Borrower (i) deposit cash with Bank in an amount equal to the amount of any Letters of Credit remaining undrawn as
collateral security for the repayment of any future drawings under such Letters of Credit, and (ii) pay in advance all Letter of Credit fees scheduled to be paid or payable over the remaining term of the Letters of Credit, and Borrower shall
promptly deposit and pay such amounts. 
 Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of
Default, Collateral Agent shall have the right to exercise any and all remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance. As used in the immediately
preceding sentence, “Exigent Circumstance” means any event or circumstance that, in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the
Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain or reinstate adequate
casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a material diminution in value of the Collateral. 

9.2 Power of Attorney. Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of Default, to: (a) endorse Borrower’s or any of its Subsidiaries’ name on any checks or other forms of
payment or security; (b) sign Borrower’s or any of its Subsidiaries’ name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly
with Account Debtors, for amounts and on terms Collateral Agent determines reasonable; (d) make, settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security
interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code
or any applicable law permits. Borrower hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower’s or any of its Subsidiaries’ name on
any documents necessary to perfect or continue the perfection of Collateral Agent’s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than inchoate indemnity obligations)
have been satisfied in full and Collateral Agent and the Lenders are under no further obligation to make Credit Extensions hereunder. Collateral Agent’s foregoing appointment as Borrower’s or any of its Subsidiaries’ attorney in fact,
and all of Collateral Agent’s rights and powers, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Collateral Agent’s and the Lenders’
obligation to provide Credit Extensions terminates. 
 9.3 Protective Payments. If Borrower or any of its Subsidiaries fail to
obtain the insurance called for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other Loan Document, Collateral Agent
may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders’ Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Collateral Agent will make
reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within a reasonable time thereafter. No such payments by Collateral Agent are deemed an
agreement to make similar payments in the future or Collateral Agent’s waiver of any Event of Default. 
 9.4 Application of
Payments and Proceeds. Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any
and all payments at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders
on the other, Collateral Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application
by Collateral Agent, and (b) the proceeds of any sale of or other realization upon all or any part of the Collateral shall be applied: first, to the  

  
 19 

 
Lenders’ Expenses; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on
such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of Borrower owing to Collateral Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered
to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted
prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant
thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share
unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s portion of any Term Loan and the
ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their
scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such
sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender
in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the
payments of amounts due on the other Lenders’ claims. To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure
that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting
Collateral Agent’s security interest therein. 
 9.5 Liability for Collateral. So long as Collateral Agent and the Lenders
comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for: (a) the
safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of
loss, damage or destruction of the Collateral. 
 9.6 No Waiver; Remedies Cumulative. Failure by Collateral Agent or any
Lender, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any Lender thereafter to demand strict
performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is given. The rights
and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative. Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity. The
exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral Agent’s or any Lender’s waiver of any Event of Default is not a continuing waiver. Collateral Agent’s or any Lender’s delay in
exercising any remedy is not a waiver, election, or acquiescence. 
 9.7 Demand Waiver. Borrower waives, to the fullest extent
permitted by law, demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and
guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable. 
  

	10.	NOTICES 

 All notices, consents, requests, approvals, demands, or other
communication (collectively, “Communication”) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual
receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper  

  
 20 

 
postage prepaid; (b) upon transmission, when sent by facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or
(d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of
Collateral Agent, Lender or Borrower may change its mailing address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10. 

 

			
	If to Borrower:	  	 VISTERRA, INC.
 One Kendall Square

Suite B3301
 Cambridge, MA 02139

Attn: David Arkowitz, Chief Financial Officer
 Fax:
617-498-1073
 Email: darkowitz@visterrainc.com

		
	with a copy (which shall not constitute notice) to:	  	 Wilmer Cutler Pickering Hale and Dorr LLP
 60
State Street
 Boston, MA
 Attn: Jamie N. Class, Esq.

Fax: 617 526 5000
 Email: jamie.class@wilmerhale.com

		
	If to Collateral Agent:	  	 OXFORD FINANCE LLC
 133 North Fairfax
Street
 Alexandria, Virginia 22314
 Attention: Legal
Department
 Fax: (703) 519-5225

Email: LegalDepartment@oxfordfinance.com

		
	with a copy to	  	 SQUARE 1 BANK
 406 Blackwell Street, Suite
240
 Durham, North Carolina 27701
 Attn: Loan Operations
Manager
 and Mara Huntington
 FAX: (919) 314-3080

		
	with a copy (which shall not constitute notice) to:	  	 Greenberg Traurig, LLP
 One International
Place
 Boston, MA 02110
 Attn: Jonathan Bell, Esq.

Fax: (617) 310-6001

Email: bellj@gtlaw.com

  

	11.	CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

 New York law governs the Loan Documents without
regard to principles of conflicts of law. Borrower, Lenders and Collateral Agent each submit to the exclusive jurisdiction of the State and Federal courts in the City of New York, Borough of Manhattan. NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT
AND THE LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH COLLATERAL AGENT AND THE LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY
OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE COLLATERAL AGENT’S AND THE LENDERS’ RIGHTS AGAINST BORROWER OR ITS PROPERTY. Borrower expressly submits and consents in advance to such jurisdiction in any action or suit
commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is
deemed appropriate 

  
 21 

 
by such court. Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other
process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section 10 of this Agreement and that service so made shall be deemed completed upon
the earlier to occur of Borrower’s actual receipt thereof or three (3) days after deposit in the U.S. mails, first class, registered or certified mail return receipt requested, proper postage prepaid. 

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, COLLATERAL AGENT, AND THE LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE
OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR EACH PARTY TO ENTER INTO THIS
AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 
  

	12.	GENERAL PROVISIONS 

 12.1 Successors and Assigns. This Agreement binds and
is for the benefit of the successors and permitted assigns of each party. Borrower may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent’s and each Lender’s prior written consent
(which may be granted or withheld in Collateral Agent’s and each Lender’s discretion, subject to Section 12.6). The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or
grant participation in (any such sale, transfer, assignment, negotiation, or grant of a participation, a “Lender Transfer”) all or any part of, or any interest in, the Lenders’ obligations, rights, and benefits
under this Agreement and the other Loan Documents; provided, however, that any such Lender Transfer (other than a transfer, pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and
benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Required Lenders (such approved assignee, an “Approved Lender”). Borrower and Collateral Agent shall be entitled to
continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered
and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require. Notwithstanding anything to the contrary
contained herein, so long as no Event of Default has occurred and is continuing, no Lender Transfer (other than a Lender Transfer (i) in respect of the Warrants or (ii) in connection with (x) assignments by a Lender due to a forced
divestiture at the request of any regulatory agency; or (y) upon the occurrence of a default, event of default or similar occurrence with respect to a Lender’s own financing or securitization transactions) shall be permitted, without
Borrower’s consent, to any Person which is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent. 

12.2 Indemnification. Borrower agrees to indemnify, defend and hold Collateral Agent and the Lenders and their respective directors,
officers, employees, agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an “Indemnified Person”) harmless against: (a) all obligations, demands, claims, and liabilities
(collectively, “Claims”) asserted by any other party in connection with; related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents; and (b) all losses or Lenders’ Expenses
incurred, or paid by Indemnified Person in connection with; related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral Agent, and/or the Lenders and Borrower (including reasonable
attorneys’ fees and expenses), except for Claims and/or losses directly caused by such Indemnified Person’s gross negligence or willful misconduct. Borrower hereby further indemnifies, defends and holds each Indemnified Person harmless
from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such
Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by
or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical  

  
 22 

 
personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions
contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the loan proceeds except for liabilities,
obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements directly caused by such Indemnified Person’s gross negligence or willful misconduct. 

12.3 Time of Essence. Time is of the essence for the performance of all Obligations in this Agreement. 

12.4 Severability of Provisions. Each provision of this Agreement is severable from every other provision in determining the
enforceability of any provision. 
 12.5 Correction of Loan Documents. Collateral Agent and the Lenders may correct patent
errors and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties so long as Collateral Agent provides Borrower with written notice of such correction and allows Borrower at least ten
(10) days to object to such correction. In the event of such objection, such correction shall not be made except by an amendment signed by both Collateral Agent and Borrower. 

12.6 Amendments in Writing; Integration. (a) No amendment, modification, termination or waiver of any provision of this Agreement
or any other Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral
Agent and the Required Lenders provided that: 
 (i) no such amendment, waiver or other modification that would have the effect of
increasing or reducing a Lender’s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender’s written consent; 

(ii) no such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without
Collateral Agent’s written consent or signature; 
 (iii) no such amendment, waiver or other modification shall, unless signed
by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with
respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any
termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for the Lenders to take any action hereunder; (D) release all or substantially
all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty
obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder);
(E) amend, waive or otherwise modify this Section 12.6 or the definitions of the terms used in this Section 12.6 insofar as the definitions affect the substance of this Section 12.6; (F) consent to the assignment, delegation
or other transfer by Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or
consolidation permitted pursuant to this Agreement; (G) amend any of the provisions of Section 9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive
their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations; or (I) amend any of the provisions of Section 12.10. It
is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence;

 (iv) the provisions of the foregoing clauses (i), (ii) and (iii) are subject to the provisions of any interlender or
agency agreement among the Lenders and Collateral Agent pursuant to which any 

  
 23 

 
Lender may agree to give its consent in connection with any amendment, waiver or modification of the Loan Documents only in the event of the unanimous agreement of all Lenders. 

(b) This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or
agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents. 

12.7 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each
of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. 
 12.8 Survival. All
covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations
which, by their terms, are to survive the termination of this Agreement) have been satisfied. The obligation of Borrower in Section 12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in
Section 12.9 below, shall survive until the statute of limitations with respect to such claim or cause of action shall have run. 

12.9 Confidentiality. In handling any confidential information of Borrower, the Lenders and Collateral Agent shall exercise the same
degree of care that it exercises for their own proprietary information, but disclosure of information may be made: (a) subject to the terms and conditions of this Agreement, to the Lenders’ and Collateral Agent’s Subsidiaries or
Affiliates, or in connection with a Lender’s own financing or securitization transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; (b) to
prospective transferees (other than those identified in (a) above) or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and Collateral Agent shall, except upon the occurrence and during the continuance of an
Event of Default, obtain such prospective transferee’s or purchaser’s agreement to the terms of this provision or to similar confidentiality terms); (c) as required by law, regulation, subpoena, or other order; (d) to
Lenders’ or Collateral Agent’s regulators or as otherwise required in connection with an examination or audit; (e) as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents; and (f) to
third party service providers of the Lenders and/or Collateral Agent so long as such service providers have executed a confidentiality agreement with the Lenders and Collateral Agent with terms no less restrictive than those contained herein.
Confidential information does not include information that either: (i) is in the public domain or in the Lenders’ and/or Collateral Agent’s possession when disclosed to the Lenders and/or Collateral Agent, or becomes part of the
public domain after disclosure to the Lenders and/or Collateral Agent; or (ii) is disclosed to the Lenders and/or Collateral Agent by a third party, if the Lenders and/or Collateral Agent does not know that the third party is prohibited from
disclosing the information. Collateral Agent and the Lenders may use confidential information for any purpose, including, without limitation, for the development of client databases, reporting purposes, and market analysis, so long as Collateral
Agent or the Lenders do not disclose Borrower’s identity or the identity of any person associated with Borrower unless otherwise expressly permitted by this Agreement. The provisions of the immediately preceding sentence shall survive the
termination of this Agreement. The agreements provided under this Section 12.9 supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section 12.9.

 12.10 Right of Set Off. Borrower hereby grants to Collateral Agent and to each Lender, a lien, security interest and right of set
off as security for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property constituting Collateral, now or hereafter in the possession,
custody, safekeeping or control of Collateral Agent or the Lenders or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit to any of them. At any time after the occurrence and during
the continuance of an Event of Default, without demand or notice, Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the
adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF
WITH RESPECT TO SUCH DEPOSITS, CREDITS OR  

  
 24 

 
OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 

12.11 Square 1 Bank as Agent. Collateral Agent hereby appoints Square 1 as its agent (and Square 1 hereby accepts such appointment) for
the purpose of perfecting Collateral Agent’s Liens in assets which, in accordance with Article 8 or Article 9, as applicable, of the Code can be perfected by possession or control, including without limitation, all Collateral Accounts
maintained at Square 1. 
 12.12 Cooperation of Borrower. If necessary, Borrower agrees to (i) execute any documents
(including new Secured Promissory Notes) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section 12.1, (ii) make Borrower’s management available to
meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments or Credit Extensions (which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is
continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may
request. Subject to the provisions of Section 12.9, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender’s possession concerning Borrower
and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation
of Borrower prior to entering into this Agreement. 
  

	13.	DEFINITIONS 

 13.1 Definitions. As used in this Agreement, the following
terms have the following meanings: 
 “Account” is any “account” as defined in the Code with such additions to
such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower. 

“Account Debtor” is any “account debtor” as defined in the Code with such additions to such term as may hereafter
be made. 
 “Affiliate” of any Person is a Person that owns or controls directly or indirectly the Person, any Person that
controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person’s managers and members.

 “Agreement” is defined in the preamble hereof. 

“Amortization Date” is, with respect to each Term Loan, October 1, 2015. 

“Ancillary Services Account” is defined in Section 6.6(a). 

“Annual Projections” is defined in Section 6.2(a). 

“Anti-Terrorism Laws” are any laws relating to terrorism or money laundering,
including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC. 

“Approved Fund” is any (i) investment company, fund, trust, securitization vehicle or conduit that is (or will be)
engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii) any Person (other than a natural person) which temporarily warehouses loans for
any Lender or any entity described in the preceding clause (i) and that, with respect to each of the preceding clauses (i) and (ii), is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) a

  
 25 

 
Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender. 

“Approved Lender” is defined in Section 12.1. 

“Bank” is defined in the preamble hereof. 

“Basic Rate” is, (A) with respect to the portion of a Term Loan advanced by Oxford shall be the per annum rate of
interest (based on a year of three hundred sixty (360) days) equal to the greater of (i) Seven and Nine Tenths percent (7.90%) and (ii) the sum of (a) the prime rate reported in the Wall Street Journal three
(3) Business Days prior to the Funding Date of such Term Loan, plus (b) Four and Sixty-Five Hundredths percent (4.65%), and (B) with respect to the portion of a Term Loan advanced by Square 1 shall be the per annum rate of interest
(based on a year of three hundred sixty (360) days) equal to the greater of (i) Six and Four-Tenths percent (6.40%) and (ii) the sum of (a) the prime rate reported in the Wall Street Journal three (3) Business
Days prior to the Funding Date of such Term Loan, plus (b) Three and Fifteen Hundredths percent (3.15%). 
 “Blocked
Person” is any Person: (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the
annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any
Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a
“specially designated national” or “blocked person” on the most current list published by OFAC or other similar list. 

“Borrower” is defined in the preamble hereof. 

“Borrower’s Books” are Borrower’s or any of its Subsidiaries’ books and records including ledgers, federal,
and state tax returns, records regarding Borrower’s or its Subsidiaries’ assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.

 “Business Day” is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed. 

“Cash Equivalents” are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or
any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either
Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc., (c) money market funds (i) which provide daily liquidity and (ii) at least ninety five percent (95%) of which constitute Cash Equivalents of
the kinds described in classes (a) and (b) of this definition, and (d) certificates of deposit maturing no more than one (1) year after issue provided that the account in which any such certificate of deposit is maintained with a
Lender or the Collateral Agent or is subject to a Control Agreement in favor of Collateral Agent. For the avoidance of doubt, the direct purchase by Borrower or any of its Subsidiaries of any Auction Rate Securities, or purchasing participations in,
or entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest in any type of Auction Rate Security by Borrower or any of its Subsidiaries shall be conclusively determined by the Lenders
as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this Agreement governing Permitted Investments. Notwithstanding the foregoing, Cash Equivalents does not include and Borrower, and each of its
Subsidiaries, are prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt instrument,
including, without limitation, any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction and more commonly referred to as an auction rate
security (each, an “Auction Rate Security”). 
 “Claims” are defined in Section 12.2. 

  
 26 

 “Code” is the Uniform Commercial Code, as the same may, from time to time, be
enacted and in effect in the State of New York; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition
of such term contained in Article or Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral
Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term “Code” shall mean the Uniform Commercial Code as enacted and in effect in such other
jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions. 

“Collateral” is any and all properties, rights and assets of Borrower described on Exhibit A. 

“Collateral Account” is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained
by Borrower or any Subsidiary that is either a Borrower or a Guarantor at any time. 
 “Collateral Agent” is, Oxford, not
in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders. 
 “Commitment
Percentage” is set forth in Schedule 1.1, as amended from time to time. 
 “Commodity Account” is any
“commodity account” as defined in the Code with such additions to such term as may hereafter be made. 

“Communication” is defined in Section 10. 

“Compliance Certificate” is that certain certificate in the form attached hereto as Exhibit C. 

“Contingent Obligation” is, for any Person, any direct or indirect liability, contingent or not, of that Person for
(a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that
Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity swap agreement,
interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation” does not include
endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably
anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” is any control agreement entered into among the depository institution at which Borrower or any of its
Subsidiaries maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains a Securities Account or a Commodity Account, Borrower and such Subsidiary, and Collateral Agent
pursuant to which Collateral Agent obtains control (within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account, or Commodity Account. 

“Copyrights” are any and all copyright rights, copyright applications, copyright registrations and like protections in each
work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret. 

“Credit Extension” is any Term Loan or any other extension of credit by Collateral Agent or Lenders for Borrower’s
benefit. 
 “Default Rate” is defined in Section 2.3(b). 

  
 27 

 “Deposit Account” is any “deposit account” as defined in the Code with
such additions to such term as may hereafter be made. 
 “Designated Deposit Account” is Borrower’s deposit account,
account number 7039003, maintained with Bank. 
 “Disbursement Letter” is that certain form attached hereto as Exhibit B-1. 
 “Dollars,” “dollars” and “$”
each mean lawful money of the United States. 
 “Effective Date” is defined in the preamble of this Agreement. 

“Eligible Assignee” is (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund and (iv) any
commercial bank, savings and loan association or savings bank or any other entity which is an “accredited investor” (as defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit or buys loans as one of
its businesses, including insurance companies, mutual funds, lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard & Poor’s Rating Group and a rating
of Baa2 or higher from Moody’s Investors Service, Inc. at the date that it becomes a Lender or (B) has total assets in excess of Five Billion Dollars ($5,000,000,000.00), and in each case of clauses (i) through (iv), which, through
its applicable lending office, is capable of lending to Borrower without the imposition of any withholding or similar taxes; provided that notwithstanding the foregoing, “Eligible Assignee” shall not include, unless an Event of Default has
occurred and is continuing, (i) Borrower or any of Borrower’s Affiliates or Subsidiaries or (ii) a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent. Notwithstanding the foregoing,
(x) in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in
connection with a Lender’s own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization
transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment
under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment
agreement from such Person or party in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral
Agent reasonably shall require. 
 “Equipment” is all “equipment” as defined in the Code with such additions to
such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 

“Equity Event” is the receipt by Borrower on or after the Effective Date, and on or before September 30, 2015, of
unrestricted gross cash proceeds of not less than Twenty-Five Million Dollars ($25,000,000) from the issuance and sale by Borrower of its equity securities (with substantial investment in such financing before or after the Effective Date by
Borrower’s existing investors and Merck & Co. (or one or more of its Affiliates)), including the gross cash proceeds of Fifteen Million Dollars ($15,000,000) received by Borrower from the Borrower’s sale of its Series B Preferred
Stock during May, 2014 prior to the Effective Date. 
 “ERISA” is the Employee Retirement Income Security Act of 1974, as
amended, and its regulations. 
 “Event of Default” is defined in Section 8. 

“Existing Indebtedness” is the indebtedness of Borrower to Lighthouse Capital Partners in the aggregate principal outstanding
amount as of the Effective Date of approximately $188,672.78 pursuant to that certain Loan and Security Agreement, dated February 28, 2011, entered into by and between Lighthouse Capital Partners and Borrower. 

  
 28 

 “Excepted Account” means each LC Account and Ancillary Services Account. 

“Final Payment” is a payment (in addition to and not a substitution for the regular monthly payments of principal plus
accrued interest) due on the earliest to occur of (a) the Maturity Date, or (b) the acceleration of any Term Loan, or (c) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d), equal to the original principal
amount of such Term Loan advanced hereunder multiplied by the Final Payment Percentage, payable to Oxford with respect to all Term Loans made hereunder (for the purposes of clarity, any Final Payment related to a Term Loan made by Square 1 hereunder
shall be payable to Oxford). 
 “Final Payment Percentage” is three percent (3.00%). 

“Foreign Subsidiary” is a Subsidiary that is not an entity organized under the laws of the United States or any territory
thereof. 
 “Funding Date” is any date on which a Credit Extension is made to or on account of Borrower which shall be a
Business Day. 
 “GAAP” is generally accepted accounting principles set forth in the opinions and pronouncements of the
Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant
segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination. 

“General Intangibles” are all “general intangibles” as defined in the Code in effect on the date hereof with such
additions to such term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or
unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles,
royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or
personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of
insurance and rights to payment of any kind. 
 “Governmental Approval” is any consent, authorization, approval, order,
license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 

“Governmental Authority” is any nation or government, any state or other political subdivision thereof, any agency,
authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization. 
 “Guarantor” is any Person providing a Guaranty in favor
of Collateral Agent. 
 “Guaranty” is any guarantee of all or any part of the Obligations, as the same may from time to
time be amended, restated, modified or otherwise supplemented. 
 “Indebtedness” is (a) indebtedness for borrowed
money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease
obligations (as such term is defined under GAAP on the Effective Date), and (d) Contingent Obligations. 
 “Indemnified
Person” is defined in Section 12.2. 

  
 29 

 “Insolvency Proceeding” is any proceeding by or against any Person under the
United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.

 “Insolvent” means not Solvent. 

“Intellectual Property” means all of Borrower’s or any Subsidiary’s right, title and interest in and to the
following: 
 (a) its Copyrights, Trademarks and Patents; 

(b) any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, operating manuals; 
 (c) any and all source code; 

(d) any and all design rights which may be available to Borrower; 

(e) any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the
obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and 

(f) all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents. 

“Inventory” is all “inventory” as defined in the Code in effect on the date hereof with such additions to such term
as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of
any Person’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above. 

“Investment” is any beneficial ownership interest in any Person (including stock, partnership interest or other securities),
and any loan, advance, payment or capital contribution to any Person. 
 “Investment Letter” is that certain letter
agreement, dated as of the Effective Date, in form and content reasonably acceptable to Collateral Agent and Oxford. 
 “Key
Person” is each of Borrower’s (i) Chief Executive Officer, who is Brian Pereira as of the Effective Date and (ii) Chief Financial Officer, who is David Arkowitz as of the Effective Date. 

“LC Account” is defined in Section 6.6(a). 

“Lender” is any one of the Lenders. 

“Lenders” are the Persons identified on Schedule 1.1 hereto and each assignee that becomes a party to this
Agreement pursuant to Section 12.1. 
 “Lenders’ Expenses” are all audit fees and expenses, costs, and expenses
(including reasonable attorneys’ fees and expenses, as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating, administering, defending and enforcing the Loan
Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan Documents. 

“Letter of Credit” is a standby or commercial letter of credit issued by Bank upon request of Borrower based upon an
application, guarantee, indemnity, or similar agreement. 

  
 30 

 “Lien” is a claim, mortgage, deed of trust, levy, charge, pledge, security
interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property. 

“Loan Documents” are, collectively, this Agreement, the Warrants, the Perfection Certificates, each Compliance Certificate,
each Disbursement Letter, each Loan Payment/Advance Request Form, the Post Closing Letter, the Investment Letter, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present or
future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified. 

“Loan Payment/Advance Request Form” is that certain form attached hereto as
Exhibit B-2. 
 “Material Adverse Change” is (a) a material
impairment in the perfection or priority of Collateral Agent’s Lien in the Collateral or in the value of such Collateral; (b) a material adverse change in the business, operations or condition (financial or otherwise) of Borrower or any
Subsidiary; or (c) a material impairment of the prospect of repayment of any portion of the Obligations. 
 “Maturity
Date” is, for each Term Loan, September 1, 2018. 
 “Obligations” are all of Borrower’s obligations to
pay when due any debts, principal, interest, Lenders’ Expenses, the Prepayment Fee, the Final Payment, and other amounts Borrower owes the Lenders now or later, in connection with, related to, following, or arising from, out of or under, this
Agreement or the other Loan Documents (other than the Warrants and the Investment Letter), or otherwise, and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower
assigned to the Lenders and/or Collateral Agent, and the performance of Borrower’s duties under the Loan Documents (other than the Warrants and the Investment Letter). 

“OFAC” is the U.S. Department of Treasury Office of Foreign Assets Control. 

“OFAC Lists” are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to
Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

 “Operating Documents” are, for any Person, such Person’s formation documents, as certified by the Secretary of
State (or equivalent agency) of such Person’s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current form,
(b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all
current amendments or modifications thereto. 
 “Patents” means all patents, patent applications and like protections
including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same. 

“Payment Date” is the first (1st) calendar day of each calendar
month, commencing on October 1, 2014. 
 “Perfection Certificate” and “Perfection Certificates” is
defined in Section 5.1. 
 “Permitted Indebtedness” is: 

(a) Borrower’s Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents; 

(b) Indebtedness existing on the Effective Date and disclosed on the Perfection Certificate(s); 

  
 31 

 (c) Subordinated Debt; 

(d) unsecured Indebtedness to trade creditors incurred in the ordinary course of business; 

(e) Indebtedness consisting of capitalized lease obligations (as such term is defined under GAAP on the Effective Date) and purchase money
Indebtedness, in each case incurred by Borrower or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the aggregate outstanding principal amount
of all such Indebtedness does not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) at any time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or
built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made); 

(f) Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower’s business; and

 (g) Indebtedness incurred in connection with interest rate and other swap arrangements that are entered into to mitigate risk and not for
speculative purposes; provided, however, the aggregate amount of such Indebtedness does not exceed $50,000 at any given time; 
 (h)
Unsecured Indebtedness constituting Permitted Investment under clauses (j) and (k) of the definition of Permitted Investments; 

(i) Letter of credit reimbursement obligations for letters of credit issued for the benefit of landlords not to exceed $120,000 or issued by a
Lender; 
 (j) Credit card reimbursement obligations; provided, however, the aggregate amount of such Indebtedness does not exceed $10,000
at any given time; 
 (k) Reimbursement obligations for ancillary banking services provided by the Bank; provided, however, the aggregate
amount of such Indebtedness does not exceed $75,000 at any given time and such obligations are not outstanding at the same time as the credit card reimbursement obligations described in clause (j) above; 

(l) Unsecured Indebtedness of the Singapore Subsidiary in connection with grants to such Subsidiary; provided, however, that the aggregate
amount of such unsecured Indebtedness does not exceed $250,000; 
 (m) Gates Repurchase Indebtedness to the extent such indebtedness is
subordinated to all Indebtedness of Borrower and/or its Subsidiaries to the Lenders (pursuant to a subordination agreement entered into between Collateral Agent, Lenders, Borrower, and/or any of its Subsidiaries, and the Bill & Melinda
Gates Foundation, which subordination agreement shall substantially be in the form agreed upon by the Collateral Agent, Lenders and Bill & Melinda Gates Foundation on or prior to the Effective Date), on terms reasonably acceptable to
Collateral Agent and the Lenders; and 
 (n) extensions, refinancings, modifications, amendments and restatements of any items of Permitted
Indebtedness (a) through (m) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon Borrower, or its Subsidiary, as the case may be. 

“Permitted Investments” are: 

(a) Investments disclosed on the Perfection Certificate(s) and existing on the Effective Date; 

  
 32 

 (b) (i) Investments consisting of cash and Cash Equivalents, and (ii) any other
Investments permitted by Borrower’s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent; 

(c) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary
course of Borrower’s business; 
 (d) Investments consisting of deposit accounts maintained in accordance with Section 6.6; 

(e) Investments in connection with Transfers permitted by Section 7.1; 

(f) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary
course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower’s Board of
Directors; not to exceed Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate for (i) and (ii) in any fiscal year, and (iii) a loan to a new Vice President of Development in an amount not to exceed $250,000 to be made on or
about September 2014; 
 (g) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of
customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; 

(h) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not
Affiliates, in the ordinary course of business; provided that this paragraph (h) shall not apply to Investments of Borrower in any Subsidiary; 

(i) non-cash Investments in joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the non-exclusive licensing of technology, the development of technology or the providing of technical support; 

(j) the creation and initial funding of the Singapore Subsidiary in an amount not to exceed $25,000 to fund initial costs, and additional
investments not exceeding $150,000 effected through a transfer of equipment and/or funds used to purchase equipment); 
 (k) Investments in
the Singapore Subsidiary to pay ordinary operating costs and expenses, not exceeding $250,000 in the aggregate during any given year; and 

(l) additional Investments that do not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate during the term of this
Agreement. 
 “Permitted Licenses” are (A) Exclusive License Agreements between Massachusetts Institute of Technology
and Visterra, Inc. disclosed on the Perfection Certificate on the Effective Date and the license granted by Borrower to the Bill & Melinda Gates Foundation pursuant to that certain Amended and Restated Letter Agreement, dated
November 7, 2013, between Borrower and the Bill & Melinda Gates Foundation, as amended on September 4, 2014, disclosed on the Perfection Certificate on the Effective Date, (B) licenses of open source, over-the-counter
software, prepackaged software and other software that is commercially available to the public, and (C) non-exclusive and exclusive licenses for the use of the Intellectual Property of Borrower or any of
its Subsidiaries entered into in the ordinary course of business, provided, that, with respect to each such license described in clause (C), (i) no Event of Default has occurred or is continuing at the time of such license; (ii) the
license constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its
Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property; (iii) in the case of any exclusive license, (x) Borrower delivers ten (10) days’ prior
written notice and a brief summary of the terms of the proposed license to Collateral Agent and the Lenders and delivers to Collateral Agent and the Lenders copies of the final executed licensing documents in connection with the exclusive license
promptly upon consummation thereof, 

  
 33 

 
and (y) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory
only as to discrete geographical areas outside of the United States; and (iv) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to Borrower or any of its Subsidiaries are
deposited into a Deposit Account that is governed by a Control Agreement. 
 “Permitted Liens” are: 

(a) Liens existing on the Effective Date and disclosed on the Perfection Certificates or arising under this Agreement and the other Loan
Documents; 
 (b) Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or
(ii) being contested in good faith and for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury
Regulations adopted thereunder; 
 (c) liens securing Indebtedness permitted under clause (e) of the definition of “Permitted
Indebtedness,” provided that (i) such liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20) days after the, acquisition, lease, repair, improvement or construction of, such
property financed or leased by such Indebtedness and (ii) such liens do not extend to any property of Borrower other than the property and improvements, accessions and attachments thereto (and proceeds thereof) acquired, leased or built, or the
improvements or repairs, financed by such Indebtedness; 
 (d) Liens of carriers, mechanics, warehousemen, suppliers, or other Persons that
are possessory in nature arising in the ordinary course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed One Hundred Thousand Dollars ($100,000.00), and which are not delinquent
or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto; 

(e) Liens to secure payment of workers’ compensation, employment insurance, old-age pensions,
social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA); 
 (f) Liens
incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the
principal amount of the indebtedness may not increase; 
 (g) leases or subleases of real property granted in the ordinary course of
Borrower’s business (or, if referring to another Person, in the ordinary course of such Person’s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other
than Intellectual Property) granted in the ordinary course of Borrower’s business (or, if referring to another Person, in the ordinary course of such Person’s business), if the leases, subleases, licenses and sublicenses do not prohibit
granting Collateral Agent or any Lender a security interest therein; 
 (h) banker’s liens, rights of setoff and Liens in favor of
financial institutions incurred in the ordinary course of business arising in connection with Borrower’s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses and
provided such accounts are maintained in compliance with Section 6.6(b) hereof; 
 (i) Liens arising from judgments, decrees or
attachments in circumstances not constituting an Event of Default under Section 8.4 or 8.7; 
 (j) Liens consisting of Permitted
Licenses; and 

  
 34 

 (k) Liens securing the obligations in clauses (i), and (j) or (k) (but not both
(j) and (k)) of the definition of Permitted Indebtedness; provided, however, such Liens are restricted to the LC Account and the Ancillary Services Accounts respectively and secure only the respective amounts of such Permitted Indebtedness.

 “Person” is any individual, sole proprietorship, partnership, limited liability company, joint venture, company,
trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Post Closing Letter” is that certain Post Closing Letter dated as of the Effective Date by and between Collateral
Agent and Borrower. 
 “Prepayment Fee” is, with respect to any Term Loan subject to prepayment prior to the
Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to:  

(i) for a prepayment made on or after the Effective Date through and including the first anniversary of the Effective Date, three percent
(3.00%) of the principal amount of such Term Loan prepaid; 
 (ii) for a prepayment made after the date which is after the first
anniversary of the Effective Date of such Term Loan through and including the second anniversary of the Effective Date, two percent (2.00%) of the principal amount of such Term Loan prepaid; and 

(iii) for a prepayment made after the date which is after the second anniversary of the Effective Date of such Term Loan and prior to the
Maturity Date, one percent (1.00%) of the principal amount of such Term Loan prepaid. 
 “Pro Rata Share” is,
as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate
outstanding principal amount of all Term Loans. 
 “Registered Organization” is any “registered
organization” as defined in the Code with such additions to such term as may hereafter be made. 
 “Required
Lenders” means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an “Original Lender”) have not assigned or transferred any of their interests in their Term Loans, Lenders holding one
hundred percent (100%) of the aggregate outstanding principal balance of the Term Loans, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Term Loans, Lenders holding at least sixty six
percent (66%) of the aggregate outstanding principal balance of the Term Loans and, in respect of this clause (ii), (A) each Original Lender that has not assigned or transferred any portion of its Term Loans, (B) each assignee or
transferee of an Original Lender’s interest in the Term Loans, but only to the extent that such assignee or transferee is an Affiliate or Approved Fund of such Original Lender and (C) any Person providing financing to any Person described
in clauses (A) and (B) above; provided, however, that this clause (C) shall only apply upon the occurrence of a default, event of default or similar occurrence with respect to such financing.  

“Requirement of Law” is as to any Person, the organizational or governing documents of such Person, and any law (statutory or
common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is
subject. 
 “Responsible Officer” is any of the President, Chief Executive Officer, or Chief Financial Officer of
Borrower acting alone. 
 “Second Draw Period” is the period commencing on the date of the occurrence of the
Equity Event and ending on the earlier of (i) September 30, 2015 and (ii) the occurrence of an Event of Default; provided, however,  

  
 35 

 
that the Second Draw Period shall not commence if on the date of the occurrence of the Equity Event an Event of Default has occurred and is continuing. 

“Secured Promissory Note” is defined in Section 2.4. 

“Secured Promissory Note Record” is a record maintained by each Lender with respect to the outstanding Obligations
owed by Borrower to Lender and credits made thereto. 
 “Securities Account” is any “securities
account” as defined in the Code with such additions to such term as may hereafter be made. 
 “Singapore
Subsidiary” is Visterra Singapore International Pte. Ltd. 
 “Solvent” is, with respect to any
Person: the fair salable value of such Person’s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of such Person’s liabilities; such Person is not left with unreasonably small capital after the
transactions in this Agreement; and such Person is able to pay its debts (including trade debts) as they mature. 

“Subordinated Debt” is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness
of Borrower and/or its Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered into between Collateral Agent, Borrower, and/or
any of its Subsidiaries, and the other creditor), on terms acceptable to Collateral Agent and the Lenders. 

“Subsidiary” is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting
stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries. 

“Term Loan” is defined in Section 2.2(a)(ii) hereof. 

“Term A Loan” is defined in Section 2.2(a)(i) hereof. 

“Term B Loan” is defined in Section 2.2(a)(ii) hereof. 

“Term Loan Commitment” is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal
amount shown on Schedule 1.1. “Term Loan Commitments” means the aggregate amount of such commitments of all Lenders. 

“Trademarks” means any trademark and servicemark rights, whether registered or not, applications to register and
registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks. 

“Transfer” is defined in Section 7.1. 

“Warrants” are those certain Warrants to Purchase Stock dated as of the Effective Date, or any date thereafter, issued
by Borrower in favor of each Lender or such Lender’s Affiliates. 
 [Balance of Page Intentionally
Left Blank] 

  
 36 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the
Effective Date. 
  

			
	BORROWER:
	
	VISTERRA, INC.
		
	By:	 	 /s/ David Arkowitz

	Name:	 	David Arkowitz
	Title:	 	Chief Operating Officer and Chief Financial Officer
	
	COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC
		
	By:	 	 /s/ T.A. Lex

	Name:	 	Timothy A. Lex
	Title:	 	Chief Operating Officer
	
	LENDER:
	
	SQUARE 1 BANK
		
	By:	 	 /s/ Wiley Becker

	Name:	 	Wiley Becker
	Title:	 	Vice President

  

[Signature Page to Loan and Security Agreement] 

 SCHEDULE 1.1 

Lenders and Commitments 
  

					
		  	Term A Loans	  	
			
	 Lender
	  	 Term Loan Commitment
	  	 Commitment Percentage

	 OXFORD FINANCE LLC
	  	$2,500,000	  	50%
	 SQUARE 1 BANK
	  	$2,500,000	  	50%
	TOTAL	  	$5,000,000	  	100.00%
			
		  	Term B Loans	  	
			
	 Lender
	  	 Term Loan Commitment
	  	 Commitment Percentage

	 OXFORD FINANCE LLC
	  	$2,500,000	  	50%
	 SQUARE 1 BANK
	  	$2,500,000	  	50%
	TOTAL	  	$5,000,000	  	100.00%
			
		  	Aggregate (all Term Loans)	  	
			
	 Lender
	  	 Term Loan Commitment
	  	 Commitment Percentage

	 OXFORD FINANCE LLC
	  	$5,000,000	  	50%
	 SQUARE 1 BANK
	  	$5,000,000	  	50%
	TOTAL	  	$10,000,000	  	100.00%

 EXHIBIT A 

Description of Collateral 
 The
Collateral consists of all of Borrower’s right, title and interest in and to the following personal property: 
 All goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (except as noted below),
commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights
(whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and 

All Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions
for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. 

Notwithstanding the foregoing, the Collateral does not include (i) any Intellectual Property; provided, however, the Collateral
shall include all Accounts and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in
such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Collateral
Agent’s security interest in such Accounts and such other property of Borrower that are proceeds of the Intellectual Property; and (ii) more than 65% of the total combined voting power of all classes of stock entitled to vote the shares of
capital stock (the “Shares”) Foreign Subsidiary, if (except as provided in Section 6.12) Borrower demonstrates to Collateral Agent’s reasonable satisfaction that a pledge of more than sixty five percent (65%) of the
Shares of such Subsidiary creates a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code; (iii) Excepted Accounts and (iv) any license, lease or contract, in each case if the granting of a Lien in
such license or contract is prohibited by or would constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable under applicable law and (B) other than to the
extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing or expiration of any such prohibition, such
license or contract, as applicable, shall automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the “Collateral.” 

Pursuant to the terms of a certain negative pledge arrangement with Collateral Agent and the Lenders, Borrower has agreed not to encumber any
of its Intellectual Property. 

 EXHIBIT B-1 

Form of Disbursement Letter 

[see attached] 

 DISBURSEMENT LETTER 

[DATE] 
 The undersigned, being the duly
elected and acting                      of VISTERRA, INC., a DELAWARE corporation with offices located at One Kendall Square, Suite B3301, Cambridge,
MA 02139 (“Borrower”), does hereby certify to OXFORD FINANCE LLC (“Oxford” and “Lender”), as collateral agent (the “Collateral Agent”) in connection with that certain Loan
and Security Agreement dated as of September 9, 2014, by and among Borrower, Collateral Agent and the Lenders from time to time party thereto (the “Loan Agreement”; with other capitalized terms used below having the meanings
ascribed thereto in the Loan Agreement) that: 
 1. The representations and warranties made by Borrower in Section 5 of the Loan
Agreement and in the other Loan Documents are true and correct in all material respects as of the date hereof, except to the extent such representations and warranties relate to a specific prior date in which case they were true and correct in all
materials respects as of such prior date. 
 2. No event or condition has occurred that would constitute an Event of Default under the Loan
Agreement or any other Loan Document. 
 3. Borrower is in compliance with the covenants and requirements contained in Sections 4, 6 and 7
of the Loan Agreement. 
 4. All conditions referred to in Section 3 of the Loan Agreement to the making of the Loan to be made on or
about the date hereof have been satisfied or waived by Collateral Agent. 
 5. No Material Adverse Change has occurred. 

6. The undersigned is a Responsible Officer. 

[Balance of Page Intentionally Left Blank] 

 7. The proceeds of the Term [A][B] Loan shall be disbursed as follows: 

 

					
	 Disbursement from Oxford:
	 			
	 Loan Amount
	 	$	            	  
	 Plus:
	 			
	 —Deposit Received
	 	$	            	  
		
	 Less:
	 			
	 [—Existing Debt Payoff to be remitted to [Lighthouse Capital Partners] per the Payoff Letter dated [DATE]
	 	($	            	)] 
	 [—Interim Interest
	 	($	            	)] 
	 [Lenders’ Expenses]
	 	($	            	)] 
		
	 Net Proceeds due from Oxford:
	 	$	            	  
		
	 Disbursement from Square 1:
	 			
	 Loan Amount
	 	$	            	  
	 Plus:
	 			
	 —Deposit Received
	 	$	            	  
		
	 Less:
	 			
		 	($	            	) 
	 [—Interim Interest
	 	($	            	)] 
	 [Lenders’ Expenses]
	 	($	            	)] 
		
	 Net Proceeds due from Square 1:
	 	$	            	  
		
	 TOTAL TERM [A][B] LOAN NET PROCEEDS FROM LENDERS
	 	$	            	  

 8. The [initial][Term Loan][Term A Loan] shall amortize in accordance with the Amortization Table
attached hereto. 
 9. The aggregate net proceeds of the Term Loans shall be transferred to the Designated Deposit Account as follows: 

 

			
	 Account Name:
	  	VISTERRA, INC.
	 Bank Name:
	  	SQUARE 1 BANK
	 Bank Address:
	  	[                    ]
	 Account Number:
	  	7039003
	 ABA Number:
	  	[                    ]

 [Balance of Page Intentionally Left Blank] 

 Dated as of the date first set forth above. 

 

			
	BORROWER:
	
	VISTERRA, INC.
		
	By	 	  

	Name:	 	  

	Title:	 	  

	
	COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC
		
	By	 	  

	Name:	 	  

	Title:	 	  

	
	LENDER:
	
	SQUARE 1 BANK
		
	By	 	  

	Name:	 	  

	Title:	 	  

 EXHIBIT B-2 

LOAN PAYMENT / ADVANCE REQUEST FORM 
  

					
	SQUARE 1 BANK	  	 	  	 
	 	  		  	AUTOMATIC DEBIT AUTHORIZATION
	Member FDIC	  	 	  	 

  

					
	 To: Square 1 Bank
	  	 
	 		 
	 Re: Loan #
	  	  
	  	 
	 
	
You are hereby authorized and instructed to charge account No.
                     in the name of VISTERRA, INC. for facility fees, principal, interest and other payments due on above referenced loan as
set forth below and credit the loan referenced above.

	 
	
 ̈ Debit the Facility Fee as it becomes due according to the terms of the Loan and Security Agreement and any renewals or
amendments thereof.

	 
	
 ̈ Debit each interest payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or
amendments thereof.

	 
	
 ̈ Debit each principal payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or
amendments thereof.

	 
	
 ̈ Debit each payment for Lenders’ Expenses as it becomes due according to the terms of the Loan and Security Agreement
and any renewals or amendments thereof.

	 
	
This Authorization is to remain in full force and effect until revoked in writing.

 

  

			
	 Borrower Signature

 
	  	 Date

 

	 	 
	 	  	 

 EXHIBIT C 

Compliance Certificate 
  

			
	TO:	  	 OXFORD FINANCE LLC, as Collateral Agent and Lender

SQUARE 1 BANK, as Lender

		
	FROM:	  	VISTERRA, INC.

 The undersigned authorized officer (“Officer”) of VISTERRA, INC. (“Borrower”), hereby
certifies, in the capacity as an officer of the Borrower, that in accordance with the terms and conditions of the Loan and Security Agreement by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the “Loan
Agreement;” capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement), 

(a) Borrower is in complete compliance for the period ending
                     with all required covenants except as noted below; 

(b) There are no Events of Default, except as noted below; 

(c) Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material
respects on this date and for the period described in (a), above; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text
thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; 

(d) Borrower, and each of Borrower’s Subsidiaries, has timely filed all required tax returns and reports, and Borrower and each of its
Subsidiaries, has timely paid all foreign and federal taxes, assessments, deposits and contributions (and all material state and local taxes, assessments, deposits and contributions owed by Borrower and such Subsidiaries, in all jurisdictions in
which Borrower or any such Subsidiary is subject to taxes i.e. all state and local taxes, assessments, deposits and contributions in an aggregate amount of $50,000 or more for Borrower and all Subsidiaries together), except as otherwise permitted
pursuant to the terms of Section 5.8 of the Loan Agreement; 
 (e) No Liens have been levied or claims made against Borrower or any of
its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders. 

Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies, in the capacity of an
officer of Borrower, that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or
footnotes and (except (i) financial statements provided for periods prior to 2015 are not prepared in conformity with GAAP, and (ii) unaudited financial statements for periods from and after 2015 will not contain GAAP footnotes and will be
subject to year-end adjustments; however such financial statements do fairly and accurately state all information regarding cash in accordance with GAAP.) 

Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under “Complies” column. 

 

															
	 	 	 	  	 Reporting

Covenant
	  	Requirement	  	Actual	  	Complies
	 1)
	 		  	Financial statements	  	Monthly within 30 days	  		  	Yes	  	No	  	N/A

															
								
	 2)
	 		  	Annual (CPA Audited) statements	  	Within 180 days after FYE	  		  	Yes	  	No	  	N/A
								
	 3)
	 		  	Annual Financial Projections/Budget (prepared on a monthly basis)	  	Annually (within 60 days after FYE or 7 days after Board approval, whichever is earlier), and when revised	  		  	Yes	  	No	  	N/A
								
	 4)
	 		  	A/R & A/P agings	  	Monthly within 30 days (upon request)	  		  	Yes	  	No	  	
								
	 5)
	 		  	8-K, 10-K and 10-Q Filings	  	If applicable, within 5 days of filing	  		  	Yes	  	No	  	N/A
								
	 6)
	 		  	Compliance Certificate	  	Monthly within 30 days	  		  	Yes	  	No	  	N/A
								
	 7)
	 		  	Total amount of Borrower’s cash and cash equivalents at the last day of the measurement period	  		  	$            	  	Yes	  	No	  	N/A
								
	 8)
	 		  	Total amount of Borrower’s Subsidiaries’ cash and cash equivalents at the last day of the measurement period	  		  	$            	  	Yes	  	No	  	N/A

 Deposit and Securities Accounts 

(Please list all accounts; attach separate sheet if additional space needed) 

 

													
	 	  	Institution Name	  	Account Number	  	New Account?	  	Account Control Agreement in place?
	1)	  		  		  	Yes	  	No	  	Yes	  	No
							
	2)	  		  		  	Yes	  	No	  	Yes	  	No
							
	3)	  		  		  	Yes	  	No	  	Yes	  	No
							
	4)	  		  		  	Yes	  	No	  	Yes	  	No

 Other Matters 
  

							
	1)	  	Have there been any changes in Key Persons since the last Compliance Certificate?	  	Yes	  	No
				
	2)	  	Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement?	  	Yes	  	No
				
	3)	  	Have there been any new or pending claims or causes of action against Borrower that involve more than Two Hundred Fifty Thousand Dollars ($250,000.00)?	  	Yes	  	No
				
	4)	  	Have there been any (i) amendments of the Operating Documents of Borrower or any of	  	Yes	  	No

							
		  	its Subsidiaries or (ii) any material amendments or other material changes to the capitalization table of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this Compliance
Certificate.	  		  	

 Exceptions 

Please explain any exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions.” Attach separate sheet if
additional space needed.) 
  

			
	VISTERRA, INC.
		
	By	 	  

	Name:	 	  

	Title:	 	  

 Date:                    

  

											
		  	LENDER USE ONLY	  		  		  	
						
		  	Received by:	  	  
	  		  	Date:	  	
						
		  	Verified by:	  	  
	  		  	Date:	  	
					
		  	Compliance Status:            Yes	  	No	  		  	

 EXHIBIT D  

Form of Secured Promissory Note 

[see attached] 

 SECURED PROMISSORY NOTE 

(Term [A][B] Loan) 
  

			
	$            	  	Dated: [DATE]

 FOR VALUE RECEIVED, the undersigned, VISTERRA, INC., a Delaware corporation with offices located at One
Kendall Square, Suite B3301, Cambridge, MA 02139 (“Borrower”) HEREBY PROMISES TO PAY to the order of [OXFORD FINANCE LLC][SQUARE 1 BANK] (“Lender”) the principal amount of
[                    ] MILLION DOLLARS ($        ) or such lesser amount as shall equal the outstanding
principal balance of the Term [A][B] Loan made to Borrower by Lender, plus interest on the aggregate unpaid principal amount of such Term [A][B] Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated
September 9, 2014 by and among Borrower, Lender, Oxford Finance LLC, as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan
Agreement”). If not sooner paid, the entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein
shall have the meaning attributed to such term in the Loan Agreement. 
 Principal, interest and all other amounts due with respect to the Term [A][B]
Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Secured Promissory Note (this “Note”). The principal amount of this Note and the interest rate applicable
thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note. 

The Loan Agreement, among other things, (a) provides for the making of a secured Term [A][B] Loan by Lender to Borrower, and (b) contains
provisions for acceleration of the maturity hereof upon the happening of certain stated events. 
 This Note may not be prepaid except as set forth in
Section 2.2 (c) and Section 2.2(d) of the Loan Agreement. 
 This Note and the obligation of Borrower to repay the unpaid principal
amount of the Term [A][B] Loan, interest on the Term [A][B] Loan and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement. 

Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and
enforcement of this Note are hereby waived. 
 Borrower shall pay all reasonable fees and expenses, including, without limitation, reasonable
attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower’s obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York. 

The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent. Notwithstanding anything else in
this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an interest in the
obligation. Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or
interest in this Note on the part of any other person or entity. 
 [Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers
thereunto duly authorized on the date hereof. 
  

			
	BORROWER:
	
	VISTERRA, INC.
		
	By	 	  

	Name:	 	  

	Title:	 	  

 LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL 

 

									
	 Date
	 	 Principal

Amount
	 	 Interest Rate
	 	 Scheduled

Payment Amount
	 	 Notation By

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

 CORPORATE BORROWING CERTIFICATE 

 

					
	BORROWER:	  	VISTERRA, INC.	  	DATE: [DATE]
	LENDERS:	  	OXFORD FINANCE LLC, as Collateral Agent and Lender	  	
		  	SQUARE 1 BANK, as Lender	  	

 I hereby certify as follows, as of the date set forth above: 

1. I am the [Secretary, Assistant Secretary or other officer] of Borrower. My title is as set forth below. 

2. Borrower’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of [Delaware]. 

3. Attached hereto as Exhibit A and Exhibit B, respectively, are true, correct and complete copies of (i) Borrower’s
Articles/Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s Bylaws. Neither such
Articles/Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Articles/Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof. 

4. The following resolutions were duly and validly adopted by Borrower’s Board of Directors at a duly held meeting of such directors (or pursuant to a
unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them
until each Lender receives written notice of revocation from Borrower. 
 5. The persons listed below are Borrower’s officers or employees with their
titles and signatures shown next to their names, and such persons may act on behalf of Borrower: 
  

							
	 Name
	  	 Title
	  	 Signature
	  	Authorized to
Add or Remove
Signatories
	  
	  	  
	  	  
	  	 ̈
				
	  
	  	  
	  	  
	  	 ̈
				
	  
	  	  
	  	  
	  	 ̈
				
	  
	  	  
	  	  
	  	 ̈

 [Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the undersigned has executed this Certificate as the
[                    ] of Borrower as of the date set forth above. 

 

			
	By:	 	  

	Name:	 	  

	Title:	 	  

  

	***	If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be
signed by a second authorized officer or director of Borrower. 

 I, the
                                        
of Borrower, hereby certify as to paragraphs 1 through 5 above, as 

                     [print title] 

of the date set forth above. 
  

			
	By:	 	  

	Name:	 	  

	Title:	 	  

					
	DEBTOR:	  	VISTERRA, INC.	  	
	SECURED PARTY:	  	 OXFORD FINANCE LLC,
 as Collateral
Agent
	  	

 EXHIBIT A TO UCC FINANCING STATEMENT 

Description of Collateral 
 The
Collateral consists of all of Debtor’s right, title and interest in and to the following personal property: 
 All goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (except as noted below),
commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights
(whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and 

All Debtor’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for,
additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. 

Notwithstanding the foregoing, the Collateral does not include (i) any Intellectual Property; provided, however, the Collateral shall
include all Accounts and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such
Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Collateral
Agent’s security interest in such Accounts and such other property of Debtor that are proceeds of the Intellectual Property; and (ii) more than 65% of the total combined voting power of all classes of stock entitled to vote the shares of
capital stock (the “Shares”) of any Foreign Subsidiary, if Debtor demonstrates to Collateral Agent’s reasonable satisfaction that a pledge of more than sixty five percent (65%) of the Shares of such Subsidiary creates a
present and existing adverse tax consequence to Debtor under the U.S. Internal Revenue Code; (iii) Excepted Accounts and (iv) any license, lease or contract, in each case if the granting of a Lien in such license or contract is prohibited
by or would constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable under applicable law and (B) other than to the extent that any such term would be rendered
ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing or expiration of any such prohibition, such license or contract, as applicable, shall
automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the “Collateral.” 

Pursuant to the terms of a certain negative pledge arrangement with Collateral Agent and the Lenders, Debtor has agreed not to encumber any of
its Intellectual Property. 
 Capitalized terms used but not defined herein have the meanings ascribed in the Uniform Commercial Code in
effect in the State of New York as in effect from time to time (the “Code”) or, if not defined in the Code, then in the Loan and Security Agreement by and between Debtor, Secured Party and the other Lenders party thereto (as modified,
amended and/or restated from time to time). 

  
 55 

 USA PATRIOT ACT 

NOTICE 
 OF 

CUSTOMER IDENTIFICATION 
 IMPORTANT INFORMATION ABOUT
PROCEDURES FOR OPENING A NEW ACCOUNT 
 To help the government fight the funding of terrorism and money laundering activities, Federal
law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. 
 WHAT THIS MEANS FOR
YOU: when you open an account, we will ask your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver’s license or other identifying documents. 

  
 56 

					
	SQUARE 1 BANK	  	 	  	 
	 	  		  	AUTOMATIC DEBIT AUTHORIZATION
	Member FDIC	  	 	  	 

  

					
	To:  Square 1 Bank	  	 
	 		 
	Re:  Loan #	  	  
	  	 
	 
	You are hereby authorized and instructed to charge account No.
                     in the name of VISTERRA, INC. for facility fees, principal, interest and other payments due on above referenced loan as
set forth below and credit the loan referenced above.
	 
	
x Debit the Facility Fee as it becomes due according to the terms of the Loan and Security Agreement and any renewals or
amendments thereof.

	 
	
x Debit each interest payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or
amendments thereof.

	 
	
x Debit each principal payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or
amendments thereof.

	 
	
x Debit each payment for Lenders’ Expenses as it becomes due according to the terms of the Loan and Security Agreement
and any renewals or amendments thereof.

	 
	
This Authorization is to remain in full force and effect until revoked in writing.

 

  

					
	 Borrower
Signature
  
	  	
Date                    

 

	 	  	 

  
 57 

 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT 

THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of April 27, 2015 (the
“Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such
capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SQUARE 1 BANK, a
North Carolina banking corporation with an office located at 406 Blackwell Street, Suite 240, Durham, NC 27701 (“Bank” or “Square 1”) (each a “Lender” and collectively, the
“Lenders”), and VISTERRA, Inc., a Delaware corporation with offices located at One Kendall Square, Suite B3301, Cambridge, MA 02139 (“Borrower”). 

WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of September 9, 2014
(as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and 

WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the
terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows: 
  

	 	1.	Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement. 

  

	 	2.	The following Section 7.12 is hereby added to and made a part of the Loan Agreement: 

 7.12
D3 Research Agreement. Voluntarily terminate the D3 Research Agreement in such a manner as would require Borrower to make any payment to or at the direction of D3 or any of its Affiliates (as such term is defined in the D3 Research Agreement)
in connection with such voluntary termination pursuant to the terms of the D3 Research Agreement or make any payment to or at the direction of D3 or any of its Affiliates (as such term is defined in the D3 Research Agreement) in connection with the
termination of the D3 Research Agreement. 
  

	 	3.	Section 8.6 of the Loan Agreement is hereby amended and restated in its entirety as follows: 

8.6 Other Agreements. There is a default in any agreement to which Borrower or any of its Subsidiaries is a party with a third party or
parties (a) resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Two Hundred Fifty Thousand Dollars ($250,000.00), (b) in connection with
any lease of real property material to the conduct of Borrower’s business, if such default or failure to perform results in the right of another party to terminate such lease, (c) that could reasonably be expected to have a Material
Adverse Change, or (d) if such agreement is the D3 Research Agreement, such default (which for the purposes hereof shall include a material breach thereof) would cause D3 to have the right to terminate the D3 Research Agreement under
Section 13.1 thereof. 
  

	 	4.	Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order: 

“D3” is D3 Biomedical Sciences Institutes, a company incorporated in Singapore and having its principal office at 31 Biopolis
Way, 01-02A Nanos, Singapore, 138669. 

  
 58 

 “D3 Research Agreement” is that Agreement for Research Collaboration between
Borrower and D3, dated as of April 27, 2015, an executed, true and complete copy of which has been provided by Borrower to Collateral Agent and the Bank on or before the Amendment Date, together with (i) the license agreement between
Exploit Technologies Pte Ltd. and Borrower contemplated under Section 8.4, 8.5 and 8.6 of the aforementioned Agreement for Research Collaboration, a form of which license agreement has been provided to Collateral Agent and the Bank on or before
the Amendment Date, and (ii) a clinical research agreement contemplated by Section 2.3 of the aforementioned Agreement for Research Collaboration, so long as such clinical research agreement complies in all material respects with the terms
set forth on Schedule 4 to the aforementioned agreement and does not include any material liabilities or obligations of Borrower not covered by such terms; provided, however, that the D3 Research Agreement for the purposes of this Agreement shall
not include any amendment or modification thereto that may increase in any material respect the liabilities or obligations of Borrower or any of Borrower’s Subsidiaries thereunder, increase in any material respect the scope of transfer or
licensing of any of Borrower’s or its Subsidiaries’ Intellectual Property to D3 or another third party pursuant thereto, or decrease in any material respect any of the rights or benefits of Borrower or of its Subsidiaries thereunder or
pursuant thereto, unless such amendment or modification has been consented to by Collateral Agent and the Required Lenders. 
  

	 	5.	Section 13.1 of the Loan Agreement is hereby amended by amending and restating the definition of “Permitted Licenses” therein as follows: 

“Permitted Licenses” are (A) Exclusive License Agreements between Massachusetts Institute of Technology and Visterra,
Inc. disclosed on the Perfection Certificate on the Effective Date and the license granted by Borrower to the Bill & Melinda Gates Foundation pursuant to that certain Amended and Restated Letter Agreement, dated November 7, 2013,
between Borrower and the Bill & Melinda Gates Foundation, as amended on September 4, 2014, disclosed on the Perfection Certificate on the Effective Date, (B) license under the D3 Research Agreement, (C) licenses of open
source, over-the-counter software, prepackaged software and other software that is commercially available to the public, and (D) non-exclusive and exclusive licenses for the use of the Intellectual Property of Borrower or any of its
Subsidiaries entered into in the ordinary course of business, provided, that, with respect to each such license described in clause (D), (i) no Event of Default has occurred or is continuing at the time of such license; (ii) the
license constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge,
grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property; (iii) in the case of any exclusive license, (x) Borrower delivers ten (10) days’ prior written notice and a brief summary of the
terms of the proposed license to Collateral Agent and the Lenders and delivers to Collateral Agent and the Lenders copies of the final executed licensing documents in connection with the exclusive license promptly upon consummation thereof, and
(y) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory only as to discrete geographical areas outside of the United
States; and (iv) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to Borrower or any of its Subsidiaries are deposited into a Deposit Account that is governed by a
Control Agreement. 
  

	 	6.	Limitation of Amendment. 

  

	 	a.	The amendments set forth in Sections 2 through 5 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver
or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as
amended hereby. 

  

	 	b.	This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein
amended, are hereby ratified and confirmed and shall remain in full force and effect. 

  
 59 

	 	7.	To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows: 

 

	 	a.	Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the
extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing; 

 

	 	b.	Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; 

 

	 	c.	The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate
and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 

  

	 	d.	The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any material
law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or
subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower; 

  

	 	e.	The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license,
authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and 

 

	 	f.	This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by
bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights. 

 

	 	8.	Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject
matter and supersede prior negotiations or agreements. 

  

	 	9.	This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower’s payment of all
Lenders’ Expenses incurred through the date hereof, which may be debited (or ACH’d) from any of Borrower’s accounts. 

  

	 	10.	This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. 

 

	 	11.	This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York. 

[Balance of Page Intentionally Left Blank] 

  
 60 

 IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to the Loan
Agreement to be executed as of the date first set forth above. 
  

			
	BORROWER:
	
	VISTERRA, INC.
		
	By	 	 /s/ David Arkowitz

	Name:	 	David Arkowitz
	Title:	 	Chief Operting Officer and Chief Financial Officer
	
	COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC
		
	By:	 	 /s/ Mark Davis

	Name:	 	Mark Davis
	Title:	 	Vice President – Finance, Secretary & Treasurer
	
	LENDER:
	
	SQUARE 1 BANK
		
	By:	 	 /s/ Ashley N. Pittman

	Name:	 	Ashley N. Pittman
	Title:	 	Vice President

 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT 

THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of September 29, 2015 (the
“Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such
capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SQUARE 1 BANK, a
North Carolina banking corporation with an office located at 406 Blackwell Street, Suite 240, Durham, NC 27701 (“Bank” or “Square 1”) (each a “Lender” and collectively, the
“Lenders”), and VISTERRA, Inc., a Delaware corporation with offices located at One Kendall Square, Suite B3301, Cambridge, MA 02139 (“Borrower”). 

WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of September 9, 2014
(as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and 

WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the
terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows: 
  

	 	1.	Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement. 

  

	 	2.	Section 2.2(a)(ii) is hereby amended and restated in its entirety as follows: 

 (ii)
Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to make term loans to Borrower in an aggregate amount up to Two Million Five Hundred Thousand Dollars ($2,500,000)
according to each Lender’s Term B Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a “Term B Loan”, and collectively as the “Term B Loans”). After
repayment, no Term B Loan may be re-borrowed. 
  

	 	3.	Section 2.2(a) is hereby amended by adding the following subsection (iii) thereto: 

(iii) Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period, to
make term loans to Borrower in an aggregate amount up to Two Million Five Hundred Thousand Dollars ($2,500,000) according to each Lender’s Term C Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to
singly as a “Term C Loan”, and collectively as the “Term C Loans”; each Term A Loan, Term B Loan or Term C Loan is hereinafter referred to singly as a “Term Loan” and the Term A Loans, the Term B
Loans and the Term C Loans are hereinafter referred to collectively as the “Term Loans”). After repayment, no Term C Loan may be re-borrowed. 
  

	 	4.	Section 2.2(b) is hereby amended and restated in its entirety as follows: 

 (b)
Repayment. Borrower shall make monthly payments of interest only in arrears commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on
the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall
make consecutive equal monthly payments (which payments shall be 

 
of both principal and interest as set forth in the amortization tables attached to the applicable Disbursement Letter), in arrears, to each Lender, as calculated by Collateral Agent (which
calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal
to thirty-six (36) months (and in the case of Term C Loans, if the Funding Date of Term C Loans is after October 1, 2015, the number of Payment Dates after such Funding Date and through and including the Maturity Date). All unpaid
principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d). 

 

	 	5.	Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order: 

“Term C Loan” is defined in Section 2.2(a)(iii). 

“Third Draw Period” is the period commencing on September 29, 2015 and ending on the earlier of
(i) December 31, 2015 and (ii) the occurrence of an Event of Default. 
  

	 	6.	Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows: 

“Amortization Date” is, with respect to each Term Loan, October 1, 2015; provided, however, if the Funding Date of the
Term C Loans is after October 1, 2015, the Amortization Date with respect to the Term C Loans shall be the first Payment Date after the Funding Date of the Term C Loans. 

“Term Loan” is defined in Section 2.2(a)(iii). 
  

	 	7.	Schedule 1.1 to the Loan Agreement is hereby amended and restated in its entirety as set forth on Exhibit A hereto. 

  

	 	8.	Exhibit D (Form of Secured Promissory Note) to the Loan Agreement is hereby amended and restated in its entirety as set forth on Exhibit B hereto. 

 

	 	9.	Limitation of Amendment. 

  

	 	a.	The amendments set forth in Sections 2 through 8 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver
or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as
amended hereby. 

  

	 	b.	This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein
amended, are hereby ratified and confirmed and shall remain in full force and effect. 

  

	 	10.	To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows: 

 

	 	a.	Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the
extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing; 

 

	 	b.	Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; 

  
 2 

	 	c.	The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate
and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 

  

	 	d.	The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any material
law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or
subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower; 

  

	 	e.	The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license,
authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and 

 

	 	f.	This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by
bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights. 

 

	 	11.	Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject
matter and supersede prior negotiations or agreements. 

  

	 	12.	This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto, (b) Borrower’s payment of all
Lenders’ Expenses incurred through the date hereof, which may be debited (or ACH’d) from any of Borrower’s accounts and (c) the funding of the Term B Loans in accordance with the provisions of the Loan Agreement as amended
hereby. 

  

	 	13.	This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. 

 

	 	14.	This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York. 

[Balance of Page Intentionally Left Blank] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to the Loan
Agreement to be executed as of the date first set forth above. 
 BORROWER: 

VISTERRA, INC. 
  

			
	 By
	 	 /s/ David Arkowitz

	Name:	 	David Arkowitz
	Title:	 	COO and CFO

 COLLATERAL AGENT AND LENDER:

 OXFORD FINANCE LLC 
  

			
	 By
	 	 /s/ Mark Davis

	 Name:
	 	 Mark Davis

	 Title:
	 	
Vice President – Finance, Secretary & Treasurer

 LENDER: 
 SQUARE 1 BANK 

 

			
	 By
	 	 /s/ Ashley N. Pittman

	 Name:
	 	 Ashley N. Pittman

	 Title:
	 	 Vice President

 [Signature Page to Second Amendment to Loan and Security Agreement] 

 Exhibit A 

SCHEDULE 1.1 

Lenders and Commitments 

Term A Loans 
  

					
	 Lender
	  	Term Loan Commitment	  	Commitment Percentage
	 OXFORD FINANCE LLC
	  	$2,500,000	  	50%
	 SQUARE 1 BANK
	  	$2,500,000	  	50%
	 TOTAL
	  	$5,000,000	  	100.00%

 Term B Loans 
  

					
	 Lender
	  	Term Loan Commitment	  	Commitment Percentage
	 OXFORD FINANCE LLC
	  	$1,250,000	  	50%
	 SQUARE 1 BANK
	  	$1,250,000	  	50%
	 TOTAL
	  	$2,500,000	  	100.00%

 Term C Loans 
  

					
	 Lender
	  	Term Loan Commitment	  	Commitment Percentage
	 OXFORD FINANCE LLC
	  	$1,250,000	  	50%
	 SQUARE 1 BANK
	  	$1,250,000	  	50%
	 TOTAL
	  	$2,500,000	  	100.00%

 Aggregate (all Term Loans) 
  

					
	 Lender
	  	Term Loan Commitment	  	Commitment Percentage
	 OXFORD FINANCE LLC
	  	$5,000,000	  	50%
	 SQUARE 1 BANK
	  	$5,000,000	  	50%
	 TOTAL
	  	$10,000,000	  	100.00%

 Exhibit B 

Form of Secured Promissory Note 

SECURED PROMISSORY NOTE 

(Term [A][B][C] Loan) 
  

			
	
$                            
            
	 	Dated: [DATE]

 FOR VALUE RECEIVED, the undersigned, VISTERRA, INC., a [Delaware] corporation with offices located at One
Kendall Square, Suite B3301, Cambridge, MA 02139 (“Borrower”) HEREBY PROMISES TO PAY to the order of [OXFORD FINANCE LLC][SQUARE 1 BANK] (“Lender”) the principal amount of
[                    ] MILLION DOLLARS
($                    ) or such lesser amount as shall equal the outstanding principal balance of the Term [A][B][C] Loan made to
Borrower by Lender, plus interest on the aggregate unpaid principal amount of such Term [A][B][C] Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated September 9, 2014 by and among Borrower, Lender,
Oxford Finance LLC, as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). If not sooner paid, the entire
principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the
Loan Agreement. 
 Principal, interest and all other amounts due with respect to the Term [A][B][C] Loan, are payable in lawful money
of the United States of America to Lender as set forth in the Loan Agreement and this Secured Promissory Note (this “Note”). The principal amount of this Note and the interest rate applicable thereto, and all payments made with
respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note. 

The Loan Agreement, among other things, (a) provides for the making of a secured Term [A][B][C] Loan by Lender to Borrower, and
(b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events. 
 This Note may not be
prepaid except as set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement. 
 This Note and the obligation
of Borrower to repay the unpaid principal amount of the Term [A][B][C] Loan, interest on the Term [A][B][C] Loan and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement. 

Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery,
performance and enforcement of this Note are hereby waived. 
 Borrower shall pay all reasonable fees and expenses, including, without
limitation, reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower’s obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York. 

The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent. Notwithstanding
anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an
interest in the obligation. Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other
claim to or interest in this Note on the part of any other person or entity. 
 [Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers
thereunto duly authorized on the date hereof. 
  

			
	BORROWER:
	
	VISTERRA, INC.
		
	By	 	  

	Name:	 	  

	Title:EX-10.14

 Exhibit 10.14 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

 

											
	AWARD/CONTRACT	 	1.	  	THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)	  	u  	  	RATING	  	 PAGE OF PAGES

      1             
70

											
	
  2.    CONTRACT (Proc. Inst. Ident.) NO.

  HHSO100201500018C
	  	 3.    EFFECTIVE DATE

See Block 20C OS160569
	  	
4.    REQUISITION/PURCHASE REQUEST/PROJECT

       NO.

											
	   6.    ISSUED BY
	 	 CODE  
	 	
ASPR-BARDA
	  	 6.    ADMINISTERED BY (If other than Item 5)
	 	 CODE  
	 	 ASPR-BARDA01

			
	  

  ASPR-BARDA
   200 Independence Ave., S.W.

  Room. 640-G
   Washington DC 20201
	  	  

ASPR-BARDA
 330 Independence Ave., SW, Room. G644

Washington DC 20201

											
	  7.    NAME AND ADDRESS OF CONTRACTOR (No., Street, City, County, State and ZIP Code)	  	
8.    DELIVERY

        ̈  FOB
ORIGIN                    x  OTHER (See below)

	  

  VISTERRA, INC 1171920
   1 KENDALL SQ ST
B3301
   CAMBRIDGE MA 02139562
	 		 		  	 9.    DISCOUNT
FOR PROMPT PAYMENT
  

	 	  	 10.    SUBMIT NOTICES

(4 copies unless otherwise specified)
 TO THE ADDRESS SHOWN
IN
	 	  
   u  
	 	  ITEM
	  CODE        1171920	 	  FACILITY CODE            	 	 	  	 	 	 	 	 

											
	   11.    SHIP TO/MAKE FOR
	 	 CODE  
	 	 HHS/OS/ASPR
	  	 12.    PAYMENT WILL MADE BY
	 	 CODE  
	 	     PSC

			
	  

  HHS/OS/ASPR
   200 C St SW

  Washington DC 20201
	  	  

PSC
 Program Supper Center

5600 Fishers Lane
 Room 17-21

Rockville MD 20852
  

	13.    AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION	  	14. ACCOUNTING AND APPROPRIATION DATA
	        
 ̈  10 U.S.C. 2304(c)(            )             ̈  41 U.S.C 253(c)(            )	  	            2015.1994045.25505

											
	  15A ITEM NO.  	  	 15B SUPPLIES/SERVICES
	  	 15C

  QUANTITY  
	  	 15D

  UNIT  
	  	  15E UNIT PRICE  	  	
  15F AMOUNT  

	 	  	 Continued
	  	 	  	 	  	 	  	 

					
	15G. TOTAL AMOUNT OF CONTRACT	  	  u  	  	            $29,149,061.00
	16. TABLE OF
CONTENTS

															
	 (X) 	  	 SEC 	  	 DESCRIPTION 	  	 PAGE(S) 	 	 (X) 	  	 SEC 	  	DESCRIPTION	  	PAGE(S)
	        PART I – THE SCHEDULE	 	        PART II – CONTRACT CLAUSES
	 	  	A	  	SOLICITATION/CONTRACT FORM	  	 	 	 	  	I	  	 	  	 
	 	  	B	  	SUPPLIES OR SERVICES AND PRICES/COSTS	  	 	 	 	  	PART III – LIST OF DOCUMENTS EXHIBITS AND OTHER ATTACH
	 	  	C	  	DESCRIPTION/SPECS./WORK STATEMENT	  	 	 	 	  	J	  	LIST OF ATTACHMENTS	  	 
	 	  	D	  	PACKAGING AND MARKING	  	 	 	 	  	PART IV – REPRESENTATIONS AND INSTRUCTIONS
	 	  	E	  	INSPECTION AND ACCEPTANCE	  	 	 	 	  	K	  	REPRESENTATIONS CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS	  	 
	 	  	F	  	DELIVERIES OR PERFORMANCE	  	 	 	 	  	  	  	 
	 	  	G	  	CONTRACT ADMINISTRATION DATA0	  	 	 	 	  	L	  	INSTRS. CONDS. AND NOTICES TO OFFERORS	  	 
	 	  	H	  	SPECIAL CONTRACT REQUIREMENTS	  	 	 	 	  	M	  	EVALUATION FACTORS FOR AWARD	  	 

			
	CONTRACTING OFFICER WILL COMPLETE ITEM 17 (SEALED BID OR
NEGOTIATED PROCUREMENT) OR 18 (SEALED-BID PROCUREMENT) AS APPLICABLE
	 17.   ̈  CONTRACTOR’S NEGOTIATED AGREEMENT (Contractor is required to sign this document and return        copies to issuing office.) Contractor
agrees to furnish and deliver all items or perform all services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject
to and governed by the following documents: (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein. (Attachments are
listed herein.)
	  	 18.   ̈  SEALED-BID AWARD (Contractor is not required to sign this document.) Your bid on Solicitation Number

including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the terms listed above and on
any continuation sheets. This award constitutes the contract which consists of the following documents: (a) the Government’s solicitation and your bid, and (b) this award/contract. No further contractual document is necessary. (Block 18 should
be checked only when awarding a sealed-bid contract.)

	
19A. NAME AND TITLE OF SIGNER (Type or print)

DAVID ARKOWITZ, CHIEF OPERATING OFFICER & CFO, VISTERRA
	  	 20A. NAME OF CONTRACTING OFFICER

LYNDA M. BROWN

											
	   19B. NAME OF CONTRACTOR

         VISTERRA, INC.
	 	 19C. DATE SIGNED  

 
 9 / 28 / 2015
	 	  20B. UNITED STATES OF AMERICA	  	 20C. DATE SIGNED  

 
 /s/ 9-28-15

	BY	 	     /s/ David Arkowitz
	 	 	 	  BY  	  	     /s/ Lynda Brown
	  	 
	 	 	 (Signature of person authorized to sign)

 
	 	 	 	 	  	 (Signature of Contracting Officer)

 
	  	 
	   AUTHORIZED FOR LOCAL REPRODUCTION

  Previous edition is NOT usable
	 		  	 STANDARD FORM 26 (REV. 3/2013)

Prescribed by GSA – FAR (48 CFR) 53.214(a)

													
	
CONTINUATION SHEET        
	  	 REFERENCE NO. OF DOCUMENT BEING
CONTINUED
 HHSO100201500018C
	  	PAGE    OF
	  	  	2               	  	70

													
	
	 NAME OF OFFEROR OR CONTRACTOR

VISTERRA, INC. 1171920

	 ITEM NO.

 
 (A)
	  	 SUPPLIES/SERVICES

 
 (B)
	  	 QUANTITY

 
 (C)
	  	 UNIT

 
 (D)
	  	 UNIT PRICE

 
 (E)
	  	 AMOUNT

 
 (F)

	 	 		 	 	
	 1

 
	  	 Tax ID Number: 32-0225657

DUNS Number: 069553049
 Visterra Cost Plus Fixed Fee Contract
award.
 Visterra Initial Proposal dated June 2, 2015, under BAA

13-100-SOL-00019.
 CAGE Code: 6G8T0

NAICS: 541711 Size Std: 500
 Appr. Yr.: 2015 CAN: 1994045 Object
Class: 25505
 FOB: Destination
 Period of Performance:
10/01/2015 to 09/14/2020
  
 ASPR-15-08134 — Visterra Inc — base period

funds for the advance development of VIS410
 Obligated Amount:
$29,149,061.00
  
	  	 	  	 	  	 	  	 29,149,061.00

 

																	
			
	 AUTHORIZED FOR LOCAL REPRO
	  		  	 OPTIONAL FORM 336 (4-86)

Sponsored by GSA

FAR (48 CFR) 53.110

  
 2 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS 

 

	B.1.	BRIEF DESCRIPTION OF SUPPLIES OR SERVICES 

 This contract is for the advanced development of VIS410.
Visterra, Inc. will develop a robust data package to support a BLA for the licensure of VIS410 as a treatment for severe/hospitalized influenza and patients at high risk of complications due to influenza infection. Options are also included for the
treatment of pediatrics. 
  

	1.	B.2. TYPE OF CONTRACT AND ESTIMATED COST 

  

	a.	This award is a COST REIMBURSEMENT (CR) type contract: Cost Plus Fixed Fee (CPFF) contract for Research and Development, with a 40 month Base Period. There are six (6) options that may or may not be exercised. The
total period of performance (PoP) is not to exceed five (5) years. Optional Services (CLINs 0007, 0009, 0010, 0011, and 0012) and Optional Data (CLIN 0008) will have staggered PoPs. 

 

	b.	The total estimated dollar value of the base period is $29,149,061.00. 

	 	The total estimated dollar value of the six options is $175,306,992.00. 

	 	The total estimated dollar value of this contract is $204,456,053.00 ($29,149,061.00 + $175,306,992.00) (Base Period + Options). 

 

	c.	Base Period of Performance: September 30, 2015 through January 31, 2019 

  

											
	 CLIN
	  	 Item Description
	  	 Cost
	  	 Fixed Fee
	  	 Cost Plus 
Fixed Fee
	 
	 0001
	  	[**]	  	[**]	  	[**]	  	 	[**]	  
	 0002
	  	[**]	  	[**]	  	[**]	  	 	[**]	  
	 0003
	  	[**]	  	[**]	  	[**]	  	 	[**]	  
	 0004
	  	[**]	  	[**]	  	[**]	  	 	[**]	  
	 0005
	  	[**]	  	[**]	  	[**]	  	 	[**]	  
	 0006
	  	[**]	  	[**]	  	[**]	  	 	[**]	  
	 Total Estimated Dollar Value (Base PoP)
	  		  	$	29,149,061.00	  

  

	d.	The total base dollar amount for this contract shall not exceed $29,149,061.00 and the Government will not be responsible for any Contractor incurred costs that exceed this amount unless a modification to
the contract is approved/signed by the Contracting Officer which expressly increases this amount. For further provisions on funding, see the LIMITATION OF COSTS clause referenced in Part II, Contract Clauses. 

  
 3 

 Visterra, Inc. 

HHSO100201500018C 
  

	e.	It is estimated that the currently allotted funds for the base PoP will cover performance of the contract through January 31, 2019. (See F.1. Period of Performance). 

 

	f.	The Contractor shall maintain records of all contract costs and such records shall be subject to the Audit and Records-Negotiation and Final Decisions on Audit Findings clauses of the General Clauses. 

 

	B.3.	OPTION PRICES (Cost Reimbursement CLINs and Firm Fixed Price CLIN 0008) 

  

	a.	Unless the Government exercises its option pursuant to the option clause referenced in I.5. ADDITIONAL CONTRACT CLAUSES, this contract consists only of the Base Period specified in the Statement of Work as defined in
SECTIONS C and F, for the price set forth under B.2. of this contract. 

  

	b.	Pursuant to FAR Clause 52.217-9, Option to Extend the Term of the Contract set forth in Part II, Section I. of this contract, the Government may, by unilateral contract modification, require the Contractor to
perform additional options set forth in the Statement of Work and also defined in Sections C and F of the contract. If the Government exercises this option, notice must be given at least [**] days prior to the expiration date of this contract.
Delivery will commence on an agreed upon schedule if an option is exercised by the Government. The price of this contract will be increased as set forth in paragraph c., below. 

 

	c.	Upon the delivery and acceptance of the Option Services or Data described in SECTION C of the contract and identified in the schedule of charges below, the Government shall pay the Contractor on a Cost
Reimbursement Price basis set forth below: 

 Option 1-Optional Services 1 [**] 2016 [**] 

(PoP flexible depending upon start) [**] 
  

											
	 CLIN
	  	 Item Description
	  	 Cost
	 	 Fixed Fee
	 	 Cost Plus 
Fixed Fee
	 
	 0007
	  	[**]	  	[**]	 	[**]	 	 	[	**] 
	 Total Estimated Dollar Value Optional Service 1
	 		 	$	[	**] 

 CLIN 0007 Go/No Go Decision Point: Interim Review 

No-Go: [**]. 
 Criteria to Start: [**] 

Optional Data Purchase: 
  

											
	 CLIN
	  	 Item Description
	  	 Firm 
Fixed Price
	 	 Unit of 
Issue
	 	 Firm 
Fixed Price
	 
	 0008
	  	[**]	  	[**]	 	[**]	 	 	[	**] 
			
	 Total Estimated Dollar Value (Optional Data)
	 		 	$	[	**] 

  
 4 

 Visterra, Inc. 

HHSO100201500018C 
  

 Option 2-Optional Services 2 ([**] 

(PoP flexible depending upon start) [**] 
  

											
	 CLIN
	  	 Item Description
	  	 Cost
	 	 Fixed Fee
	 	 Cost Plus 
Fixed Fee
	 
	 0009
	  	[**]	  	[**]	 	[**]	 	 	[	**] 
	 Total Estimated Dollar Value Optional Service 2
	 		 	$	[	**] 

 CLIN 0009 Criteria to Start: [**]. 

Option 3-Optional Services 3 ([**] 2018 [**] 
 (PoP
flexible depending upon start) [**] 
  

											
	 CLIN
	  	 Item Description
	  	 Cost
	 	 Fee
	 	 Cost Plus

Fixed Fee
	 
	 0010
	  	[**]	  	[**]	 	[**]	 	 	[	**] 
	 Total Estimated Dollar Value Optional Service 3
	 		 	$	[	**] 

 CLIN 0010 Go/No Go Decision Point: Interim Review. 

No-Go: [**]. 
 Criteria to Start: [**]. 

Option 4-Optional Services 4 [**] 2018 [**] 
 (PoP
flexible depending upon start) [**] 
  

											
	 CLIN
	  	 Item Description
	  	 Cost
	 	 Fee
	 	 Cost Plus 
Fixed Fee
	 
	 0011
	  	[**]	  	[**]	 	[**]	 	 	[	**] 
	 Total Estimated Dollar Value Optional Service 4
	 		 	$	[	**] 

 CLIN 0011 Criteria to Start: [**]. 

Option 5-Optional Services 5 [**] 2018 [**]  

(PoP flexible depending upon start) [**] 
  

											
	 CLIN
	  	 Item Description
	  	 Cost
	 	 Fee
	 	 Cost Plus 
Fixed Fee
	 
	 0012
	  	[**]	  	[**]	 	[**]	 	 	[	**] 
	 Total Estimated Dollar Value Optional Service 5
	 		 	$	[	**] 

  
 5 

 Visterra, Inc. 

HHSO100201500018C 
  

 CLIN 0012 Criteria to Start: [**]. 

 

	 	B.4.	ADVANCE UNDERSTANDINGS 

 1. Publications: Any manuscript or scientific meeting
abstract containing data generated under this contract must be submitted to the Contracting Officer and Contracting Officer’s Representative for review no less than thirty (30) Calendar days for manuscripts and fifteen (15) Calendar
days for abstracts before submission for public presentation or publication. Contract support shall be acknowledged in all such publications. A “publication” is defined as an issue of printed material offered for distribution or any
communication or oral presentation of information. Refer to H.13. 
 2. Export control notification: Contractor is responsible for
ensuring compliance with all export control laws and regulations that may be applicable to the export of and foreign access to their proposed technologies. Contractor may consult with the Department of State with any questions regarding the
International Traffic in Arms Regulation (ITAR) (22 CRF Parts 120-130) and /or the Department of Commerce regarding the Export Administration Regulations (15 CRF Parts 730-774). 

3. Man-in-Plant: With [**] days advanced notice to the Contractor, in writing from the Contracting Officer, the Government may place one
(1) man-in-plant in the Contractor’s facility. The individual shall be subject to the Contractor’s policies and procedures regarding security and facility access at all times while in the Contractor’s facility. 

4. Subcontracts, Consultants Equipment and Materials: Except as set forth below, award of any FFP subcontract that exceeds $[**]
or [**]% of the total estimated cost of the contract, whichever is greater; or consulting agreements, cost reimbursement contracts, 

  
 6 

 Visterra, Inc. 

HHSO100201500018C 
  

 equipment or material purchase shall require Contracting Officer Approval (COA). Award of
this contract shall constitute a COA for the following consulting agreement for the Base Period, which was presented in the Cost Proposal and evaluated during negotiations: 
  

					
	 Consultant
	  	 Base Period Cost
	 
	 [**]
	  	$	[	**] 

 NOTE: Visterra, Inc. will be required to notify the Contracting Officer and keep a COA log that contains the
SOW, Master Consulting Services Agreement, and any proposed resumes of key subcontractor personnel. 
 5. All files may be audited by
the US Government at any time, during normal business hours, with a three (3) business day written notice. Subject to Section B.4.4 above, Contracting Officer Authorization (COA) is required for all subcontracts and consulting agreements and
supporting documentation required by FAR 52.244-2 must be submitted with the request. After receiving written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract and consulting agreement shall be
provided to the Contracting Officer within thirty (30) days. 
 6. Disclosure of information/data that is sensitive in nature, in
whole or in part, by the Contractor can only be made after the Contractor receives prior written approval from the Contracting Officer. Whenever the Contractor is uncertain with regard to the proper handling of information/data under the contract,
the Contractor shall obtain a written determination from the Contracting Officer. Notwithstanding the foregoing, Contractor may share sensitive information/data with subcontractors, consultants, advisors and other affiliated individuals for purposes
of performing Contractor’s obligations, duties and other undertakings of this contract. 
 Notwithstanding the foregoing, such
information/data shall not be deemed of a sensitive nature with respect to the Contractor for purposes of this contract if such information/data: (a) was already known to the Contractor; (b) was generally available or known, or was
otherwise part of the public domain, at the time of its disclosure to the Contractor; (c) became generally available or known, or otherwise became part of the public domain, after its disclosure to, or, with respect to the information/data by,
the Contractor through no fault of the Contractor; (d) was disclosed to the Contractor, other than under an obligation of confidentiality or non-use, by a third party who had no obligation to the Government that controls such information/data
not to disclose such information/data to others; or (e) was independently discovered or developed by the Contractor, as evidenced by its written records, without the use of information/data belonging to the Government. 

Contractor may disclose information/data of a sensitive nature provided by the Government to the extent that such disclosure is: (a) made
in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial or local governmental or regulatory body of competent jurisdiction; provided, however, that the
Contractor shall first have given immediate notice to the Government and give the Government a reasonable opportunity to quash such order and/or to obtain a protective order 

  
 7 

 Visterra, Inc. 

HHSO100201500018C 
  

 
requiring that the information/data of a sensitive nature that is the subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which
the order was issued. The Government has the right to elect any and all remedies available to it in responding to any such order or similar legal document; and provided further that if a disclosure order is not quashed or a protective order
is not obtained, the information/data disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order; (b) made by the
Contractor to the Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval; provided, however, that all such information will be provided in advance to the Contracting Officer for review
and reasonable measures shall be taken to assure confidential treatment of such information/data. Notwithstanding the foregoing, Contractor may disclose information/data sensitive to the Government if such disclosure is deemed by Contractor legal
counsel to be required for purposes of complying with laws, rules or regulations of other governmental agencies, such as the Food and Drug Administration or the Securities and Exchange Commission. In the event of any such required disclosure,
Contractor will notify the Contracting Officer in advance. 
 7. The Government acknowledges that research cell banks, clones of cell
banks, end process cell banks, working cell banks and master cell banks (hereinafter “Cell Banks”) prepared and/or used in the performance of this contract include and reflect intellectual property developed by the Contractor at its
expense with private funds and prior to commencement of this contract. The Government retains the right to require the Contractor to ship any Cell Banks prepared under this contract to the Government following completion of the contract. However, to
protect limited rights data imbedded in the Cell Banks, the Contractor will include in the packaging for any such delivery the Limited Rights Notice prescribed by Alternate II (Dec 2007) of FAR 52.227-14 (the “Notice”) and legends warning
Government employees of criminal penalties under 18 USC 1905 for releasing the information outside the Government and stating that release under the Freedom of Information Act, 5 USC 552 et. seq., is prohibited. The Government agrees to comply with
and to use the Cell Banks strictly in accordance with the terms of the Notice. The Government will not direct the Contractor to ship Cell Banks to any location outside of the Government unless the Contractor and the Government mutually agree to such
a transfer. 
  

	B.5.	DIRECT COSTS 

  

	a.	Items Unallowable Unless Otherwise Provided 

 Notwithstanding Clause 52.216-7, ALLOWABLE
COST AND PAYMENT incorporated in this contract, unless authorized in writing by the Contracting Officer, the costs of the following items or activities shall be unallowable as direct costs: 

 

	 	(1)	Conferences and Meetings unrelated to performance of this contract; 

  

	 	(2)	Food for Meals, Light Refreshments, and Beverages; 

  

	 	(3)	Promotional Items [includes, but is not limited to: clothing and commemorative items such as pens, mugs/cups, folders/folios, lanyards, and conference bags that are sometimes provided to visitors, employees,
grantees, or conference attendees]; 

  
 8 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	(4)	Acquisition, by purchase or lease, of any interest in real property; 

  

	 	(5)	Special rearrangement or alteration of facilities; 

  

	 	(6)	Purchase or lease of any item of general purpose office furniture or office equipment regardless of dollar value. (General purpose equipment is defined as any items of personal property which are usable for
purposes other than research, such as office equipment and furnishings, pocket calculators, etc.); 

  

	 	(7)	Travel to attend general scientific meetings; 

  

	 	(8)	Consultant Costs; 

  

	 	(9)	Accountable Government Property (defined as non-expendable personal property with an acquisition cost of $3,000 or more) and “sensitive items” (defined as items of personal property (supplies and equipment
that are highly desirable and easily converted to personal use)), regardless of acquisition value; 

  

	 	(10)	Printing Costs (as defined in the Government Printing and Binding Regulations; and 

  

	 	(11)	Overtime (premium) compensation. 

  

	b.	Items requiring written Contracting Officer’s Authorization prior to approval: 

  

	 	1)	Entering into certain types of subcontract arrangements (See B.4.4 for specific obligations). Note that most consulting agreements require approval. 

 

	 	2)	Foreign Travel (see Subparagraph c.1); 

  

	 	3)	Light Refreshment and Meal Expenditures - Requests to use contract funds to provide light refreshments and/or meals to either federal or nonfederal employees must be submitted to the Contracting Officer’s
Representative (COR), with a copy to the Contracting Officer, at least six (6) weeks in advance of the event and are subject to “HHS Policy on Promoting Efficient Spending: Use of Appropriate Funding for Conferences and Meetings, Food and
Promotional Items and Printing and Publications.” The request shall contain the following information: (a) name, date, and location of the event at which the light refreshments and/or meals will be provide; (b) a brief description of
the purpose of the event; (c) a cost breakdown of the estimated light refreshments and/or meals costs; (d) the number of nonfederal and federal attendees receiving light refreshments and/or meals; and (e) if the event will be held at
a government facility. 

  

	 	4)	Clinical Study Protocols- a draft must be submitted for review and approval in advance of IRB submission. 

  

	 	5)	Animal Study Protocols- a draft must be submitted for review and approval in advance of IACUC submission. 

  

	c.	Travel Costs 

  

	 	1)	Foreign Travel: Total expenditures for foreign travel (transportation, lodging, subsistence, and incidental expenses) incurred in direct performance of this contract shall not exceed $ [**] without the
prior written approval of the Contracting Officer. 

  

	 	2)	 The Contractor shall invoice and be reimbursed for all travel costs in accordance with

  
 9 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	
Federal Acquisition Regulations (FAR) 31.2 - Contracts with Commercial Organizations, Subsection 31.205-46, Travel Costs 

In the event foreign travel is required, requests for foreign travel must be submitted at least four weeks in advance and shall contain the
following: 
  

	 	(a)	meeting (s) and place(s) to be visited, with costs and dates; 

  

	 	(b)	name(s) and title(s) of Contractor personnel to travel and their functions in the contract project; 

  

	 	(c)	contract purposes to be served by the travel; 

  

	 	(d)	how travel of Contractor personnel will benefit and contribute to accomplishing the contract project, or will otherwise justify the expenditure of ASPR contract funds; 

 

	 	(e)	how such advantages justify the costs for travel and absence from the project of more than one person if such are suggested; and 

  

	 	(f)	what additional functions may be performed by the travelers to accomplish other purposes of the contract and thus further benefit the project. 

  
 10 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT 

 

	C.1.	STATEMENT OF WORK 

  

	a.	Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed
to perform the Statement of Work, dated August 18, 2015, set forth below: 

 Statement of Work (SOW) 

Independently and not as an agent of the Government, Visterra shall be required to furnish all the necessary services, qualified personnel, material,
equipment, and facilities, not otherwise provided by the Government, as needed to perform the SOW submitted in response to BAA-13-100-SOL-00019. The Government reserves the right to modify the milestones, progress, schedule, budget, or product to
add or delete products, process, or schedule as need may arise. Because of the nature of this R&D contract and complexities inherent in this and prior programs, at designated milestones the Government will evaluate whether work should be
redirected, removed, or whether schedule or budget adjustments should be made. In any event, the Government reserves the right to change product, process, schedule, or event to add or delete part or all of these elements as the needs arise. 

Statement of Objectives and Overall Scope 
 The overall
objective is to achieve US licensure for VIS410, a fully human IgG1 antibody directed against the HA protein of the influenza A virus, for treatment of influenza A infection, including seasonal strains and potential pandemic strains such as H5N1,
H7N9 or H10N8 in hospitalized patients and patients at high risk of complications. As such, the scope of work includes the proposed clinical studies, clinical and commercial supply manufacturing plans, BLA-enabling CMC activities, and RDT
nonclinical studies. The proposal includes a base and option periods; however, Visterra will conduct the option periods (Phase 3 clinical manufacturing and Phase 2b) concurrently based upon the acceptability of the Phase 2a challenge and
uncomplicated studies. Similarly, Visterra will conduct the option periods (Phase 3 and pediatric studies) concurrently based upon the acceptability of the Phase 2b clinical data. Conducting the Phase 3 and pediatric studies
concurrently will expedite the development of VIS410 for use in target populations and is gated upon positive efficacy data in the Phase 2b study. 

Base Contract (Months 1-40) 
  

							
	 SOW
	  	 WBS
	 	  	 Tasks

	 3.2.1
	  	 	1.1.1.1	  	  	Program Work Plans.
	3.2.2	  	 	1.1.2	  	  	Program Communication and Reporting Plan. The Project Communication and Reporting Plan will be prepared and implemented. This plan will prescribe the methods and schedule for communications and reporting within Visterra
and its subcontractors and consultants as well as with our government sponsors.
	3.2.3	  	 	1.1.3	  	  	Risk Management. The Risk Management Plan for this project will be adapted from Visterra’s existing plan. Reviews of existing and newly identified risks will be reviewed monthly and mitigations will be logged in the
Risk Register.

  
 11 

 Visterra, Inc. 

HHSO100201500018C 
  

					
	3.2.4	  	1.1.4	  	Earned Value Management System (EVMS).
	3.2.5	  	1.2.2	  	Nonclinical Toxicology: Safety. The following studies will be conducted: (1) [**].
	3.2.6	  	1.3.3	  	Nonclinical-Efficacy and Safety. [**].
	3.2.7	  	1.4.2	  	Clinical: Phase 2. The following study will be conducted: Phase 2a study in outpatients with uncomplicated influenza.
	3.2.8	  	1.5.1	  	Regulatory: [**].
	3.2.9	  	1.6.1	  	CMC: Chemistry (Formulation). [**].
	3.2.10	  	1.6.2	  	CMC: Process Validation. The following activities will be performed: ([**].
	3.2.11	  	1.6.3	  	Clinical Supply Manufacturing: Phase 2.
	3.2.12	  	1.6.4	  	CMC: Creation of a Working Cell Bank
	3.2.13	  	1.6.5	  	CMC: Controls (Analytical/Validation). [**].

 Option 1 (Months [**] 
  

					
	 SOW
	  	 WBS
	  	 Tasks

	 3.3.1
	  	1.1	  	Program Management.
	 3.3.2
	  	1.4.2	  	Clinical: [**].
	 3.3.3
	  	1.5.1	  	Regulatory: [**].

 Option 2 (Months [**] 
  

					
	 SOW
	  	 WBS
	  	 Tasks

	 3.4.1
	  	1.1	  	Program Management.
	 3.4.2
	  	1.5.1	  	Regulatory: [**].
	 3.4.3
	  	1.6.3	  	CMC: [**].

 Option 3 (Months [**] 
  

					
	 SOW
	  	 WBS
	  	 Tasks

	3.5.1	  	1.1	  	Program Management.
	3.5.2	  	1.4.3	  	Clinical: [**]

  
 12 

 Visterra, Inc. 

HHSO100201500018C 
  

					
	 SOW
	  	 WBS
	  	 Tasks

	3.5.3	  	1.5.1	  	Regulatory: [**].
	3.5.4	  	1.6.2	  	CMC: Process Validation. [**].
	3.5.5	  	1.6.5	  	CMC: [**].

 Option 4 (Months [**] 
  

					
	 SOW
	  	 WBS
	  	 Tasks

	 3.6.1
	  	1.1	  	Program Management.
	 3.6.2
	  	1.4.4	  	Clinical: [**].
	 3.6.3
	  	1.5.1	  	Regulatory: [**]

 3.7 Option 5 (Months [**] 
  

					
	 SOW
	  	 WBS
	  	 Tasks

	 3.7.1
	  	1.1	  	Program Management.
	 3.7.2
	  	1.4.5	  	Clinical: [**].
	 3.7.3
	  	1.5.1	  	Regulatory: [**]

 Technical Requirements, Base Contract 
  

	3.2.1	Program Work Plans (WBS 1.1.1.1) 

 The Program Management Plan (PMP) will be prepared and
will specify the relevant activities required for effective direction of the project. The PMP will define expectations and key program deliverables. Critical components of the PMP are: 1) the Integrated Development Plan which aligns project strategy
with resource allocations, 2) the SOW and WBS which define the relevant activities/deliverables of the project as well as the responsible party, 3) the Project Budget - the agreed upon project budget by activity will be included in the PMP, 4)
Schedule and Timelines which will include task, subtask and activity breakdowns, associated budgets, resource allocations and will provide the baseline for program and schedule control, 5) Risk Register and Management Plan for tracking and
monitoring potential program risks, their potential probability, impacts, and mitigations, and 6) Stakeholder Management Plan to document stakeholders, relevant contact information, communication requirements and engagement levels. 

  
 13 

 Visterra, Inc. 

HHSO100201500018C 
  

	3.2.2	Program Communication and Reporting Plan (WBS 1.1.2) 

 Functional area managers within
Visterra are responsible for defining the activities to be conducted by potential vendors, such as Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) for competitive bidding, awarding contracts, and managing the
progress of the work. Functional area managers serve as the point of contact for subcontractors. Contract organizations are managed by a combination of tools and activities, including Gantt charts, teleconferences, face-to-face meetings, and written
progress reports at a frequency appropriate to the scope and timeline of the work. Substantive communications between Visterra and the subcontractors are documented. Visterra staff work proactively with vendors to carry out work on schedule and
within budget. Functional area managers will work with each subcontractor and consultant to monitor performance, ensuring that schedules, progress reports, and data collection are fully integrated with Visterra’s management processes. For each
subcontractor and consultant, specific elements of the Work Breakdown Structure (WBS) are identified with clearly articulated subcontracted responsibilities. Visterra’s functional area managers will ensure that subcontracted efforts are
conducted in accordance with the overall scope, schedule, and budget plans. Both subcontractors and consultants will be involved in creation of baseline plans, and where cost or schedule variances have been exceeded, will work with Visterra to
implement corrective actions. Full visibility into subcontractor and consultant performance will be maintained via internal progress discussions (as often as needed) and program management reviews covering technical progress, budget, schedule, and
quality. 
  

	3.2.3	Risk Management (WBS 1.1.3) 

 Visterra will generate a Risk Management Plan and process
to identify and mitigate potential problems. Visterra will conduct a monthly review to address existing and newly identified risks and use a Risk Register to identify, monitor, control, and report risks. All potential risks are categorized according
to impact and probability. 
  

	3.2.4	Earned Value Management System (EVMS) (WBS 1.1.4) 

 The project EVMS will be designed,
implemented, and launched at the start of the Base Contract. EVM parameters will be calculated on a monthly basis and trends monitored for early detection of developing variances. 

 

	3.2.5	Nonclinical Toxicology: Safety (WBS 1.2.2) 

  

			
	 WBS
	  	 Description/Details

	 1.2.2.2
	  	[**]
		
	 1.2.2.3
	  	[**]

  
 14 

 Visterra, Inc. 

HHSO100201500018C 
  

			
	 WBS
	  	 Description/Details

		
	 1.2.2.4
	  	[**]
		
	 1.2.2.5
	  	[**]
		
	 1.2.2.6
	  	[**]
		
	 1.2.2.7
	  	[**]
		
	 1.2.2.8
	  	[**]

 [**] (WBS 1.2.2.9) 

Visterra will consider performing a [**]. 
 Visterra will conduct
[**]. 

  
 15 

 Visterra, Inc. 

HHSO100201500018C 
  

	3.2.6	Nonclinical Efficacy and Safety (WBS 1.3.3) 

 Visterra will conduct [**] 

 

	3.2.7	Clinical: Phase 2a Study in Outpatients with Uncomplicated Influenza (WBS 1.4.2) 

  

			
	 Study Title
	  	[**]
		
	 No. of Subjects
	  	[**]
	 Dose Levels
	  	[**]
	 Endpoints and

Expected

Results
	  	[**]
	 Design
	  	[**]
	 Assessments
	  	[**]

  

	*	Subject to discussion with BARDA and BARDA approval 

  

	3.2.8	Regulatory: [**] (WBS 1.5.1) 

 The following activities will be performed: [**]. 

  
 16 

 Visterra, Inc. 

HHSO100201500018C 
  

	3.2.9	CMC: Chemistry (Formulation) (WBS 1.6.1) 

 Visterra will [**]. 

 

	3.2.10	CMC: Process Validation (WBS 1.6.2) 

 Process Optimization (WBS 1.6.2.1) 

Visterra will [**]. 
 Process
Characterization (WBS 1.6.2.2) [**]. 
  

	3.2.11	CMC: Clinical Supply Manufacturing (WBS 1.6.3) 

 Visterra is [**]. 

 

	3.2.12	CMC: Creation of a Working Cell Bank (WBS 1.6.4) 

 Visterra will manufacture and
characterize a working cell bank (WCB) from the VIS410 Master Cell Bank. 

  
 17 

 Visterra, Inc. 

HHSO100201500018C 
  

	3.2.13	CMC: Controls (Analytical/Validation) (WBS 1.6.5) 

 [**] (WBS 1.6.5.3) 

[**]. 
 [**] (WBS 1.6.5.4)

 Visterra has [**]. 

Technical Requirements, Option 1 [**] 
  

	3.3.1	Program Management (WBS 1.1) 

 All components of the Project Management Plan as
implemented for the Base Contract will be reviewed and amended to reflect specific needs for Option 1 and the outcome of continuous process improvement evaluations. 
  

	3.3.2	Clinical: [**] (WBS 1.4.2) 

  

			
	Study Title	  	[**]
		
	No. of Subjects	  	[**]
		
	Dose Levels	  	[**]
		
	Population	  	 Inclusion:
 [**]

Exclude: [**]

		
	Design	  	[**]
		
	Endpoints & Expected Results	  	 • Primary: [**]
 •
Secondary: [**]
 • Exploratory: [**]

Expected results: [**]

  
 18 

 Visterra, Inc. 

HHSO100201500018C 
  

	3.3.3	Regulatory: [**] (WBS 1.5.1) 

 The following activities will be performed: 

[**]. 
 Technical Requirements, Option 2 [**]

  

	3.4.1	Program Management (WBS 1.1) 

 All components of the Project Management Plan as
implemented for the Base Contract and Option 1 will be reviewed and amended to reflect specific needs for Option 2 and the outcome of continuous process improvement evaluations. 

 

	3.4.2	Regulatory: [**] (WBS 1.5.1) 

 The following activities will be performed: [**]. 

 

	3.4.3	CMC: Clinical Supply Manufacturing (WBS 1.6.3) 

 The following activities will be
performed: [**]. 
 Technical Requirements, Option 3 [**] 
  

	3.5.1	Program Management (WBS 1.1) 

 All components of the Project Management Plan as
implemented for the Base Contract and Options 1-2 will be reviewed and amended to reflect specific needs for Option 3 and the outcome of continuous process improvement evaluations. 

 

	3.5.2	[**] (WBS 1.4.3) 

 The goal of the [**]. 

 

	3.5.3	Regulatory: [**] (WBS 1.5.1) 

 The following activities will be performed: [**]. 

  
 19 

 Visterra, Inc. 

HHSO100201500018C 
  

	3.5.4	CMC: Process Validation (WBS 1.6.2) 

 [**]. 

 

	3.5.5	CMC: [**] (WBS 1.6.5) 

 The following activities will be performed: [**]. 

Technical Requirements, Option 4 [**] 
  

	3.6.1	Program Management (WBS 1.1) 

 All components of the Project Management Plan as
implemented for the Base Contract and Options 1-3 will be reviewed and amended to reflect specific needs for Option 4 and the outcome of continuous process improvement evaluations. 

 

	3.6.2	Clinical [**] (WBS 1.4.4) 

 For the purposes of this [**]. 

 

	3.6.3	Regulatory: [**] (WBS 1.5.1) 

 [**]. 

  
 20 

 Visterra, Inc. 

HHSO100201500018C 
  

 Technical Requirements, Option 5 [**] 

 

	3.7.1	Program Management (WBS 1.1) 

 All components of the Project Management Plan as
implemented for the Base Contract and Options 1-4 will be reviewed and amended to reflect specific needs for Option 5 and the outcome of continuous process improvement evaluations. 

 

	3.7.2	Clinical: [**] (WBS 1.4.5) 

 [**]. 

 

	3.7.3	Regulatory: [**] (WBS 1.5.1) 

 The following will be performed: [**]. 

  
 21 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION D - PACKAGING, MARKING AND SHIPPING 

Report Deliverables 
 All reports and
deliverables required under this contract shall be packaged, marked and shipped in accordance with Government specifications. At a minimum, all deliverables shall be marked with the contract number and Contractor name. The Contractor shall guarantee
that all required materials shall be delivered in immediate usable and acceptable condition. 
 Unless otherwise specified by the Contracting
Officer, delivery of reports to be furnished to the Government under this contract (including invoices) shall be delivered to BARDA both in Hard Copy, and Electronically along with a concurrent email notification to the Contracting Officer and COR
(as defined in SECTION G, CONTRACT ADMINISTRATION) summarizing delivery as follows: 
  

			
	 Mailing Address
	  	 Mailing Address

	 [**]
 Contracting Officer’s
Representative
 DHHS/OS/ASPR/BARDA
 330 Independence Avenue,
S.W.
 Room G644 Washington, D.C. 20201
	  	 Lynda Brown
 Contracting Officer

DHHS/OS/APSR/AMCG
 330 Independence Avenue, S.W.

Room G644 Washington, D.C. 20201

		
	 E-Mailing Address
	  	 E-Mailing Address

	[**]	  	 [**]

  
 22 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION E - INSPECTION AND ACCEPTANCE 

 

	a.	The Contracting Officer or the duly authorized representative will perform inspection and acceptance of materials and services to be provided under this contract. 

 

	b.	For the purpose of this SECTION, the designated Contracting Officer’s Representative (COR) is the authorized representative of the Contracting Officer. 

 

	 	•	 	The COR will review all deliverables for timeliness and completeness, as identified in F.2., Deliverables and F.3., Reporting Requirements, prior to acceptance. 

 

	 	•	 	In accordance with F.7., In-Process-Reviews will also be conducted in order to make a determination to proceed with proposed option(s). 

 

	c.	For report deliverables, inspection and acceptance will be performed at: 

 Office of Acquisition
Management, Contracts, and Grants (AMCG) 
 Office of the Assistant Secretary for Preparedness and Response 

U.S. Department of Health and Human Services 

330 Independence Avenue, S.W., Room G644 

Washington, D.C. 20201 
  

	d.	For option items, inspection and acceptance will be performed at the specified delivery site. 

  
 23 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION F - DELIVERIES OR PERFORMANCE 

 

	F.1.	PERIOD OF PERFORMANCE 

  

	a.	The period of performance of this contract shall be from September 30, 2015 through January 31, 2019 for the base period. 

 

	F.2.	DELIVERABLES 

 Satisfactory performance of the final contract shall be deemed to occur upon performance
of the work described in the Statement of Work in SECTION C of this contract and upon delivery and acceptance by the Contracting Officer, or the duly authorized representative, of the following items in accordance with the stated delivery schedule:

  

	a.	The items specified in SOW will be required to be delivered F.O.B. Destination as set forth in FAR 52.247-35, F.O.B. DESTINATION, WITHIN CONSIGNEES PREMISES (APRIL 1984), and in accordance with and by the dates
specified in Section B, PoP Schedule. 

  

	F.3.	REPORTING REQUIREMENTS 

 All reports required herein shall be submitted in electronic format. In
addition, one hardcopy of each report shall be submitted to the Contracting Officer. 
 All electronic reports submitted shall be compliant with
Section 508 of the Rehabilitation Act of 1973. Additional information about testing documents for Section 508 compliance, including specific checklists, by application, can be found at: http://www.hhs.gov/web/508/index.html under
“Helpful Resources.” 
 All paper/hardcopy documents/reports submitted under this contract shall be printed or copied, double-sided, on at least
30 percent post-consumer fiber paper, whenever practicable, in accordance with FAR 4.302(b). 
  

					
	 Item Description
	  	 Delivery Date
	  	 Deliver To

			
	 Initial Project Management Deliverables
	  		  	
			
	 1. Performance Measurement Baseline
	  	120 days after award effective date	  	CO via email
			
	 2. Risk Register
	  	120 days after award effective date	  	
			
	 Routine or Monthly Deliverables
	  		  	
			
	1. Technical Progress Report in the format requested by the Contracting Officer describing project progress over the previous month	  	The [**] of Contract performance	  	CO and COR via e-mail and
FedEx/UPS. Additionally, email
invoices to PSC_Invoices@psc.hhs.gov

  
 24 

 Visterra, Inc. 

HHSO100201500018C 
  

					
	 Item Description
	  	 Delivery Date
	  	 Deliver To

	2. EV-CPR, Format 1, Format 5, and Supplemental CAP Report, and Integrated Master Schedule in MS excel and .xml export of the raw EVMS data out of their EVMS database	  	The [**] of Contract performance	  	
	  
 3. Bi-Weekly Conference Call Minutes
	  	Proposed agenda 2 days prior to call. Minutes within [**] business days following each conference call	  
	  
 4. Quarterly Site Visit Minutes for face-to-face meetings at
Recipient or BARDA location
	  	Within 10 days following each site visit	  
	  
 5. Monthly Invoices
	  	Within [**] days of the end of each month	  
			
	  
 6. Weekly Clinical Report during Active Enrollment Periods.
Format TBD
	  	The Monday following the week being reported	  	COR via e-mail
			
	  
 7. Clinical Site Enrollment Reporting and Updates to support the
BARDA Clinical Trial Database
	  	The [**] of Contract performance when clinical trials are	  	Direct transfer to a secure data capture
system (BARDA Tracking Tool)
			
	Periodic or As-Necessary Deliverables	  		  	
			
	  
 1. Study Protocols for each non-clinical or clinical
trial
	  	No later than 10 days before submission to the FDA	  	CO and COR via e-mail and, if
requested, CD-ROM
	 2. Study Reports for each non-clinical or clinical trial

 
	  	No later than 15 days before submission to the FDA	  
	 3. Manufacturing Campaign Reports for contract funded clinical trial material and registration lots

 
	  	No later than 15 days before submission to the FDA	  
	  
 4. Technical Documents from contract funded activities such as
Process Development Report, Assay Validation Plan/Report, Assay Technology Transfer Report, Batch Records, SOPs, Master Production Records, Certificate of Analysis
	  	Within 10 days upon request by CO/COR or 15 days prior to submission to FDA	  
	  
 5. Portfolio Progress Milestone Presentation.
Annual or event driven review of program
	  	No later than 10 days before Milestone Review Meeting	  

  
 25 

 Visterra, Inc. 

HHSO100201500018C 
  

					
	 Item Description
	  	 Delivery Date
	  	 Deliver To

	6. Incident Report for any critical programmatic concerns, risks or potential risks	  	Within [**] hours of incident	  	
	  
 7. QA Audit Reports including findings, results and next steps.
BARDA reserves the right to participate in the audits.
	  	Within 5 days of report completion	  
	  
 8. Quality Agreements with Subcontractors.
	  	Within 10 days upon request by CO/COR	  
	  
 9. Formal FDA Submissions of any kind pertaining to the scope of
the project as necessary during Contract performance
	  	No later than [**] days before submission to the FDA BARDA will coordinate with Contractor for reviewing BLA sections	  
	  
 10. Memo with Date and Time of Scheduled Meetings with FDA. BARDA
reserves the right to attend FDA meetings relevant to contract funded activities
	  	As soon as possible after scheduling	  
	  
 11. Communications from FDA related to contract funded
activities
	  	Within [**] business days of receipt from FDA	  
	  
 12. Minutes for Formal Meetings with FDA
	  	Within [**] business days of receipt from FDA	  
			
	  
 13. Raw Data and Analysis Pertaining to Scope of the Project
Generated Using USG Funds
	  	Within a reasonable time after request	  	CO via electronic delivery
			
	  
 14. Regulatory or Legal Strategies Pertaining to Scope of the
Project
	  	Within a reasonable time after request	  	CO via electronic delivery
			
	  
 15. Draft Final Report
	  	No later than 45 days prior to contract expiration	  	CO and COR via e-mail
			
	  
 16. Final Report
	  	No later than contract expiration	  	CO and COR via e-mail
			
	  
 17. Publications/Presentations
	  	No later than 30 days before submission for publications and 15 days for presentations	  	CO and COR via e-mail

 Note: If “business days” not specified, the number of days referenced is calendar days. 

  
 26 

 Visterra, Inc. 

HHSO100201500018C 
  

	a.	Technical Reports 

 In addition to those reports required by the other terms of this
contract, the Contractor shall prepare and submit the following reports in the manner stated below and in accordance with the DELIVERIES in SECTION F of this contract: 
  

	 	1.	Monthly Progress Report 

 This report shall include a description of the activities
during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period
shall consist of full Calendar months. 
 The Contractor shall submit a Monthly Progress Report. The format should include: 

A cover page that includes the contract number and title; the type of report and period that it covers; the Contractor’s name, address,
telephone number, fax number, and e-mail address; and the date of submission; The progress report shall conform to the requirements set forth in the DELIVERABLES in SECTION F of this contract. 

 

	 	•	 	SECTION I - An introduction covering the purpose and scope of the contract effort 

  

	 	•	 	SECTION II – PROGRESS 

  

	 	•	 	SECTION II Part A: OVERALL PROGRESS - A description of overall progress. 

  

	 	•	 	SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE - A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues
(e.g., evaluating, and managing subcontractor performance, and personnel changes). A standing organizational chart is to be included in this section. 

  

	 	•	 	SECTION II Part C: TECHNICAL PROGRESS - For each activity related to Gantt chart, document the results of work completed and cost incurred during the period covered in relation to proposed progress, effort and budget.
The report shall be in sufficient detail to explain comprehensively the results achieved. The description shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions
resulting from analysis and scientific evaluation of data accumulated to date under the contract. The report shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress, why the
differences have occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the project. 

 

	 	•	 	SECTION II Part D: PROPOSED WORK - A summary of work proposed related to Gantt chart for the next reporting period, preprints/reprints of papers and abstracts and any revisions to the Timeline, Work Breakdown Structure
(WBS) and Risk Assessment. 

  

	 	•	 	 SECTION III Part A: Earned Value Management Reporting: Contractor will provide a monthly Contract Performance Report (CPR) at an agreed upon reporting
level (WBS level 2) using the BARDA provided WBS and a Variance Analysis Report. 

  
 27 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	 
EVMS shall be applied to all Cost Plus Fixed Fee CLINs as part of the Integrated Master Project Plan following the Seven Principles of Earned Value Management. In accordance with FAR 52.215-2,
Audit and Records-Negotiation, Contracting Officer may request, on a quarterly or ad hoc basis that the Contractor provide raw data. HHS may request additional data at a reporting level, as Contracting Officer deems necessary. Contracting Officer
may request additional data at lower reporting levels (up to WBS level 5), as it deems necessary, upon sufficient notification to the Contractor, who will provide the subject additional data prospectively. 

A Monthly Progress Report will not be required in the same month that the Annual Technical Progress Report is submitted. 

The first report shall be due the 15th Calendar day after completion of the first full Calendar month and portion thereof of
performance. Thereafter, reports shall be due on or before the 15th Calendar day following each reporting period. 
  

	 	2.	Draft Final Technical Progress Report and Final Technical Progress Report 

 A Draft Final
Report will be submitted to the Contracting Officer’s Representative for review and comment at least 45 days prior to the contract completion date. Within 15 days of receipt, the Contracting Officer’s Representative will provide the
Contractor written comments on the Draft Final Report. 
 These reports are to include a summation of the work performed and results obtained
for the entire contract period of performance. This report shall be in sufficient detail to describe comprehensively the results achieved. The Draft Final Report and Final Report shall be submitted in accordance with the DELIVERIES in SECTION F of
the contract. An Annual Technical Progress Report will not be required for the period when the Final Technical Progress Report is due. The Draft Final Technical Progress Report and the Final Technical Progress Report shall be submitted in accordance
with the dates set forth in F.2. of this contract. The report shall conform to the following format: 
  

	 	a.	Cover page to include the contract number, contract title, performance period covered, Contractor’s name and address, telephone number, fax number, e-mail address and submission date. 

 

	 	b.	SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract effort including a summary of the major accomplishments relative to the specific activities set forth in the Statement of Work.

  

	 	c.	SECTION II: RESULTS - A detailed description of the work performed related to the Gantt chart, the results obtained, and the impact of the results on the scientific and/or public health community including a listing of
all manuscripts (published and in preparation) and abstracts presented during the entire period of performance and a summary of all inventions. 

  
 28 

 Visterra, Inc. 

HHSO100201500018C 
  

 Draft Technical Progress Report: The Contractor is required to submit the Draft Final
Technical Progress Report to the Contracting Officer’s Representative and Contracting Officer. This report is due 45 Calendar days before the completion date of the contract. The Contracting Officer’s Representative and Contracting Officer
will review the Draft Final Technical Progress Report and provide the Contractor with comments within 15 Calendar days after receipt. 

Final Technical Progress Report: The Contractor shall incorporate all BARDA comments into the Final Technical Progress Report. The
Contractor will deliver the final version of the Final Technical Progress Report 30 Calendar days post technical period of performance. 
  

	 	3.	Summary of Salient Results 

 The Contractor shall submit, with the Final Report, a
summary (not to exceed 400 words) of salient results achieved during the performance of the contract. 
  

	 	4.	Other Reports/Deliverables 

  

	 	a.	Study/Experiment/Test Plans - The Contractor shall submit all study/experiment/test plans, designs, and protocols upon request by the COR. 

 

	 	b.	Meeting Minutes - The Contractor shall provide an electronic copy of conference call meeting minutes/summaries to the Contracting Officer’s Representative and Contracting Officer within five
(5) business days after the conference call is held. 

  

	 	c.	Audit Reports - Report is required whenever an audit occurs. 

  

	 	d.	Reporting of Financial Conflict of Interest (FCOI) - All reports and documentation required by 45 CFR Part 94, Responsible Prospective Contractors including, but not limited to, the New FCOI Report, Annual FCOI
Report, Revised FCOI Report, and the Mitigation Report, shall be submitted to the Contracting Officer in Electronic format. Thereafter, reports shall be due in accordance with the regulatory compliance requirements in 45 CFR Part 94. 45 CFR
Part 94 is available at: http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=0af84ca649a74846^102aaf664da1623&rgn=div5&view=text&node =45:1.0.1.1.51&idno=45. See Part 94.5, Management and reporting of financial conflicts of
interest for complete information on reporting requirements. 

  

	 	e.	Report on Select Agents or Toxins and/or Highly Pathogenic Agents For work involving the possession, use, or transfer of a Select Agent or Toxin and/or a Highly Pathogenic Agent, the following information shall
also be included in each Monthly Progress Report: 

  

	 	1.	 Any changes in the use of the Select Agent or Toxin including initiation of “restricted experiments,” and/or a Highly Pathogenic Agent, that
have resulted in a change in the required biocontainment level, and any resultant change in location, if applicable, as determined by the IBC or equivalent body or institutional biosafety

  
 29 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	official. 

  

	 	2.	If work with a new or additional Select Agent or Toxin and/or a Highly Pathogenic Agent will be conducted in the upcoming reporting period, provide: 

 

	 	a.	A list of each new or additional Select Agent or Toxin and/or a Highly Pathogenic Agent that will be studied; 

  

	 	b.	A brief description of the work that will be done with each new or additional Select Agent or Toxin and/or a Highly Pathogenic Agent and whether or not the work is a Select Agent or Toxin restricted experiment as
defined in the Select Agents Regulation 42 CFR Part 73, Section 13.b (http://www.selectagents.gov/Regulations.html); 

  

	 	c.	The name and location for each biocontainment resource/facility, including the name of the organization that operates the facility, and the biocontainment level at which the work will be conducted, with documentation of
approval by your IBC or equivalent body or institutional biosafety official. It must be noted if the work is being done in a new location or different location. 

  

	 	d.	For work with Select Agents performed in the U.S., provide documentation of registration status and inspectional reports/outcomes for all domestic organizations where Select Agent(s) will be used. For work with Select
Agents performed in a non-U.S. country prior BARDA approval is required. 

 If the IBC or equivalent body or institutional
biosafety official has determined, for example, by conducting a risk assessment, that the work that has been performed or is planned to be performed under this contract may be conducted at a biocontainment safety level that is lower than BSL3, a
statement to that affect shall be included in each Monthly Progress Report. 
 If no work involving a Select Agent or Toxin and/or a Highly
Pathogenic Agent has been performed or is planned to be performed under this contract, a statement to that affect shall be included in each Monthly Progress Report. 
  

	F.4.	SUBJECT INVENTION REPORTING REQUIREMENT 

 All reports and documentation required by FAR
Clause 52.227-11 Patent Rights-Ownership by the Contractor, including, but not limited to, the invention disclosure report, the confirmatory license, and the Government support certification, one copy of an annual utilization report, and a copy of
the final invention statement, shall be submitted to the Contracting Officer. A final invention statement (see FAR 27.303 (b)(2)(ii)) shall be submitted to the Contracting Officer on the expiration date of the contract. Reports and documentation
submitted to the Contracting Officer shall be sent to the following email and/or address: 
 Lynda Brown 

Contracting Officer 

DHHS/OS/ASPR/BARDA 
 330
Independence Avenue, S.W. 
 Room 644G Washington, D.C. 20201 

  
 30 

 Visterra, Inc. 

HHSO100201500018C 
  

 If no invention is disclosed or no activity has occurred on a previously disclosed invention
during the applicable reporting period, a negative report shall be submitted to the Contracting Officer at the address listed above. 
  

	F.5.	BI-WEEKLY CONFERENCE CALLS 

 One conference call between the Contracting
Officer’s Representative (COR) and the Contractor shall occur every month, or as directed by the Contracting Officer’s Representative. During these calls the Principal Investigator will discuss the activities performed and
deliverables achieved during the reporting period, any problems that have arisen and the activities planned for the ensuing reporting period. The first reporting period consists of the first half month of performance plus any fractional part of the
initial month. Thereafter, the reporting period shall consist of each half Calendar month. The Contractor may choose to include other key personnel on the conference call to give detailed updates on specific projects or this may be requested by the
Contracting Officer’s Representative. 
  

	F.6.	PROJECT MEETINGS 

 The Contractor shall participate in quarterly Project Meetings to
coordinate the performance of the contract, as requested by the Contracting Officer’s Representative. These meetings may include face-to-face meetings with AMCG/BARDA in Washington, D.C. and at work sites of the Contractor. Such meetings may
include, but are not limited to, meetings of the Contractor to discuss study designs, site visits to the Contractor’s facilities, and meetings with the Contractor and HHS officials to discuss the technical, regulatory, and ethical aspects of
the program. Subject to the data rights provisions in this contract, the Contractor must provide data, reports, and presentations to USG personnel as required by the Contracting Officer’s Representative in order to facilitate review of contract
activities. Contractor will provide data, reports and presentations to outside experts only if such experts are bound by appropriate contractual obligations to keep such information confidential. 

 

	F.7.	IN-PROCESS-REVIEW 

 At its discretion, the Government may conduct an In-Process-Review
(IPR) to evaluate whether to continue activities covered by the contract. Contractor shall provide a presentation detailing technical progress made towards completion of milestones following a prescribed template provided by the Government at an
agreed upon date. The IPR will typically be conducted at DHHS facilities in Washington, DC. The contractor will be notified by the Government of its intention to hold an IPR at least 30 calendar days prior to the scheduled IPR Presentation. 

 

	 	•	 	Contractor shall provide final presentation 10 business days prior to each IPR Presentation. 

  

	 	•	 	Contractor shall submit written justification of progress towards satisfying success criteria. 

  

	 	•	 	If draft is provided prior to the final presentation submission, the Government will provide a written or verbal response, as appropriate. 

  
 31 

 Visterra, Inc. 

HHSO100201500018C 
  

	F.8.	SITE VISITS AND INSPECTIONS 

 At the discretion of the USG and independent of activities
conducted by the Contractor, with ten (10) business days notice to the Contractor, the USG reserves the right to conduct site visits and inspections on an as needed basis. 

  
 32 

 Visterra, Inc. 

HHSO100201500018C 
  

	F.9.	CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998) 

 This contract incorporates the following clause by
reference, with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make its full text available. Also, the full text of a clause may be accessed electronically at this address:
http://www.acquisition.gov/comp/far/index.html . 
 FEDERAL ACQUISITION REGULATION (48 CFR CHAPTER 1) CLAUSE: 

52.242-15, Stop Work Order (AUGUST 1989) with ALTERNATE I (APRIL 1984). 52.247-35, F.O.B. Destination Within Consignees Premises
(APRIL 1984). 

  
 33 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION G - CONTRACT ADMINISTRATION DATA 

 

	G.1.	CONTRACTING OFFICER 

 The following Contracting Officer (CO) will represent the Government for the
purpose of this contract: 
 Lynda Brown, Contracting Officer 

HHS/OS/ASPR/AMCG 330 

Independence Avenue, S.W. 
 Room
G644 Washington, D.C. 20201 
 E-mail: [**] 
  

	1)	The Contracting Officer is the only individual who can legally commit the Government to the expenditure of public funds. No person other than the Contracting Officer can make any changes to the terms, conditions,
general provisions, or other stipulations of this contract. 

  

	2)	The Contracting Officer is the only person with the authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to (1) direct or negotiate any changes in the
statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimburse to the Contractor of any costs incurred during the performance of this contract; (5) otherwise change
any terms and conditions of this contract. 

  

	3)	No information, which may be received from any person employed by the US Government, or otherwise, shall be considered grounds for deviation from any stipulation of this contract, unless it is information which may be
contained in an authorized modification to this contract, duly issued by the Contracting Officer. 

  

	4)	The Government may unilaterally change its CO designation. 

  

	G.2.	CONTRACTING OFFICER’S REPRESENTATIVE (COR) 

 The following Contracting Officer’s Representative
(COR) will represent the Government for the purpose of this contract: 
 [**] 

Contracting Officer’s Representative (COR) 

Biomedical Advanced Research and Development Authority (BARDA) 

Office of the Assistant Secretary for Preparedness and Response 

Department of Health and Human Services 
 The COR
is responsible for: 
  

	1)	Monitoring the Contractor’s technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; 

 

	2)	Assisting the Contracting Officer in interpreting the statement of work and any other technical performance requirements; 

  
 34 

 Visterra, Inc. 

HHSO100201500018C 
  

	3)	Performing technical evaluation as required; 

  

	4)	Performing technical inspections and acceptances required by this contract; and 

  

	5)	Assisting in the resolution of technical problems encountered during performance. 

 The COR will assist in
resolving technical issues that arise during performance. The COR however is not authorized to change any contract terms or authorize any changes in the Statement of Work or modify or extend the period of performance, or authorize reimbursement of
any costs incurred during performance. The Contractor is advised to review Federal Acquisition Regulation (“FAR”) Clause 52.243-2 (Changes-Cost reimbursement contracts Alternative V), which is incorporated by reference into this contract.
(See 1.1.) 
 The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer
has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs
incurred during the performance of this contract; or (5) otherwise change any terms and conditions of this contract. The Government may unilaterally change its COR designation. 

 

	G.3.	INVOICE SUBMISSION/CONTRACT FINANCIAL REPORT 

  

	1)	Financial reports on the attached Financial Report of Individual Project/Contract (see Attachments 7 and 8) shall be submitted by the Contractor in accordance with the instructions for completing this form, which
accompany the form, in hard copy and an electronic copy, not later than the 15th business day after the close of the reporting period. The line entries for subdivisions of work and elements of cost (expenditure categories) which shall be reported
within the total contract are discussed in paragraph 5, below. Subsequent changes and/or additions in the line entries shall be made in writing. 

  

	2)	Unless otherwise stated in that part of the instructions for completing this form, entitled “PREPARATION INSTRUCTIONS,” (see Attachment 8) all columns A through J, shall be completed for each report submitted.

  

	3)	The first financial report shall cover the period consisting of the first full calendar month following the date of the contract, in addition to any fractional part of the initial month. Thereafter, reports will be on a
Monthly basis. If the contractor fails to submit timely financial reports and invoices or is delinquent on submission of financial reports by an excess of 90 Calendar days, a “Stop Work Order” may be issued by the Government, until
the delay is resolved. 

  

	4)	The Contracting Officer may require the Contractor to submit detailed support for costs contained in one or more interim financial reports. This clause does not supersede the record retention requirements in FAR Part
4.7. 

  

	5)	The listing of expenditure categories to be reported is incorporated within the Attachment entitled, “Financial Report of Individual Project/Contract,” located in SECTION J and made a part of this contract.

  
 35 

 Visterra, Inc. 

HHSO100201500018C 
  

	G.4.	INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORTING 

  

	1)	The billing address that should be shown on the invoice is the same as defined in G.1. of this contract. 

  

	2)	The Contractor shall submit two paper copies to the address provided in G.1. of this contract, as well as an electronic copy of contract Monthly invoices/financial reports to the Contracting Officer as defined
above, in G.4. of this contract. 

  

	3)	Contractor invoices/financial reports shall conform to the form, format, and content requirements of the instructions for Invoice/Financing requests and Contract Financial Reporting made a part of the contract in
Section J (See Attachments 1, 2, 7 and 8) . 

  

	4)	Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the Government. 

 

	5)	The Contractor agrees to immediately notify the Contracting Officer in writing if there is an anticipated overrun (any amount) or unexpended balance (greater than 10 percent) of the estimated costs for the base segment
or any option segment(s) (See estimated costs under B.2. and B.3., of the contract) and the reasons for the variance. Also refer to the requirements of the Limitation of Cost FAR 52.232-20 clause in the contract. 

 

	6)	All invoice submissions shall be in accordance with FAR Clause 52.232-25(a)(3) in Section I of this contract. 

  

	7)	The Contractor shall reference any applicable Contractor Officer Authority (COA) numbers when requesting reimbursement on the invoice. 

 

	G.5.	REIMBURSEMENT OF COST 

  

	1)	The Government shall reimburse the Contractor the cost determined by the Contracting Officer to be allowable (hereinafter referred to as allowable cost) in accordance with the clause entitled Allowable Cost and Payment
in Section I, Contract Clauses, and FAR Subpart 31.2. Examples of allowable costs include, but are not limited to, the following: 

  

	 	a)	All direct materials and supplies that are used in the performing of the work provided for under the contract, including those purchased for subcontracts and purchase orders. 

 

	 	b)	All direct labor, including supervisory, that is properly chargeable directly to the contract, plus fringe benefits. 

  

	 	c)	All other items of cost budgeted for and accepted in the negotiation of this basic contract or modifications thereto. 

  

	 	d)	Travel costs including per diem or actual subsistence for personnel while in an actual travel status in direct performance of the work and services required under this contract subject to the following and the
restrictions in B.4(c): 

  
 36 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	(i)	Air travel shall be by the most direct route using “air coach” or “air tourist” (less than first class) unless it is clearly unreasonable or impractical (e.g., not available for reasons other than
avoidable delay in making reservations, would require circuitous routing or entail additional expense offsetting the savings on fare, or would not make necessary connections). 

 

	 	(ii)	Rail travel shall be by the most direct route, first class with lower berth or nearest equivalent. 

  

	 	(iii)	Costs incurred for lodging, meals, and incidental expenses shall be considered reasonable and allowable to the extent that they comply with FAR 31.2. 

 

	 	(iv)	Travel via privately owned automobile shall be reimbursed at not more than the current General Services Administration (GSA) FTR established mileage rate. 

 

	e)	For further guidance on funding, see the LIMITATION OF COSTS clause referenced in Part II, Contract Clauses. 

  

	G.6.	GOVERNMENT PROPERTY 

  

	a.	In addition to the requirements of the clause, GOVERNMENT PROPERTY, incorporated in SECTION I of this contract, the Contractor shall comply with the provisions of HHS Publication, “HHS Contracting Guide for
Contract of Government Property,” which is incorporated into this contract by reference. This document can be accessed at: http://oamp.od.nih.gov/sites/default/files/appendix_q_hhs_contracting_guide.pdf 

Among other issues, this publication provides a summary of the Contractor’s responsibilities regarding purchasing authorizations and
inventory and reporting requirements under the contract. 
 Requests for information regarding property under this contract should be
directed to the Contracting Officer. 
  

	b.	Notwithstanding the provisions outlined in the HHS Publication, “HHS Contracting Guide for Contract of Government Property,” which is incorporated in this contract in paragraph a. above, the Contractor shall
use the form entitled, “Report of Government Owned, Contractor Held Property” for submitting summary reports required under this contract, as directed by the Contracting Officer or his/her designee. This form is included as an attachment
in SECTION J of this contract. 

  

	G.7.	POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE 

  

	a.	Contractor Performance Evaluations 

 Interim and final evaluations of Contractor
performance will be prepared on this contract in accordance with FAR Subpart 42.15. The final performance evaluation will be prepared at 

  
 37 

 Visterra, Inc. 

HHSO100201500018C 
  

 
the time of completion of work. In addition to the final evaluation, interim evaluation will be prepared After completion of one year of performance. 

Interim and final evaluations will be provided to the Contractor as soon as practicable after completion of the evaluation. The Contractor will
be permitted thirty days to review the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties, the matter will be referred to an individual one level above the Contracting Officer,
whose decision will be final. 
 Copies of the evaluations, Contractor responses, and review comments, if any, will be retained as part of
the contract file, and may be used to support future award decisions. 
  

	b.	Electronic Access to Contractor Performance Evaluations 

 Contractors may access
evaluations through a secure Web site for review and comment at the following address: http://www.cpars.gov. 
  

	G.8.	PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (December 2013) 

  

	a.	Upon receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such
payment is otherwise required under the applicable contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor. 

 

	b.	The acceleration of payments under this clause does not provide any new rights under the prompt Payment Act. 

  

	c.	Include the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.

  

	G.9.	INDIRECT COST RATES 

 In accordance with Federal Acquisition Regulation (FAR) (48 CFR Chapter 1) Clause
52.216-7 (d)(2), Allowable Cost and Payment incorporated by reference in this contract in PART II, SECTION I, the cognizant Contracting Office responsible for negotiating provisional and/or final indirect cost rates is identified as follows: 

Lynda Brown 
 DHHS/OS/ASPR/AMCG

 330 Independence Avenue, S.W. 

Room G644 
 Washington, D.C. 20201

 These rates below are hereby incorporated without further action of the Contracting Officer. 

(End of Clause) 

  
 38 

 Visterra, Inc. 

HHSO100201500018C 
  

 G.10. ESTABLISHMENT OF INDIRECT COST RATE 

The following contractor established provisional billing rates are incorporated into the contract, and will be utilized for billing purposes during both the
base and contract option periods pending the establishment of final indirect cost rates for each fiscal year or until revised by the contracting officer in accordance with the provisions of FAR 42.705-1. See FAR Clause 52.2167. 

Fringe benefits rate: [**]% of total salaries 
 Overhead: [**]%
of total direct labor costs 
 G&A: [**]% of total direct costs excluding subcontract costs 

Supplemental G&A: [**]% of subcontract costs only 
 Use of
the above provisional rates does not change any cost ceilings, contract obligations, or specific allowance or disallowance provided for in the contract. 

Contractor must notify the contracting officer promptly for an adjustment of the provisional rates if it becomes evident that the rates would cause
substantial overpayment or underpayment of indirect expenses to Visterra, Inc. 
 The final billing rates for each fiscal year will be based on the
incurred cost submission subject to Government audit determination. Indirect costs rate proposals must be submitted to the cognizant agency’s contracting officer within 6 months subsequent to each of the contractor’s fiscal year ends. (See
also FAR Clause 52.216-7(d) (2) incorporated herein). Copies of the indirect cost submission for each fiscal year must also be submitted to the AMCG contracting officer, and the AMCG auditor identified as follows: 

Director, Acquisition Program Support Office of Acquisition Management, Contracts and Grants (AMCG) Office of the Assistant Secretary for Preparedness and
Response (ASPR) US Department of Health and Human Services (DHHS) 300 Independence Avenue, SW, Room G644 Washington, DC 20201 
  

	G11.	OVERTIME COMPENSATION 

 No overtime (premium) compensation is authorized under the subject contract.
Billing of labor costs will be limited to total actual hours worked in the billing period. 

  
 39 

 Visterra, Inc. 

HHSO100201500018C 
  

 SECTION H - SPECIAL CONTRACT REQUIREMENTS 

 

	H.1.	PROTECTION OF HUMAN SUBJECTS, HHSAR 352.270-4(b) (January 2006) 

  

	a.	The Contractor agrees that the rights and welfare of human subjects involved in research under this contract shall be protected in accordance with 45 CFR Part 46 and with the Contractor’s current Assurance of
Compliance on file with the Office for Human Research Protections (OHRP), Department of Health and Human Services. The Contractor further agrees to provide certification at least annually that the Institutional Review Board has reviewed and approved
the procedures, which involve human subjects in accordance with 45 CFR Part 46 and the Assurance of Compliance. 

  

	b.	The Contractor shall bear full responsibility for the performance of all work and services involving the use of human subjects under this contract and shall ensure that work is conducted in a proper manner and as safely
as is feasible. The parties hereto agree that the Contractor retains the right to control and direct the performance of all work under this contract. The Contractor shall not deem anything in this contract to constitute the Contractor or any
subcontractor, agent or employee of the Contractor, or any other person, organization, institution, or group of any kind whatsoever, as the agent or employee of the Government. The Contractor agrees that it has entered into this contract and will
discharge its obligations, duties, and undertakings and the work pursuant thereto, whether requiring professional judgment or otherwise, as an independent contractor without imputing liability on the part of the Government for the acts of the
Contractor or its employees. 

  

	c.	If at any time during the performance of this contract, the Contracting Officer determines, in consultation with OHRP that the Contractor is not in compliance with any of the requirements and/or standards stated in
paragraphs (a) and (b) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. The Contracting Officer may communicate the
notice of suspension by telephone with confirmation in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written notice of suspension, the Contracting Officer may,
after consultation with OHRP, terminate this contract in whole or in part, and the Contractor’s name may be removed from the list of those contractors with approved Human Subject Assurances. (End of clause) 

 

	H.2.	HUMAN SUBJECTS 

 Research projects involving humans and/or human specimens can only be initiated with
written approval by the Contracting Officer’s Representative. 
 The Good Clinical Practice Regulations (GCP)(21 CFR Parts 50, 54, 56 312)(45 CFR Part
46)(ICH E6) as well as other applicable Federal and state regulations will be standards that apply for use of human subject and/or human specimens in clinical studies. 

If at any time during the life of the contract, the Contractor fails to comply with GCP as identified by regulations outline above , the Contractor shall have
thirty (30) Calendar days from the time such material failure is identified to cure such or initiate cure to the satisfaction of the 

  
 40 

 Visterra, Inc. 

HHSO100201500018C 
  

 
Government Contracting Officer’s Representative. If the Contractor fails to take such an action within the thirty (30) Calendar day period, then the contract may be terminated. 

ARTICLE H.3.   HUMAN MATERIALS (ASSURANCE OF OHRP COMPLIANCE) 
  

	a.	The acquisition and supply of all human specimen material (including fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable State and Local laws and the
provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise, will be offered to any person to influence their donation of human material. 

The Contractor shall provide written documentation that all human materials obtained as a result of research involving human subjects conducted
under this contract, by collaborating sites, or by subcontractors identified under this contract, were obtained with prior approval by the Office for Human Research Protections (OHRP) of an Assurance to comply with the requirements of 45 CFR 46 to
protect human research subjects. This restriction applies to all collaborating sites without OHRP-approved Assurances, whether domestic or foreign, and compliance must be ensured by the Contractor. 

Provision by the Contractor to the Contracting Officer of a properly completed “Protection of Human Subjects Assurance Identification/IRB
Certification/Declaration of Exemption”, Form OMB No. 0990-0263(formerly Optional Form 310), certifying IRB review and approval of the protocol from which the human materials were obtained constitutes the written documentation required.
The human subject certification can be met by submission of a self designated form, provided that it contains the information required by the “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of
Exemption”, Form OMB No. 0990-0263(formerly Optional Form 310). 
  

	H.3.	MANUFACTURING STANDARDS 

 If at any time during the life of the contract, the Contractor fails to comply
with GMP in the manufacturing, processing, packaging, storage, stability and other testing of the manufactured drug substance or product and delivery of this product and such failure results in a material adverse effect on the safety, purity or
potency of the product (a material failure) as identified by the FDA, the Contractor shall have thirty (30) Calendar days from the time such material failure is identified to cure such material failure. If the Contractor fails to take such an
action to the satisfaction of the Contracting Officer’s Representative within the thirty (30) Calendar day period, then the contract may be terminated. 
  

	H.4.	NEEDLE DISTRIBUTION 

 The Contractor shall not use contract funds to carry out any program of
distributing sterile needles or syringes for the hypodermic injection of any illegal drug. 
  

	H.5.	ACKNOWLEDGEMENT OF FEDERAL FUNDING 

 The Contractor shall clearly state, when issuing statements, press
releases, requests for proposals, 

  
 41 

 Visterra, Inc. 

HHSO100201500018C 
  

 
bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money: that Federal funding is being utilized in whole or in part in performance of
said research and development project. 
  

	H.6.	CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH 

 The Contractor shall not use contract funds for
(1) the creation of a human embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on
fetuses in utero under 45 CFR 46.204(b) and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). The term “human embryo or embryos” includes any organism, not protected as a human subject under 45 CFR 46 as of the date
of the enactment of this Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells. 

Additionally, in accordance with a March 4, 1997 Presidential Memorandum, Federal funds may not be used for cloning of human beings. 

 

	H.7.	DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION 

 The Contractor shall not use contract
funds to disseminate information that is deliberately false or misleading. 
  

	H.8.	PRIVACY ACT APPLICABILITY 

  

	1)	Notification is hereby given that the Contractor and its employees are subject to criminal penalties for violation of the Privacy Act to the same extent as employees of the Government. The Contractor shall assure that
each of its employees knows the prescribed rules of conduct and that each is aware that he or she can be subjected to criminal penalty for violation of the Act. A copy of 45 CFR Part 5b, Privacy Act Regulations, may be obtained at 

http://www.gpo.gov/fdsys/granule/CFR-2007-title45-vol1/CFR-2007-title45-vol1-part5b 

 

	2)	The COR is hereby designated as the official who is responsible for monitoring contractor compliance with the Privacy Act. 

  

	3)	The Contractor shall follow the Privacy Act guidance as contained in the Privacy Act System of Records number 09-25-0200. This document may be obtained at the following link:
http://www.hhs.gov/foia/privacy/sorns.html 

  

	H.9.	OMB CLEARANCE 

 In accordance with HHSAR 352.201-70, Paperwork Reduction Act, the Contractor shall not
proceed with surveys or interviews until such time as Office of Management and Budget (OMB) Clearance for conducting interviews has been obtained by the Contracting Officer’s Representative (COR) and the Contracting Officer has issued written
approval to proceed. 

  
 42 

 Visterra, Inc. 

HHSO100201500018C 
  

	H.10.	FULL EARNED VALUE MANAGEMENT SYSTEM, HHSAR 352.234-3 (October 2008) 

  

	a.	The Contractor shall use an Earned Value Management System (EVMS) that has been validated and accepted by the Cognizant Federal Agency (CFA) as being compliant with the guidelines in ANSI/EIA Standard-748 (current
version at the time of award) to manage this contract. If the Contractor’s current EVMS has not been validated and accepted by the CFA at the time of award, see paragraph (b) of this clause. The Contractor shall submit EVM reports in
accordance with the requirements of this contract. 

  

	b.	If, at the time of award, the Contractor’s EVM system has not been validated and accepted by the CFA as complying with EVMS guidelines in ANSI/EIA Standard-748 (current version at time of award), the Contractor
shall: 

  

	 	1.	Apply the current system to the contract; and 

  

	 	2.	Take necessary and timely actions to meet the milestones in the Contractor’s EVMS plan approved by the Contracting Officer. 

  

	c.	HHS requires the Contractor to obtain validation and acceptance of its EVM system by the CFA during the base period of performance of this contract. The Contracting Officer or designee will conduct a Compliance Review
to assess the Contractor’s compliance with its approved plan. If the Contractor does not follow the approved implementation schedule or correct all resulting system deficiencies noted during the Compliance Review within a reasonable time, the
Contracting Officer may take remedial action, which may include, but is not limited to, suspension of or reduction in progress payments, or a reduction in fee. 

  

	d.	HHS will conduct an Integrated Baseline Review (IBR). If a pre-award IBR has not been conducted, a post-award IBR will be conducted by HHS as early as practicable, but no later than ninety (90) days after contract
award. The Contracting Officer may also require an IBR as part of the exercise of an option or the incorporation of a major modification. 

  

	e.	Unless a waiver is granted by the CFA, Contractor-proposed EVMS changes require approval of the CFA prior to implementation. The CFA will advise the Contractor of the acceptability of such changes within 30 calendar
days after receipt of the notice of proposed changes from the Contractor. If the advance approval requirements are waived by the CFA, the Contractor shall disclose EVMS changes to the CFA at least 14 calendar days prior to the effective date of
implementation. 

  

	f.	The Contractor shall provide access to all pertinent records and data requested by the Contracting Officer or a duly authorized representative as necessary to permit Government surveillance to ensure that the EVMS
conforms, and continues to conform, with the requirements referenced in paragraph (a) of this clause. 

  

	g.	The Contractor shall require the subcontractors specified below to comply with the requirements of the clause: (Insert list of applicable subcontractors.) 

(End of clause) 

  
 43 

 Visterra, Inc. 

HHSO100201500018C 
  

	H.11.	CONFLICT OF INTEREST 

 The Contractor represents and warrants that, to the best of the Contractor’s
knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational conflict of interest, as defined in FAR Subpart 9.5, or that the Contractor has disclosed all such relevant information. Prior to
commencement of any work, the Contractor agrees to notify the Contracting Officer promptly that, to the best of its knowledge and belief, no actual or potential conflict of interest exists or to identify to the Contracting Officer any actual or
potential conflict of interest the Contractor may have. In emergency situations, however, work may begin but notification shall be made within five (5) working days. The Contractor agrees that if an actual or potential organizational conflict
of interest is identified during performance, the Contractor shall promptly make a full disclosure in writing to the Contracting Officer. This disclosure shall include a description of actions which the Contractor has taken or proposes to take,
after consultation with the Contracting Officer, to avoid, mitigate, or neutralize the actual or potential conflict of interest. The Contractor shall continue performance until notified by the Contracting Officer of any contrary action to be taken.
Remedies include termination of this contract for convenience, in whole or in part, if the Contracting Officer deems such termination necessary to avoid an organizational conflict of interest. If the Contractor was aware of a potential
organizational conflict of interest prior to award or discovered an actual or potential conflict after award and did not disclose it or misrepresented relevant information to the Contracting Officer, the Government may terminate the contract for
default, debar the Contractor from Government contracting, or pursue such other remedies as may be permitted by law or this contract. 
  

	H.12.	ADDITIONAL BACKGROUND PATENT REQUIREMENTS 

 The Contractor shall promptly notify the Government in
writing upon the award of any subcontract containing Patent Rights identifying the Subcontractor, and the work to be performed under the subcontract. Upon the request of the Government the Contractor shall furnish a copy of the subcontract. In the
event that the contractor awards a subcontract covering the subject invention, the mutual obligations of the contractor to the US Government shall become the mutual contractual obligations between the subcontractor and the US Government. The
contractor shall ensure that the rights granted the US Government under FAR Clause 52.227-11 and FAR Subpart 27.3 are incorporated into any subcontract, covering any subject invention, regardless of the tier , pursuant to FAR clause 52.227-11(k)(3).

  

	H.13.	PUBLICATION AND PUBLICITY 

 No information related to data obtained under this contract shall be released
or publicized without the prior written consent of BARDA, unless expedited regulatory reporting requirements are involved. In this case, BARDA will be informed no later than the regulatory agency requiring the information. 

In addition to the requirements set forth in HHSAR Clause 352.227-70, Publications and Publicity incorporated by reference in SECTION I of this
contract, Section 507 of P.L. 104-208 mandates that Contractors funded with Federal dollars, in whole or in part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other
documents.  

  
 44 

 Visterra, Inc. 

HHSO100201500018C 
  

 For purposes of this contract “publication” is defined as an issue of printed material offered for
distribution or any communication or oral presentation of information, including any manuscript or scientific meeting abstract. Any publication containing data generated under this contract must be submitted for BARDA review no less than thirty
(30) Calendar days for manuscripts and fifteen (15) Calendar days for abstracts before submission for public presentation or publication. Contract support shall be acknowledged in all such publications substantially as follows: 

“This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the
Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500018C 
  

	H.14.	REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE 

 Anyone who becomes aware of the existence or
apparent existence of fraud, waste and abuse in HHS funded programs is encouraged to report such matters to the HHS Inspector General’s Office in writing or on the Inspector General’s Hotline. The toll free number is 1-800-HHS-TIPS
(1-800-447-8477). All telephone calls will be handled confidentially. The website to file a complaint on-line is: http://oig.hhs.gov/fraud/hotline/ and the mailing address is: 

US Department of Health and Human Services 

Office of Inspector General 

ATTN: OIG HOTLINE OPERATIONS 

P.O. Box 23489 
 Washington, D.C.
20026 
  

	H.15.	PROHIBITION ON CONTRACTOR INVOLVEMENT WITH TERRORIST ACTIVITIES 

 The Contractor acknowledges that U.S.
Executive Orders and Laws, including but not limited to E.O. 13224 and P.L. 107-56, prohibit transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of
the Contractor to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract. 
  

	H.16.	USE OF FUNDS FOR PROMOTIONAL ITEMS 

 The Contractor shall not use contract funds to purchase promotional
items. Promotional items include, but are not limited to: clothing and commemorative items such as pens, mugs/cups, folders/folios, lanyards, and conference bags that are sometimes provided to visitors, employees, grantees, or conference attendees.
This includes items or tokens given to individuals as these are considered personal gifts for which contract funds may not be expended. 
  

	H.17.	EPA ENERGY STAR REQUIREMENTS 

 In compliance with Executive Order 12845 (requiring Agencies to purchase
energy efficient computer equipment) all microcomputers, including personal computers, monitors, and printers that are purchased using Government funds in performance of a contract shall be equipped with

  
 45 

 Visterra, Inc. 

HHSO100201500018C 
  

 
or meet the energy efficient low-power standby feature as defined by the EPA Energy Star program unless the equipment always meets EPA Energy Star efficiency levels. The microcomputer, as
configured with all components, must be Energy Star compliant. 
 This low-power feature must already be activated when the computer equipment is delivered
to the agency and be of equivalent functionality of similar power managed models. If the equipment will be used on a local area network, the vendor must provide equipment that is fully compatible with the network environment. In addition, the
equipment will run commercial off-the-shelf software both before and after recovery from its energy conservation mode. 
  

	H.18.	SECURITY PLAN REQUIREMENTS 

 The Contractor is required to have an established security plan for the
manufacturing, storage and distribution work performed under this contract that ensures against theft, tampering or destruction of pertinent documents and the specific equipment deliverables. The Contractor’s security plan shall demonstrate how
the physical facilities will be protected using, for example, fencing, controlled access, surveillance equipment, tamper evident packaging, and armed guards. 

The Security Plan shall also describe the procedures to be utilized to control the general internal operations of the firm and a description of the
facility(ies) in which the work will be performed, including any subcontractors. The Security Plan shall also describe the Contractor’s process for conducting background investigations for all employees and subcontractors who will have access
to the development, manufacturing and storage of the product. 
 This plan shall include the security measures to be used to protect the ventilators to be
stored at the Contractor’s facility (e.g., alarm systems, backup electrical power generator systems, etc.), and the contingency plan (including any backup or redundant facilities) to accommodate any manufacturing and storage problems caused by
natural or man-made disasters, power loss, refrigerant loss, equipment failures, etc. The contingency plan shall include a description of the timeline for restarting production. 

 

	H.19.	CARE OF LIVE VERTEBRATE ANIMALS, HHSAR 352.270-5(b) (October 2009) 

  

	a.	Before undertaking performance of any contract involving animal-related activities where the species is regulated by USDA, the Contractor shall register with the Secretary of Agriculture of the United States in
accordance with 7 U.S.C. 2136 and 9 CFR sections 2.25 through 2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer. 

  

	b.	The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CFR Sections 2.1-2.11, or from a source that is exempt from licensing
under those sections. 

  

	c.	 The Contractor agrees that the care, use and intended use of any live vertebrate animals in the performance of this contract shall conform with the
Public Health Service (PHS) Policy on Humane Care of Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the
pertinent laws and regulations of the United States 

  
 46 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	
Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR Subchapter A, Parts 14). In case of conflict between standards, the more stringent standard shall govern. 

 

	d.	If at any time during performance of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is
not in compliance with any of the requirements and standards stated in paragraphs (a) through (c) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the
Contractor corrects the noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s
written notice of suspension, the Contracting Officer may, in consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor’s name may be removed from the list of those contractors with approved Assurances.

 Note: The Contractor may request registration of its facility and a current listing of licensed dealers from the
Regional Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program may be
obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (E-mail: ace@aphis.usda.gov; Web site: (http://www.aphis. usda.gov/animal_welfare). 

(End of Clause) 
  

	H.20.	ANIMAL WELFARE 

 All research involving live, vertebrate animals shall be conducted in accordance with
the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy). The PHS Policy can be accessed at: http://grants1.nih.gov/grants/olaw/references/phspol.htm 

 

	H.21.	RESTRICTION ON PORNOGRAPHY ON COMPUTER NETWORKS 

 The Contractor shall not use contract funds to maintain
or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography. 
  

	H.22.	GUN CONTROL 

 The Contractor shall not use contract funds in whole or in part, to advocate or promote gun
control. 
  

	H.23.	CERTIFICATION OF FILING AND PAYMENT OF TAXES 

 The contractor must be in compliance with Section 518
of the Consolidated Appropriations Act of FY 2014. 

  
 47 

 Visterra, Inc. 

HHSO100201500018C 
  

	H.24.	KEY PERSONNEL, HHSAR 352.242-70 (January 2006) 

 The key personnel specified in this contract are
considered to be essential to work performance. At least 30 days prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the
employ of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement request (including proposed substitutions for key personnel) to permit evaluation by the
Government of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The Government may modify the contract to add or delete key
personnel at the request of the Contractor or Government. (End of Clause) 
 The following individuals are considered to be essential to the work being
performed hereunder: 
  

					
	 Individual
	  	 Organization
	  	 Role

	 [**]
	  	Visterra	  	Clinical development
			
	 [**]
	  	Visterra	  	Project management and financial reporting
			
	 [**]
	  	Visterra	  	Nonclinical development
			
	 [**]
	  	Visterra	  	Nonclinical development/clinical assay development
			
	 [**]
	  	Visterra	  	Clinical operations
			
	 [**]
	  	Visterra	  	Regulatory Affairs
			
	 [**]
	  	Visterra	  	Biopharmaceutical consulting; CMC program manager*
			
	 [**]
	  	[**]	  	Clinical development and regulatory consultant
			
	 [**]
	  	[**]	  	PK/PD design and analysis

  

	*	Note: Visterra intends to convert the CMC lead to a full-time employee. Initial discussions with the CMC lead regarding this matter have already occurred. Visterra will submit any key personnel revision to HHS
Contracting Officer for review. 

  

	H.25.	HIGHLY PATHOGENIC AGENTS 

 The work being conducted under this contract may involve a Highly Pathogenic
Agent (HPA). The NIAID defines an HPA as a pathogen that, under any circumstances, warrants a biocontainment safety level of BSL3 or higher according to either: 
  

	1.	The current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) and can be accessed at http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm 

 

	2.	The Contractor’s Institutional Biosafety Committee (IBC) or equivalent body, 

  

	3.	The Contractor’s appropriate designated institutional biosafety official, or 

  
 48 

 Visterra, Inc. 

HHSO100201500018C 
  

	4.	Documentation of compliance with CDC and USDA Select Agent Programs, where appropriate, for example in the case of testing with highly pathogenic avian influenza viruses (e.g. H5N1 and H7N9). 

If there is ambiguity in the BMBL guidelines and/or there is disagreement among the BMBL, an IBC or equivalent body, or institutional biosafety official, the
highest recommended containment level must be used. 
  

	H.26.	CLINICAL RESEARCH 

 These Clinical Terms apply to all grants and contracts that involve clinical
research. 
 The Government shall have unlimited rights to all protocols, data generated from the execution of these protocols, and final reports, funded by
the Government under this contract, as defined in Rights in Data Clause in FAR 52.227-14 (Alternative II). The Government reserves the right to request that the Contractor provide any contract deliverable in a non-proprietary form, to ensure the
Government has the ability to review and distribute the deliverables, as the Government deems necessary within the context of this contract. 
  

	H.27.	SAFETY AND MONITORING ISSUES 

 Institutional Review Board (IRB) or Independent Ethics Committee (IEC)
Approval 
 Before award and then with the annual progress report, the Contractor must submit to the Government a copy of the current IRB or IEC approved
informed consent document, documentation of continuing review and approval and the Office of Human Research Protections (OHRP) FWA number for the institution or site. 

If other institutions are involved in the research (e.g., a multicenter clinical trial or study), each institution’s IRB or IEC must review and approve
the protocol. They must also provide the Government initial and annual documentation of continuing review and approval, including the current approved informed consent document and FWA number. 

The grantee institution must ensure that the applications as well as all protocols are reviewed by their IRB or IEC. 

To help ensure the safety of participants enrolled in BARDA-funded studies, the Contractor must provide the Government a summary explanation and copies of
documents related to all major changes in the status of ongoing protocols, including the following: 
  

	1.	All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is valid. 

  

	2.	All changes in informed consent documents, identified by version number, date, or both and dates it is valid. 

  

	3.	Termination or temporary suspension of patient accrual. 

  

	4.	Termination or temporary suspension of the protocol. 

  

	5.	Any change in IRB approval. 

  
 49 

 Visterra, Inc. 

HHSO100201500018C 
  

	6.	Any other problems or issues that could affect the participants in the studies. 

 Contractors must notify BARDA
through the Contracting Officer’s Representative (COR) or Contracting Officer (CO) of any of the above changes by email within 72 hours for items 3 - 6 and 7 days for items 1 - 2, followed by a letter signed by the institutional business
official, detailing notification of the change of status to the local IRB and a copy of any responses from the IRB or IEC. 
 If a clinical protocol has
been reviewed by an Institutional Bio-safety Committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval, if any. See the NIH Guidelines for
Research Involving Recombinant DNA Molecules. 
  

	H.28.	DATA AND SAFETY MONITORING REQUIREMENTS 

 The Contractor may be required to conduct independent safety
monitoring for clinical trials of investigational drugs, devices, or biologics; clinical trials of licensed products; and clinical research of any type involving more than minimal risk to volunteers. Independent monitoring can take a variety of
forms. Phase III clinical trials must have an assigned independent data and safety monitoring board (DSMB); other trials may require DSMB oversight as well. The Contractor shall inform the Government of any upcoming site visits and/or audits of
Contractor or Subcontractor facilities funded under this effort. BARDA reserves the right to accompany the Contractor on site visits and/or audits of Contractor or Subcontractor facilities funded under this contract, as the Government deems
necessary. 
 The type of monitoring to be used in a particular clinical trial shall be mutually agreed upon between the Contractor and the Government
during the process of finalizing study protocol. Discussions with the responsible BARDA COR regarding appropriate safety monitoring and approval of the final monitoring plan by BARDA must occur before clinical trial begins and may include, but not
limited to the discussions about the appointment of one of the following: 
  

	 	1.	Independent Safety Medical Monitor (ISM) - a physician or other medically qualified expert who is independent of the study and available in real time to review and recommend appropriate action regarding
adverse events and other safety issues. 

  

	 	2.	Independent Data Monitoring Committee (IDMC) - a group of individuals with pertinent expertise that reviews on a regular basis accumulating data from an ongoing clinical trial. The IDMC advises the sponsor
regarding the continuing safety of current participants and those yet to be recruited, as well as the continuing validity and scientific merit of the trial. The Contractor may be required to use relevant members from an established BARDA IDMC or to
organize an independent IDMC. The Contractor will submit the composition of the IDMC to the Contracting Officer’s Representative for review. All phase III clinical trials must be reviewed by IDMC; other trials may require IDMC oversight as
well. Please refer to FDA Guidance for Clinical Trials Sponsors “Establishment and Operation of Clinical Trial Data Monitoring Committees”. The Government retains the right to place a nonvoting member on the IDMC. 

When a safety monitoring entity is organized, a description of it, its charter or operating procedures (including a proposed meeting schedule and plan
for review of adverse events), and roster and curriculum vitae from all members must be submitted to the Government before  

  
 50 

 Visterra, Inc. 

HHSO100201500018C 
  

 
enrollment starts. 
 Additionally, the Contractor must submit written summaries of all reviews
conducted by the monitoring group to the Government within 30 days of reviews or meetings. 
  

	H.29.	BARDA PROTOCOL REVIEW PROCESS BEFORE PATIENT ENROLLMENT BEGINS 

 BARDA has a responsibility to ensure
that mechanisms and procedures are in place to protect the safety of participants in BARDA-supported clinical trials. Therefore, before patient accrual or participant enrollment, the Contractor must provide the following (as applicable) for review
and approval by the Government: 
  

	 	1.	Draft clinical research protocol identified by version number, date, or both, including details of study design, proposed interventions, patient eligibility, and exclusion criteria. 

 

	 	2.	Documentation of IRB or IEC approval, including OHRP FWA number, IRB or IEC registration number, and IRB or IEC name. 

  

	 	3.	Draft informed consent template, identified by version number, date, or both and date it is valid. 

  

	 	4.	Plans for the management of side effects. 

  

	 	5.	Procedures for assessing and reporting adverse events. 

  

	 	6.	Plans for data and safety monitoring, and monitoring of the clinical study site, pharmacy, and laboratory. 

  

	 	7.	Documentation that the Contractor and all study staff responsible for the design or conduct of the research have received Good Clinical Practice (GCP) training in the protection of human subjects. 

BARDA comments will be forwarded to the Contractor within two weeks (10 business days) of receipt of the above information. The Contractor must address in
writing all study design, safety, regulatory, ethical, and conflict of interest concerns raised by the BARDA COR to the satisfaction of the Government before patient accrual or participant enrollment can begin. After the Government receives the
corrected documentation, a written Contract Officer Authorization (COA) Letter will be provided to the Contractor. This COA provides authorization to the Contractor to execute the specific clinical study funded in part or in whole by the Government.

  

	H.30.	REQUIRED TIME SENSITIVE NOTIFICATION 

 Under the contract, the Contractor must submit to the Contracting
Officer’s representative (COR) as follows: 
  

	 	1.	Expedited safety report of unexpected or life-threatening experience or death - A copy of any report of unexpected or life-threatening experience or death associated with the use of an IND drug, which must be
reported to FDA by telephone or fax as soon as possible but no later than seven days after the IND sponsor’s receipt of the information, must be submitted within 24 hours of knowledge of the event by the Contractor. 

 

	 	2.	 Expedited safety reports of serious, and unexpected adverse experiences - A copy of any report of unexpected and serious adverse experience
associated with use of an IND drug 

  
 51 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	
or any finding from tests in laboratory animals that suggests a significant risk for human subjects, which must be reported in writing to FDA as soon as possible but no later than 15 days after
the IND sponsor’s receipt of the information, must be submitted to the BARDA Contracting Officer’s Representative within 48 hours of knowledge of the event by the Contractor. 

 

	 	3.	IDE reports of unanticipated adverse device effect - A copy of any reports of unanticipated adverse device effect submitted to FDA must be submitted to the BARDA Contracting Officer’s Representative within
24 hours of the occurrence of the event. 

  

	 	4.	Expedited safety reports - should be sent to the BARDA COR concurrently with the report to FDA. 

  

	 	5.	Other adverse events documented during the course of the trial should be included in the annual IND or IDE report and reported to the BARDA annually. 

In case of problems or issues, the BARDA COR will contact the Contractor within 10 working days by email, followed within 7 calendar days by an official
letter to the Contractor. The Contractor shall forward the official letter to the principal investigator listing issues and appropriate actions to be discussed. 

Safety reporting for research not performed under an IND or IDE 

Ongoing safety reporting requirements for research not performed under an IND or IDE shall be mutually agreed upon by the BARDA Contracting Officer’s
Representative and the Contractor. 
  

	H.31.	BARDA CLINICAL TRIAL DATABASE INFORMATION REPORTING 

 The contractor must be prepared to provide initial
information on each clinical study conducted under this contract to BARDA. Study specific information is required at [**] and [**] will be required. Study specific information may include [**]. Clinical site information may include [**]. 

Updated information on enrollment will include [**]. Enrollment information will be provided on [**] as determined by BARDA prior to study start. 

It is expected to have an [**]. Standard Data Submissions refers to the [**]. BARDA’s information management system is [**]. Submission of data to
BARDA’s [**]. Data submission can be done [**]. Similarly, in most cases data will be able to be [**]. The [**] 

  
 52 

 Visterra, Inc. 

HHSO100201500018C 
  

	H.32.	cGMP MANUFACTURING 

 When manufacturing material for use in human clinical trials, all product shall be
manufactured according to cGMP guidelines. Any manufacturing deviations that could result in loss of drug product for use in clinical trials shall be reported to the Contracting Officer via a deviation summary report. 

  
 53 

 Visterra, Inc. 

HHSO100201500018C 
  

 PART II - CONTRACT CLAUSES 

SECTION I - CONTRACT CLAUSES 
 FAR 52.252-2 Clauses
Incorporated by Reference (Feb 1998) 
 This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in
full text. Upon request, the Contracting Officer will make their full text available. 
  

	1.1	FEDERAL ACQUISITION REGULATION (FAR) (48 CFR Chapter 1) CLAUSES 

 Full text of the FAR clauses may be
accessed electronically at: 
 https://www.acquisition.gov/far/index.html. 
  

							
	 Reg
	  	 Clause
	  	 Date
	  	 Clause Title

	FAR	  	52.202-1	  	Nov 2013	  	Definitions
	FAR	  	52.203-3	  	Apr 1984	  	Gratuities
	FAR	  	52.203-5	  	May 2014	  	Covenant Against Contingent Fees
	FAR	  	52.203-6	  	Sep 2006	  	Restrictions on Subcontractor Sales to the Government
	FAR	  	52.203-7	  	May 2014	  	Anti-Kickback Procedures
	FAR	  	52.203-8	  	May 2014	  	Cancellation, Rescission, and Recover of Funds for Illegal or Improper Activity
	FAR	  	52.203-10	  	May 2014	  	Price or Fee Adjustment for Illegal or Improper Activity
	FAR	  	52.203-12	  	Oct 2010	  	Limitation on Payments to Influence Certain Federal Transactions
	FAR	  	52.203-13	  	Apr 2010	  	Contractor Code of Business Ethics and Conduct
	FAR	  	52.203-14	  	Dec 2007	  	Display of Hotline Poster(s)
	FAR	  	52.203-17	  	Apr 2014	  	Contractor Employee Whistleblower Rights and Requirement To Inform Employees of Whistleblower Rights
	FAR	  	52.204-4	  	May 2011	  	Printed or Copied Double-Sided on Postconsumer Fiber Content Paper
	FAR	  	52.204-7	  	Jul 2013	  	System for Award Management
	FAR	  	52.204-10	  	Jul 2013	  	Reporting Executive Compensation and First-Tier Subcontract Awards
	FAR	  	52.204-13	  	Jul 2013	  	System for Award Management Maintenance
	FAR	  	52.204-19	  	Dec 2014	  	Incorporation by Reference or Representations and Certifications
	FAR	  	52.209-6	  	Aug 2013	  	Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment
	FAR	  	52.209-10	  	Dec 2014	  	Prohibition on Contracting with Inverted Domestic Corporations

  
 54 

 Visterra, Inc. 

HHSO100201500018C 
  

							
	 Reg
	  	 Clause
	  	 Date
	  	 Clause Title

	FAR	  	52.210-1	  	Apr 2011	  	Market Research
	FAR	  	52.215-2	  	Oct 2010	  	Audit and Records - Negotiation
	FAR	  	52.215-8	  	Oct 1997	  	Order of Precedence - Uniform Contract Format
	FAR	  	52.215-10	  	Aug 2011	  	Price Reduction for Defective Cost or Pricing Data
	FAR	  	52.215-11	  	Aug 2011	  	Price Reduction for Defective Certified Cost or Pricing Data - Modifications.
	FAR	  	52.215-12	  	Oct 2010	  	Subcontractor Certified Cost or Pricing Data
	FAR	  	52.215-13	  	Oct 2010	  	Subcontractor Certified Cost or Pricing Data - Modifications
	FAR	  	52.215-15	  	Oct 2010	  	Pension Adjustments and Asset Reversions
	FAR	  	52.215-18	  	Jul 2005	  	Reversion or Adjustment of Plans for Postretirement Benefits (PRB) other than Pensions
	FAR	  	52.215-19	  	Oct 1997	  	Notification of Ownership Changes
	FAR	  	52.215-21	  	Oct 2010	  	Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data -Modifications
	FAR	  	52.215-23	  	Oct 2009	  	Limitations on Pass-Through Charges
	FAR	  	52.216-7	  	Jun 2013	  	Allowable Cost and Payment
	FAR	  	52.216-8	  	Jun 2011	  	Fixed Fee
	FAR	  	52.219-28	  	July 2013	  	Post-Award Small Business Program Representation
	FAR	  	52.222-1	  	Feb 1997	  	Notice to the Government of Labor Disputes
	FAR	  	52.222-3	  	Jun2003	  	Convict Labor
	FAR	  	52.222-21	  	Apr 2015	  	Prohibition of Segregated Facilities
	FAR	  	52.222-26	  	Apr 2015	  	Equal Opportunity
	FAR	  	52.222-29	  	Apr 2015	  	Notification of Visa Denial.
	FAR	  	52.222-35	  	Jul 2014	  	Equal Opportunity for Veterans
	FAR	  	52.222-36	  	Jul 2014	  	Equal Opportunity for Workers with Disabilities
	FAR	  	52.222-37	  	Jul 2014	  	Employment Reports on Veterans
	FAR	  	52.222-38	  	Sept 2010	  	Compliance with Veterans’ Employment Reporting Requirements
	FAR	  	52.222-40	  	Dec 2010	  	Notification of Employee Rights Under the National Labor Relations Act
	FAR	  	52.222-41	  	May 2014	  	Service Contract Labor Standards
	FAR	  	52.222-43	  	May 2014	  	Fair Labor Standards Act and Service Contract Labor Standards - Price Adjustment (Multiple Year and Option Contracts)
	FAR	  	52.222-50	  	Mar 2015	  	Combating Trafficking in Persons
	FAR	  	52.222-54	  	Aug 2013	  	Employment Eligibility Verification

  
 55 

 Visterra, Inc. 

HHSO100201500018C 
  

							
	 Reg
	  	 Clause
	  	 Date
	  	 Clause Title

	FAR	  	52.223-6	  	May 2001	  	Drug-Free Workplace
	FAR	  	52.223-18	  	Aug 2011	  	Encouraging Contractor Policy to Ban Text Messaging While Driving
	FAR	  	52.224-1	  	April 1984	  	Privacy Act Notification
	FAR	  	52.224-2	  	April 1984	  	Privacy Act
	FAR	  	52.225-13	  	Jun 2008	  	Restrictions on Certain Foreign Purchases
	FAR	  	52.225-25	  	Dec 2012	  	Prohibition on Contracting with Entities Engaging in Certain Activities or Transactions Relating to Iran - Representation and Certifications
	FAR	  	52.226-1	  	Jun 2000	  	Utilization of Indian Organizations and Indian-Owned Economic Enterprises.
	FAR	  	52.227-1	  	Dec 2007	  	Authorization and Consent, Alternate 1 (APR 1984)
	FAR	  	52.227-2	  	Dec 2007	  	Notice and Assistance Regarding Patent and Copyright Infringement
	FAR	  	52.227-14	  	May 2014	  	 Rights in Data - General, Alt. II
  

Completed portion as follows:
  

Limited Rights Notice (Dec 2007)
  

(a) These data are submitted with limited rights under Government Contract No. HHSO1002015000018C. These data may be reproduced and used by the G overnment
with the express limitation that they will not, without written permission of the Contractor, be used for purposes of manufacture nor disclosed outside the Government; except that the Government may disclose these data outside the Government for the
following purposes, if any, provided that the Government makes such disclosure subject to prohibition against further use and disclosure:
  

Use (except for purposes of manufacture) by support service contractors to support the Government’s performance of this contract.

 
 This Notice shall be marked on any reproduction of these data, in whole or in
part.

	FAR	  	52.227-16	  	June 1987	  	Additional Data Requirements
	FAR	  	52.228-7	  	Mar 1996	  	Insurance - Liability to Third Persons

  
 56 

 Visterra, Inc. 

HHSO100201500018C 
  

							
	 Reg
	  	 Clause
	  	 Date
	  	 Clause Title

	FAR	  	52.229-3	  	Feb 2013	  	Federal, State and Local Taxes
	FAR	  	52.232-1	  	Apr 1984	  	Payments
	FAR	  	52.232-2	  	Apr 1984	  	Payments under Fixed-Price Research and Development Contracts
	FAR	  	52.232-8	  	Feb 2002	  	Discounts for Prompt Payment
	FAR	  	52.232-9	  	Apr 1984	  	Limitation on Withholding of Payments
	FAR	  	52.232-11	  	Apr 1984	  	Extras
	FAR	  	52.232-17	  	May 2014	  	Interest
	FAR	  	52.232-18	  	Apr 1984	  	Availability of Funds
	FAR	  	52.232-20	  	Apr 1984	  	Limitation of Cost
	FAR	  	52.232-23	  	May 2014	  	Assignment of Claims
	FAR	  	52.232-25	  	Jul 2013	  	Prompt Payment
	FAR	  	52.232-33	  	Jul 2013	  	Payment by Electronic Funds Transfer - System for Award Management
	FAR	  	52.233-1	  	May 2014	  	Disputes
	FAR	  	52.233-3	  	Aug 1996	  	Protest After Award, Alternate I
	FAR	  	52.233-4	  	Oct 2004	  	Applicable Law for Breach of Contract Claim
	FAR	  	52.242-1	  	Apr 1984	  	Notice of Intent to Disallow Costs
	FAR	  	52.242-3	  	May 2014	  	Penalties for Unallowable Costs
	FAR	  	52.242-4	  	Jan 1997	  	Certification of Final Indirect Costs
	FAR	  	52.242-13	  	Jul 1995	  	Bankruptcy
	FAR	  	52.243-1	  	Aug 1987	  	Changes - Fixed-Price Alternate V (Apr 1984).
	FAR	  	52.243-2	  	Aug 1987	  	Changes - Cost-Reimbursement Alternate V (Apr 1984).
	FAR	  	52.243-6	  	Apr 1984	  	Change Order Accounting.
	FAR	  	52.243-7	  	Apr 1984	  	Notification of Changes
	FAR	  	52.244-2	  	Oct 2010	  	Subcontracts, Alternate 1 (Jun 2007)
	FAR	  	52.244-5	  	Dec 1996	  	Competition in Subcontracting
	FAR	  	52.244-6	  	Apr 2015	  	Subcontracts for Commercial Items
	FAR	  	52.245-1	  	Apr 2012	  	Government Property
	FAR	  	52.245-9	  	Apr 2012	  	Use and Charges
	FAR	  	52.246-7	  	Apr 1996	  	Inspection of Research and Development - Fixed-Price

  
 57 

 Visterra, Inc. 

HHSO100201500018C 
  

							
	 Reg
	  	 Clause
	  	 Date
	  	 Clause Title

	FAR	  	52.246-8	  	May 2001	  	Inspection of Research and Development - Cost-Reimbursement
	FAR	  	52.246-25	  	Feb 1997	  	Limitation of Liability - Services
	FAR	  	52.248-1	  	October 2010	  	Value Engineering
	FAR	  	52.249-2	  	Apr 2012	  	Termination for the Convenience of the Government (Fixed-Price)
	FAR	  	52.249-6	  	May 2004	  	Termination (Cost-Reimbursement)
	FAR	  	52.249-8	  	Apr 1984	  	Default (Fixed-Price Supply and Service)
	FAR	  	52.249-9	  	Apr 1984	  	Default (Fixed-Price Research and Development)
	FAR	  	52.249-14	  	Apr 1984	  	Excusable Delays
	FAR	  	52.253-1	  	Jan 1991	  	Computer Generated Forms

  

	I.2.	DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION 

 (HHSAR) (48 CFR Chapter 3) CLAUSES

 Full text of the HHSAR clauses can be found at http://www.hhs.gov/grants/contracts/ contract-policies-regulations/hhsar/tocindetail/index.html.

  

							
	HHSAR	  	352.201-70	  	Sept 2010	  	Paperwork Reduction Act
	HHSAR	  	352.202-1	  	Jan 2006	  	Definitions - with Alternate paragraph (h)
	HHSAR	  	352.203-70	  	Mar 2012	  	Anti-Lobbying
	HHSAR	  	352.216-70	  	Jan 2006	  	Additional Cost Principles
	HHSAR	  	352.222-70	  	Jan 2010	  	Contractor Cooperation in Equal Employment Opportunity Investigations
	HHSAR	  	352.223-70	  	Sept 2010	  	Safety and Health
	HHSAR	  	352.224-70	  	Jan 2006	  	Privacy Act
	HHSAR	  	352.227-70	  	Jan 2006	  	Publications and Publicity
	HHSAR	  	352.228-7	  	Dec 1991	  	Insurance - Liability to Third Persons
	HHSAR	  	352.231-71	  	Jan 2001	  	Pricing of Adjustments
	HHSAR	  	352.233-71	  	Jan 2006	  	Litigation and Claims
	HHSAR	  	352.242-73	  	Jan 2006	  	Withholding of Contract Payments
	HHSAR	  	352.242-74	  	Apr 1984	  	Final Decisions on Audit Findings
	HHSAR	  	352.270-4	  	Sept 2010	  	Protection of Human Subjects
	HHSAR	  	352.270-6	  	Jan 2006	  	Restriction on use of Human Subjects

  

	I.3.	ADDITIONAL CONTRACT CLAUSES 

  

	I.3.1.	Additional HHS Acquisition Regulation (HHSAR) Clauses - In Full Text 

 352.231-70 Salary rate
limitation 
  

	(a)	The Contractor shall not use contract funds to pay the direct salary of an individual at a rate in excess of the Federal Executive Schedule Level II in effect on the date the funding was obligated. The Contractor shall
not use contract funds to pay the direct salary of an individual at a rate in excess of the Federal Executive Schedule Level II in effect on the date the funding was obligated. 

  
 58 

 Visterra, Inc. 

HHSO100201500018C 
  

	(b)	For purposes of the salary rate limitation, the terms ‘‘direct salary,’’ ‘‘salary,’’ and ‘‘institutional base salary’’ have the same meaning and are
collectively referred to as ‘‘direct salary’’ in this clause. An individual’s direct salary is the annual compensation that the Contractor pays for an individual’s direct effort (costs) under the contract. Direct salary
excludes any income that an individual may be permitted to earn outside of duties to the Contractor. Direct salary also excludes fringe benefits, overhead, and general and administrative expenses (also referred to as indirect costs or facilities and
administrative costs). 

 The salary rate limitation does not restrict the salary that an organization may pay an individual
working under a Department of Health and Human Services contract or order; it merely limits the portion of that salary that may be paid with federal funds. 
  

	(c)	The salary rate limitation also applies to individuals under subcontracts. 

  

	(d)	If this is a multiple-year contract or order, it may be subject to unilateral modification by the Contracting Officer to ensure that an individual is not paid at a rate that exceeds the salary rate limitation provision
established in the HHS appropriations act used to fund this contract. 

  

	(e)	See the salaries and wages pay tables on the U.S. Office of Personnel Management website for federal Executive Schedule salary levels. 

(End of clause) 
  

	I.3.2.	Additional Federal Acquisition Regulation (FAR) (48 CFR Chapter 1) Clauses - In Full Text 

 52.209-9
Updates of Publicly Available Information Regarding Responsibility Matters (Jul 2013) 
  

	 	(a)	The Contractor shall update the information in the Federal Awardee Performance and Integrity Information System (FAPIIS) on a semi-annual basis, throughout the life of the contract, by posting the required information
in the Central Contractor Registration database via https://www.acquisition.gov. 

  

	 	(b)	As required by section 3010 of the Supplemental Appropriations Act, 2010 (Pub. L. 111- 212), all information posted in FAPIIS on or after April 15, 2011, except past performance reviews, will be publicly available.
FAPIIS consists of two segments— 

  

	 	(1)	The non-public segment, into which Government officials and the Contractor post information, which can only be viewed by— 

  

	 	(i)	Government personnel and authorized users performing business on behalf of the Government; or 

  

	 	(ii)	The Contractor, when viewing data on itself; and 

  
 59 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	(2)	The publicly-available segment, to which all data in the non-public segment of FAPIIS is automatically transferred after a waiting period of 14 calendar days, except for— 

 

	 	(i)	Past performance reviews required by subpart 42.15; 

  

	 	(ii)	Information that was entered prior to April 15, 2011; or (iii) Information that is withdrawn during the 14-calendar-day waiting period by the Government official who posted it in accordance with paragraph
(c)(1) of this clause. 

  

	 	(c)	The Contractor will receive notification when the Government posts new information to the Contractor’s record. 

  

	 	(1)	If the Contractor asserts in writing within 7 calendar days, to the Government official who posted the information, that some of the information posted to the non-public segment of FAPIIS is covered by a disclosure
exemption under the Freedom of Information Act, the Government official who posted the information must within 7 calendar days remove the posting from FAPIIS and resolve the issue in accordance with agency Freedom of Information procedures, prior to
reposting the releasable information. The Contractor must cite 52.209-9 and request removal within 7 calendar days of the posting to FAPIIS. 

  

	 	(2)	The Contractor will also have an opportunity to post comments regarding information that has been posted by the Government. The comments will be retained as long as the associated information is retained, i.e.,
for a total period of 6 years. Contractor comments will remain a part of the record unless the Contractor revises them. 

  

	 	(3)	As required by section 3010 of Pub. L. 111-212, all information posted in FAPIIS on or after April 15, 2011, except past performance reviews, will be publicly available. 

 

	 	(d)	Public requests for system information posted prior to April 15, 2011, will be handled under Freedom of Information Act procedures, including, where appropriate, procedures promulgated under E.O. 12600.

 (End of clause) 

52.217-9,        Option to Extend the Term of the Contract (Mar 2000) 

 

	(a)	The Government may extend the term of this contract by written notice to the Contractor within 10 working days provided that the Government gives the Contractor a preliminary written notice of its intent
to extend at least 30 days before the contract expires. The preliminary notice does not commit the Government to an extension. 

  

	(b)	If the Government exercises this option, the extended contract shall be considered to include this option clause. 

  
 60 

 Visterra, Inc. 

HHSO100201500018C 
  

	(c)	The total duration of this contract, including the exercise of any options under this clause, shall not exceed 60 months/5 years. 

(End of Clause) 
 52.222-2, Payment for
Overtime Premiums (JUL 1990) 
  

	(a)	The use of overtime is authorized under this contract if the overtime premium does not exceed $0 or the overtime premium is paid for work - 

 

	 	(1)	Necessary to cope with emergencies such as those resulting from accidents, natural disasters, breakdowns of production equipment, or occasional production bottlenecks of a sporadic nature; 

 

	 	(2)	By indirect-labor employees such as those performing duties in connection with administration, protection, transportation, maintenance, standby plant protection, operation of utilities, or accounting; 

 

	 	(3)	To perform tests, industrial processes, laboratory procedures, loading or unloading of transportation conveyances, and operations in flight or afloat that are continuous in nature and cannot reasonably be interrupted or
completed otherwise; or 

  

	 	(4)	That will result in lower overall costs to the Government. 

  

	(b)	Any request for estimated overtime premiums that exceeds the amount specified above shall include all estimated overtime for contract completion and shall - 

 

	 	(1)	Identify the work unit; e.g., department or section in which the requested overtime will be used, together with present workload, staffing, and other data of the affected unit sufficient to permit the Contracting
Officer to evaluate the necessity for the overtime; 

  

	 	(2)	Demonstrate the effect that denial of the request will have on the contract delivery or performance schedule; 

  

	 	(3)	Identify the extent to which approval of overtime would affect the performance or payments in connection with other Government contracts, together with identification of each affected contract; and 

 

	 	(4)	Provide reasons why the required work cannot be performed by using multishift operations or by employing additional personnel. (End of clause) 

52.227-11 Patent Rights-Ownership by the Contractor (May 2014) 
  

	(a)	As used in this clause- 

 “Invention” means any invention or discovery that is or may be patentable
or otherwise protectable under title 35 of the U.S. Code, or any variety of plant that is or may be protectable under the Plant Variety Protection Act (7 U.S.C. 2321, et seq.) 

“Made” means— 

  
 61 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	(1)	When used in relation to any invention other than a plant variety, the conception or first actual reduction to practice of the invention; or 

 

	 	(2)	When used in relation to a plant variety, that the Contractor has at least tentatively determined that the variety has been reproduced with recognized characteristics. 

“Nonprofit organization” means a university or other institution of higher education or an organization of the type described in section 501(c)(3)
of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)), or any nonprofit scientific or educational organization qualified under a State nonprofit
organization statute. 
 “Practical application” means to manufacture, in the case of a composition of product; to practice, in the case of a
process or method; or to operate, in the case of a machine or system; and, in each case, under such conditions as to establish that the invention is being utilized and that its benefits are, to the extent permitted by law or Government regulations,
available to the public on reasonable terms. 
 “Subject invention” means any invention of the Contractor made in the performance of work under
this contract. 
  

	(b)	Contractor’s rights: 

  

	 	(1)	Ownership. The Contractor may retain ownership of each subject invention throughout the world in accordance with the provisions of this clause. 

 

	 	(2)	License: 

  

	 	(i)	The Contractor shall retain a nonexclusive royalty-free license throughout the world in each subject invention to which the Government obtains title, unless the Contractor fails to disclose the invention within the
times specified in paragraph (c) of this clause. The Contractor’s license extends to any domestic subsidiaries and affiliates within the corporate structure of which the Contractor is a part, and includes the right to grant sublicenses to
the extent the Contractor was legally obligated to do so at contract award. The license is transferable only with the written approval of the agency, except when transferred to the successor of that part of the Contractor’s business to which
the invention pertains. 

  

	 	(ii)	The Contractor’s license may be revoked or modified by the agency to the extent necessary to achieve expeditious practical application of the subject invention in a particular country in accordance with the
procedures in FAR 27.302(i)(2) and 27.304-1(f). 

  

	(c)	Contractor’s obligations: 

  

	 	(1)	 The Contractor shall disclose in writing each subject invention to the Contracting Officer within 2 months after the inventor discloses it in writing
to Contractor personnel responsible for patent matters. The disclosure shall identify the inventor(s) and this contract under which the subject invention was made. It shall be sufficiently complete in technical detail to convey a clear understanding
of the subject invention. The disclosure shall also identify any publication, on sale (i.e., sale or offer for sale), 

  
 62 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	
or public use of the subject invention, or whether a manuscript describing the subject invention has been submitted for publication and, if so, whether it has been accepted for publication. In
addition, after disclosure to the agency, the Contractor shall promptly notify the Contracting Officer of the acceptance of any manuscript describing the subject invention for publication and any on sale or public use. 

 

	 	(2)	The Contractor shall elect in writing whether or not to retain ownership of any subject invention by notifying the Contracting Officer within 2 years of disclosure to the agency. However, in any case where publication,
on sale, or public use has initiated the 1-year statutory period during which valid patent protection can be obtained in the United States, the period for election of title may be shortened by the agency to a date that is no more than 60 days prior
to the end of the statutory period. 

  

	 	(3)	The Contractor shall file either a provisional or a nonprovisional patent application or a Plant Variety Protection Application on an elected subject invention within 1 year after election. However, in any case where a
publication, on sale, or public use has initiated the 1-year statutory period during which valid patent protection can be obtained in the United States, the Contractor shall file the application prior to the end of that statutory period. If the
Contractor files a provisional application, it shall file a nonprovisional application within 10 months of the filing of the provisional application. The Contractor shall file patent applications in additional countries or international patent
offices within either 10 months of the first filed patent application (whether provisional or nonprovisional) or 6 months from the date permission is granted by the Commissioner of Patents to file foreign patent applications where such filing has
been prohibited by a Secrecy Order. 

  

	 	(4)	The Contractor may request extensions of time for disclosure, election, or filing under paragraphs (c)(1), (c)(2), and (c)(3) of this clause. 

 

	(d)	Government’s rights— 

  

	 	(1)	Ownership. The Contractor shall assign to the agency, on written request, title to any subject invention: 

  

	 	(i)	If the Contractor fails to disclose or elect ownership to the subject invention within the times specified in paragraph (c) of this clause, or elects not to retain ownership; provided, that the agency may request
title only within 60 days after learning of the Contractor’s failure to disclose or elect within the specified times. 

  

	 	(ii)	In those countries in which the Contractor fails to file patent applications within the times specified in paragraph (c) of this clause; provided, however, that if the Contractor has filed a patent application in a
country after the times specified in paragraph (c) of this clause, but prior to its receipt of the written request of the agency, the Contractor shall continue to retain ownership in that country. 

  
 63 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	(iii)	In any country in which the Contractor decides not to continue the prosecution of any application for, to pay the maintenance fees on, or defend in reexamination or opposition proceeding on, a patent on a subject
invention. 

  

	 	(2)	License. If the Contractor retains ownership of any subject invention, the Government shall have a nonexclusive, nontransferable, irrevocable, paid-up license to practice, or have practiced for or on its behalf, the
subject invention throughout the world. 

  

	(e)	Contractor action to protect the Government’s interest. (1) The Contractor shall execute or have executed and promptly deliver to the agency all instruments necessary to- 

 

	 	(i)	Establish or confirm the rights the Government has throughout the world in those subject inventions in which the Contractor elects to retain ownership; and 

 

	 	(ii)	Assign title to the agency when requested under paragraph (d) of this clause and to enable the Government to obtain patent protection and plant variety protection for that subject invention in any country.

  

	 	(2)	The Contractor shall require, by written agreement, its employees, other than clerical and nontechnical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent
matters and in the Contractor’s format, each subject invention in order that the Contractor can comply with the disclosure provisions of paragraph (c) of this clause, and to execute all papers necessary to file patent applications on
subject inventions and to establish the Government’s rights in the subject inventions. The disclosure format shall require, as a minimum, the information required by paragraph (c)(1) of this clause. The Contractor shall instruct such employees,
through employee agreements or other suitable educational programs, as to the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U.S. or foreign statutory bars. 

 

	 	(3)	The Contractor shall notify the Contracting Officer of any decisions not to file a nonprovisional patent application, continue the prosecution of a patent application, pay maintenance fees, or defend in a reexamination
or opposition proceeding on a patent, in any country, not less than 30 days before the expiration of the response or filing period required by the relevant patent office. 

 

	 	(4)	The Contractor shall include, within the specification of any United States nonprovisional patent or plant variety protection application and any patent or plant variety protection certificate issuing thereon covering a
subject invention, the following statement, “This invention was made with Government support under (identify the contract) awarded by (identify the agency). The Government has certain rights in the invention.” 

 

	(f)	 Reporting on utilization of subject inventions. The Contractor shall submit, on request, periodic reports no more frequently than annually on the
utilization of a subject invention or on efforts at obtaining utilization of the subject invention that are being made by the Contractor or its licensees or assignees. The reports shall include information regarding the

  
 64 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	
status of development, date of first commercial sale or use, gross royalties received by the Contractor, and other data and information as the agency may reasonably specify. The Contractor also
shall provide additional reports as may be requested by the agency in connection with any march-in proceeding undertaken by the agency in accordance with paragraph (h) of this clause. The Contractor also shall mark any utilization report as
confidential/proprietary to help prevent inadvertent release outside the Government. As required by 35 U.S.C. 202(c)(5), the agency will not disclose that information to persons outside the Government without the Contractor’s permission.

  

	(g)	Preference for United States industry. Notwithstanding any other provision of this clause, neither the Contractor nor any assignee shall grant to any person the exclusive right to use or sell any subject invention in
the United States unless the person agrees that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the United States. However, in individual cases, the requirement
for an agreement may be waived by the agency upon a showing by the Contractor or its assignee that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture
substantially in the United States, or that under the circumstances domestic manufacture is not commercially feasible. 

  

	(h)	March-in rights. The Contractor acknowledges that, with respect to any subject invention in which it has retained ownership, the agency has the right to require licensing pursuant to 35 U.S.C. 203 and 210(c), and in
accordance with the procedures in 37 CFR 401.6 and any supplemental regulations of the agency in effect on the date of contract award. 

  

	(i)	Special provisions for contracts with nonprofit organizations. If the Contractor is a nonprofit organization, it shall— 

  

	 	(1)	Not assign rights to a subject invention in the United States without the written approval of the agency, except where an assignment is made to an organization that has as one of its primary functions the management of
inventions, provided, that the assignee shall be subject to the same provisions as the Contractor; 

  

	 	(2)	Share royalties collected on a subject invention with the inventor, including Federal employee co-inventors (but through their agency if the agency deems it appropriate) when the subject invention is assigned in
accordance with 35 U.S.C. 202(e) and 37 CFR 401.10; 

  

	 	(3)	Use the balance of any royalties or income earned by the Contractor with respect to subject inventions, after payment of expenses (including payments to inventors) incidental to the administration of subject inventions
for the support of scientific research or education; and 

  

	 	(4)	 Make efforts that are reasonable under the circumstances to attract licensees of subject inventions that are small business concerns, and give a
preference to a small business concern when licensing a subject invention if the 

  
 65 

 Visterra, Inc. 

HHSO100201500018C 
  

	 	
Contractor determines that the small business concern has a plan or proposal for marketing the invention which, if executed, is equally as likely to bring the invention to practical application
as any plans or proposals from applicants that are not small business concerns; provided, that the Contractor is also satisfied that the small business concern has the capability and resources to carry out its plan or proposal. The decision whether
to give a preference in any specific case will be at the discretion of the Contractor. 

  

	 	(5)	Allow the Secretary of Commerce to review the Contractor’s licensing program and decisions regarding small business applicants, and negotiate changes to its licensing policies, procedures, or practices with the
Secretary of Commerce when the Secretary’s review discloses that the Contractor could take reasonable steps to more effectively implement the requirements of paragraph (i)(4) of this clause. 

 

	(j)	Communications shall be addressed to the Contracting Officer. 

  

	(k)	Subcontracts: 

  

	 	(1)	The Contractor shall include the substance of this clause, including this paragraph (k), in all subcontracts for experimental, developmental, or research work to be performed by a small business concern or nonprofit
organization. 

  

	 	(2)	The Contractor shall include in all other subcontracts for experimental, developmental, or research work the substance of the patent rights clause required by FAR Subpart 27.3. 

 

	 	(3)	At all tiers, the patent rights clause must be modified to identify the parties as follows: references to the Government are not changed, and the subcontractor has all rights and obligations of the Contractor in the
clause. The Contractor shall not, as part of the consideration for awarding the subcontract, obtain rights in the subcontractor’s subject inventions. 

  

	 	(4)	In subcontracts, at any tier, the agency, the subcontractor, and the Contractor agree that the mutual obligations of the parties created by this clause constitute a contract between the subcontractor and the agency with
respect to the matters covered by the clause; provided, however, that nothing in this paragraph is intended to confer any jurisdiction under the Contract Disputes Act in connection with proceedings under paragraph (h) of this clause.

 PART III - ATTACHMENTS 

SECTION J - LIST ATTACHMENTS 
 The following documents are
attached and incorporated in this contract: 
 Attachment 1: Invoice/Financing Request Instructions and Contract Financial Reporting
Instructions for BARDA Cost-Reimbursement Type Contracts, 6 pages. 
 Attachment 2: Sample Invoice Form 

  
 66 

 Visterra, Inc. 

HHSO100201500018C 
  

 Attachment 3: Disclosure of Lobbying Activities, SF-LLL, dated 7/1997, 2 pages.
Located at: http://www.whitehouse.gov/sites/default/files/omb/grants/sflllin.pdf. 
 Attachment 4: Report of Government
Owned, Contractor Held Property, dated 10/2014, 1 page. 
 Located at:
http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/ Govt-Owned-Prop.pdf 
 Attachment 5: Safety and Health, HHSAR
Clause 352.223-70, dated 1/2006 
 Attachment 6: Use Link; then input form # (i.e., dd2734- _) 

Contract Performance Reports (EVM): http://www.dtic.mil/whs/directives/forms/index.htm 

Format 1: Work Breakdown Structure; Form dd2734-1 

Format 2: Organizational Categories, Form dd2734-2 

Format 3: Baseline, Form dd2734-3 

Format 4: Staffing, Form dd2734-4 

Format 5: Explanations and Problem Analyses, Form dd2734-5 

Attachment 7: Financial Report of Individual Project/Contract 

Attachment 8: Instructions for Completing Financial Report of Individual Project/Contract 

Attachment 9: Milestone Table - Major Deliverables 

  
 67 

 ATTACHMENT 1 

INVOICE/FINANCING REQUEST INSTRUCTIONS - FOR COST-REIMBURSEMENT 

TYPE CONTRACTS 
 Format: Payment
requests shall be submitted on the Contractor’s self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard Form 1034, Public Voucher for Purchases and Services Other Than
Personal, may be used in lieu of the Contractor’s self-generated form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter with the payment request. 

Number of Copies: Payment requests shall be submitted in the quantity specified in the Invoice Submission Instructions in Section G of the Contract
Schedule. 
 Frequency: Payment requests shall not be submitted more frequently than once every two weeks in accordance with the Allowable Cost and
Payment Clause incorporated into this contract. Small business concerns may submit invoices/financing requests more frequently than every two weeks when authorized by the Contracting Officer. 

Cost Incurrence Period: Costs incurred must be within the contract performance period or covered by pre-contract cost provisions. 

Billing of Costs Incurred: If billed costs include (1) costs of a prior billing period, but not previously billed, or (2) costs incurred
during the contract period and claimed after the contract period has expired, the Contractor shall site the amount(s) and month(s) in which it incurred such costs. 

Contractor’s Fiscal Year: Payment requests shall be prepared in such a manner that the Government can identify costs claimed with the
Contractor’s fiscal year. 
 Currency: All BARDA contracts are expressed in United States dollars. When the Government pays in a currency other
than United States dollars, billings shall be expressed, and payment by the Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the
Contractor. Notwithstanding the above, the total of all invoices paid under this contract may not exceed the United States dollars authorized. 
 Costs
Requiring Prior Approval: Costs requiring the Contracting Officer’s approval, including those set forth in an Advance Understanding in the contract, shall be identified and reference the Contracting Officer’s Authorization (COA)
Number. In addition, the Contractor shall show any cost set forth in an Advance Understanding as a separate line item on the payment request. 

Invoice/Financing Request Identification: Each payment request shall be identified as either: 

 

	(a)	Interim Invoice/Contract Financing Request: These are interim payment requests submitted during the contract performance period. 

 

	(b)	Completion Invoice: The completion invoice shall be submitted promptly upon completion of the work, but no later than one year from the contract completion date, or within 120 days after settlement of the final
indirect cost rates covering the year in which the contract is physically complete (whichever date is later). The Contractor shall submit the completion invoice when all costs have been assigned to the contract and it completes all performance
provisions. 

  
 68 

					
	Attachment 1	  		  	
 69

  

	(c)	Final Invoice: A final invoice may be required after the amounts owed have been settled between the Government and the Contractor (e.g., resolution of all suspensions and audit exceptions). 

Preparation and Itemization of the Invoice/Financing Request: The Contractor shall furnish the information set forth in the instructions below. The
instructions are keyed to the entries on the Sample Invoice/Financing Request. 
  

	(a)	Designated Billing Office Name and Address: Enter the designated billing office name and address, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule. 

 

	(b)	Contractor’s Name, Address, Point of Contact, VIN, and DUNS or DUNS+4 Number: Show the Contractor’s name and address exactly as they appear in the contract, along with the name, title, phone number, and
e-mail address of the person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds Transfer, to whom payment is to be sent. Provide the Contractor’s Vendor Identification Number (VIN),
and Data Universal Numbering System (DUNS) number or DUNS+4. The DUNS number must identify the Contractor’s name and address exactly as stated on the face page of the contract. When an approved assignment has been made by the Contractor, or a
different payee has been designated, provide the same information for the payee as is required for the Contractor (i.e., name, address, point of contact, VIN, and DUNS). 

 

	(c)	Invoice/Financing Request Number: Insert the appropriate serial number of the payment request. 

  

	(d)	Date Invoice/Financing Request Prepared: Insert the date the payment request is prepared. 

  

	(e)	Contract Number and Order Number (if applicable): Insert the contract number and order number (if applicable). 

  

	(f)	Effective Date: Insert the effective date of the contract or if billing under an order, the effective date of the order. 

  

	(g)	Total Estimated Cost of Contract/Order: Insert the total estimated cost of the contract, exclusive of fixed-fee. If billing under an order, insert the total estimated cost of the order, exclusive of fixed-fee.
For incrementally funded contracts/orders, enter the amount currently obligated and available for payment. 

  

	(h)	Total Fixed-Fee: Insert the total fixed-fee (where applicable) or the portion of the fixed-fee applicable to a particular invoice as defined in the contract. 

 

	(i)	Two-Way/Three-Way Match: Identify whether payment is to be made using a two-way or three- way match. To determine required payment method, refer to the Invoice Submission Instructions in Section G of the Contract
Schedule. 

  

	(j)	Office of Acquisitions: Insert the name of the Office of Acquisitions, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule. 

 

	(k)	Central Point of Distribution: Insert the Central Point of Distribution, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule. 

 

	(l)	Billing Period: Insert the beginning and ending dates (month, day, and year) of the period in which costs were incurred and for which reimbursement is claimed. 

					
	Attachment 1	  		  	70

  

	(m)	Amount Billed - Current Period: Insert the amount claimed for the current billing period by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line
items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item. 

  

	(n)	Amount Billed - Cumulative: Insert the cumulative amounts claimed by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the
contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item. 

  

	(o)	Direct Costs: Insert the major cost elements. For each element, consider the application of the paragraph entitled “Costs Requiring Prior Approval” on page 1 of these instructions. 

 

	 	(1)	Direct Labor: Include salaries and wages paid (or accrued) for direct performance of the contract. List individuals by name, title/position, hourly/annual rate, level of effort (actual hours or % of effort),
breakdown by task performed by personnel, and amount claimed. 

  

	 	(2)	Fringe Benefits: List any fringe benefits applicable to direct labor and billed as a direct cost. Do not include in this category fringe benefits that are included in indirect costs. 

 

	 	(3)	Accountable Personal Property: Include any property having a unit acquisition cost of $5,000 or more, with a life expectancy of more than two years, and sensitive property regardless of cost (see the HHS
Contractor’s Guide for Control of Government Property)(e.g. personal computers). Note this is not permitted for reimbursement without pre-authorization from the CO. 

On a separate sheet of paper attached to the payment request, list each item for which reimbursement is requested. Include reference to the
following (as applicable): 
 Item number for the specific piece of equipment listed in the Property Schedule, and 

COA number, if the equipment is not covered by the Property Schedule. 

The Contracting Officer may require the Contractor to provide further itemization of property having specific limitations set forth in the
contract. 
  

	 	(4)	Materials and Supplies: Include all consumable material and supplies regardless of amount. Detailed line-item breakdown (e.g. receipts, quotes, etc.) is required. 

 

	 	(5)	Premium Pay: List remuneration in excess of the basic hourly rate. 

  

	 	(6)	Consultant Fee: List fees paid to consultants. Identify consultant by name or category as set forth in the contract or COA, as well as the effort (i.e., number of hours, days, etc.) and rate billed.

  

	 	(7)	Travel: Include domestic and foreign travel. Foreign travel is travel outside of Canada, the United States and its territories and possessions. However, for an organization located outside Canada, the United
States and its territories and possessions, foreign travel means travel outside that country. Foreign travel must be billed separately from domestic travel. 

  

	 	(8)	 Subcontract Costs: List subcontractor(s) by name and amount billed. Provide subcontract invoices/receipts as backup documentation. If
subcontract is of the cost-reimbursement 

					
	Attachment 1	  		  	
 71

  

	 	
variety, detailed breakdown will be required. Regardless, include backup documentation (e.g. subcontractor invoices, quotes, etc.). 

 

	 	(9)	Other: Include all other direct costs not fitting into an aforementioned category. If over $1,000, list cost elements and dollar amounts separately. If the contract contains restrictions on any cost element, that
cost element must be listed separately. 

  

	(p)	Cost of Money (COM): Cite the COM factor and base in effect during the time the cost was incurred and for which reimbursement is claimed, if applicable. 

 

	(q)	Indirect Costs: Identify the indirect cost base (IDC), indirect cost rate, and amount billed for each indirect cost category. 

 

	(r)	Fixed-Fee: Cite the formula or method of computation for fixed-fee, if applicable. The fixed-fee must be claimed as provided for by the contract. 

 

	(s)	Total Amounts Claimed: Insert the total amounts claimed for the current and cumulative periods. 

  

	(t)	Adjustments: Include amounts conceded by the Contractor, outstanding suspensions, and/or disapprovals subject to appeal. 

  

	(u)	Grand Totals 

  

	(v)	Certification of Salary Rate Limitation: If required by the contract (see Invoice Submission Instructions in Section G of the Contract Schedule), the Contractor shall include the following certification at the
bottom of the payment request: 

 “I hereby certify that the salaries billed in this payment request are in compliance
with the Salary Rate Limitation Provisions in Section H of the contract.” 
  

	**	Note the Contracting Officer may require the Contractor to submit detailed support for costs claimed on payment requests. Every cost must be determined to be allocable, reasonable, and allowable per FAR Part 31.

 ATTACHMENT 2 – SAMPLE INVOICE 

 

							
	
Company Name
	 	 
	 Designated Billing
Office Name and Address:
  
 DHHS/OS/ASPR/AMCG

Attn: Contracting Officer

200 C St., S.W.
  
	 	Invoice/Finance Number:
	 Washington, D.C. 20201
	 	Date Invoice Prepared:
	 	 
	 Contractor’s Address and Contact
Information:
	 	 Contract No.

 
 Effective Date:

	 	 	  

Total Estimated Cost of Order:
  

Office of Acquisitions:
 Contracting Officer (insert name
here)
 Office of Acquisitions Management, Contracts, and Grants (AMCG)
  

	
POC: Name of accountant or COO or signatory authority for invoice

Title:
 Phone:

E-Mail:
  

TIN:
 DUNS
#:
	 	Central Point of Distribution:

This invoice represents reimbursable costs for the period from 
  

									
	  	 	  	  	Amount Billed	  	  
	Expenditure Category	 	  	  	Current	  	Cumulative	  	Contract Value
	Direct Costs:	 	 	  	 	  	 	  	 
	 Direct Labor
	 	 	  	 	  	 	  	 
	 Fringe Benefits 
	 	0.00%	  	 	  	 	  	 
	Total Labor Costs:	 	 	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	Overhead 	 	0.00%	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	 Travel
	 	 	  	 	  	 	  	 
	 Subcontracts
	 	 	  	 	  	 	  	 
	 Consultant Fees
	 	 	  	 	  	 	  	 
	 Materials and Supplies
	 	 	  	 	  	 	  	 
	 Other
	 	 	  	 	  	 	  	 
	Total Direct Costs	 	 	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	G&A Rate 	 	0.00%	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	Subtotal:	 	 	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	Fixed Fee 	 	0.0%	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	Total Amount Claimed	 	 	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	Adjustments	 	 	  	 	  	 	  	 
	 	 	 	  	 	  	 	  	 
	Grand Total	 	 	  	$—  	  	 	  	 

 I certify that all payments requested are for appropriate purposes and in accordance with the contract. 

 

			
	  

	Name/signature of signatory authority for invoicing

					
	 Attachment 3:     DISCLOSURE OF LOBBYING ACTIVITIES 

Complete this form to disclose lobbying activities pursuant to 31 U.S.C. 1352

(See reverse for public burden disclosure.)
	 	 Approved by OMB

0348-0046

  

											
	1. Type of Federal Action:	  	2. Status of Federal Action:	 	3. Report Type:
	 	 	 
	
     ̈ a. contract

        b. grant

        c. cooperative agreement

        d. loan

        e. loan guarantee

        f. loan insurance
  
	  	
     ̈ a. bid/offer/application

        b. initial award

        c. post-award
	 	      ̈ a.initial filing
         b.material change

For Material Change Only:
 year
             quarter                 

date of last report
                        

	4. Name and Address of Reporting Entity:	 	5. If Reporting Entity in No. 4 is a Subawardee, Enter Name and Address of Prime:
	  

 ̈    Prime
                                    
 ̈    Subawardee

                          
                          Tier             , if
known: 
  
 Congressional District, if known : 4c

 
	 	 Congressional District,
if known :
  

	 	 
	6. Federal Department/Agency:	 	 7. Federal Program
Name/Description:
  
 CFDA Number, if applicable:
                            

 

	 	 
	8. Federal Action Number, if known :	 	 9. Award Amount, if
known: 
 $            

 

	 	 
	 10.
a. Name and Address of Lobbying Registrant
 (if individual, last name, first name, MI):

 
	 	 b. Individuals Performing Services
(including address if different from No. 10a )
 (last name, first name, MI):

	 		 
	11. Information requested through this form is authorized by title 31 U.S.C.
section 1352. This disclosure of lobbying activities is a material representation of fact upon which reliance was placed by the tier above when this transaction was made or entered into. This disclosure is required pursuant to 31 U.S.C. 1352. This
information will be available for public inspection. Any person who fails to file the required disclosure shall be subject to a civil penalty of not less than $10,000 and not more than $100,000 for each such failure.	 	Signature:	 	  

	 	Print Name	 	  

	 	Title:	 	  

	 	Telephone No.:	 	  
	  	Date:                 
	 		 		  	 
	 		 		  	 
	 		 		  	 
	 	 	 	 	  	 
	 	 
	Federal Use Only:	 	Authorized for Local Reproduction Standard Form LLL (Rev. 7-97)

  

			
	  

    PRINT    

 
	 	

 ATTACHMENT 3 

INSTRUCTIONS FOR COMPLETION OF SF-LLL, DISCLOSURE OF LOBBYING ACTIVITIES 

This disclosure form shall be completed by the reporting entity, whether subawardee or prime Federal recipient, at the initiation or receipt of a covered
Federal action, or a material change to a previous filing, pursuant to title 31 U.S.C. section 1352. The filing of a form is required for each payment or agreement to make payment to any lobbying entity for influencing or attempting to influence an
officer or employeeof any agency, a Member of Congress, an officer or employee ofCongress, or an employeeof a Member of Congress in connection with a covered Federalaction. Completeall items that apply for both the initial filing and material change
report. Refer to the implementing guidance published by the Office of Management and Budget for additional information. 
 Identify the type of covered
Federal action for which lobbying activity is and/or has been secured to influence the outcome of a covered Federal action. 
 Identify the status of the
covered Federal action. 
 Identify the appropriateclassification of this report. If this is a followup report caused by a material change to the
information previously reported, enter the year and quarter in which the change occurred. Enter the date of the last previously submitted report by this reporting entity for this covered Federal action. 

Enter the full name, address, city, State and zip code of the reporting entity. Include Congressional District, if known. Check the appropriateclassification
of the reporting entity that designates if it is, or expects to be, a prime or subaward recipient. Identify the tier of the subawardee, e.g., the first subawardee of the prime is the 1st tier. Subawards include but are not limited to subcontracts,
subgrants and contract awards under grants. 
 If the organization filing the report in item 4 checks “Subawardee,” then enter the full name,
address, city, State and zip code of the prime Federal recipient. Include Congressional District, if known. 
 Enter the name of the Federal agency making
the award or loan commitment. Include at least one organizationallevel below agency name, if known. For example, Department of Transportation, United States Coast Guard. 

Enter the Federal program name or description for the covered Federal action (item 1). If known, enter the full Catalog of Federal Domestic Assistance (CFDA)
number for grants, cooperative agreements, loans, and loan commitments. 
 Enter the most appropriate Federal identifying number available for the Federal
action identified in item 1 (e.g., Request for Proposal (RFP) number; Invitation for Bid (IFB) number; grant announcement number; the contract, grant, or loan award number; the application/proposal control number assigned by the Federal agency).
Include prefixes, e.g., “RFP-DE-90-001.” 
 For a covered Federal action where there has been an award or loan commitment by the Federal agency,
enter the Federal amount of the award/loan commitment for the prime entity identified in item 4 or 5. 
  

	(a)	Enter the full name, address, city, State and zip code of the lobbying registrant under the Lobbying Disclosure Act of 1995 engaged by the reporting entity identified in item 4 to influence the covered Federal action.

  

	 	(b)	Enter the full names of the individual(s) performing services, and include full address if different from 10 (a). Enter Last Name, First Name, and Middle Initial (MI). 

The certifying official shall sign and date the form, print his/her name, title, and telephone number. 

 

According to the Paperwork Reduction Act, as amended, no persons are required to respond to a collection of information unless
it displays a valid OMB Control Number. The valid OMB control number for this information collection is OMB No. 0348-0046. Public reporting burden for this collection of information is estimated to average 10 minutes per response, including time for
reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of
information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0046), Washington, DC 20503. 

  

					
		 	Attachment 3	 	2

 ATTACHMENT 4 
  

															
	REPORT OF GOVERNMENT OWNED, CONTRACTOR HELD PROPERTY
	CONTRACTOR:	  	 	  	 	  	 	  	 	 	CONTRACT NUMBER:  

	ADDRESS:	  	 	  	 	  	 	  	 	 	REPORT DATE:
	ADDRESS1:	  	 	  	 	  	 	  	 	 	 
	ADDRESS2:	  	 	  	 	  	 	  	 	 	FISCAL YEAR:
	CITY:	  	 	  	 	  	 	  	 	 		  		  	 
	STATE:	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	ZIP:	  	 	  	 	  	 	  	 	 	 
	CLASSIFICATION	  	BEGINNING OF
PERIOD	  	ADJUSTMENTS	  	END OF PERIOD
	  	  	#ITEMS	  	VALUE	  	 GFP

ADDED
	  	CAP
ADDED	 	DELETIONS	  	#ITEMS	  	VALUE
	LAND >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	LAND <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	OTHER REAL >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	OTHER REAL <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	PROPERTY UNDER CONST >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	PROPERTY UNDER CONST <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	PLANT EQUIP >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	PLANT EQUIP <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	SPECIAL TOOLING >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	SPECIAL TOOLING <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	SPECIAL TEST EQUIP >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	SPECIAL TEST EQUIP <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	AGENCY PECULIAR >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	AGENCY PECULIAR <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	MATERIAL >=$25K (CUMULATIVE)	  	 	  	 	  	 	  	 	  	 
	PROPERTY UNDER MFR >=$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	PROPERTY UNDER MFR <$25K	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	SIGNED BY:	  	 	  	 	  	 	  	 	 	 	  	 	  	 
	SIGNATURE	  	 	  	DATE SIGNED:	 	 	  	 	  	 
	NAME PRINTED	  	 	  	Email	 	 	  	 	  	 
	TITLE	  	 	  	TELEPHONE	 	 	  	 	  	 

 Report of Government Owned, Contractor Held Property (Rev 10/2014) 

 ATTACHMENT 5 

Safety and Health (January 2006) 

(a) To help ensure the protection of the life and health of all persons, and to help prevent damage to property, the Contractor shall comply
with all federal, State, and local laws and regulations applicable to the work being performed under this contract. These laws are implemented or enforced by the Environmental Protection Agency, Occupational Safety and Health Administration (OSHA)
and other regulatory/enforcement agencies at the federal, State, and local levels. 
 (1) In addition, the Contractor shall comply with the
following regulations when developing and implementing health and safety operating procedures and practices for both personnel and facilities involving the use or handling of hazardous materials and the conduct of research, development, or test
projects: 
 (i) 29 CFR 1910.1030, Bloodborne pathogens; 29 CFR 1910.1450, Occupational exposure to hazardous chemicals in
laboratories; and other applicable occupational health and safety standards issued by OSHA and included in 29 CFR Part 1910. These regulations are available at http://www.osha.gov/. 

(ii) Nuclear Regulatory Commission Standards and Regulations, pursuant to the Energy Reorganization Act of 1974 (42 U.S.C. 5801 et
seq.). The Contractor may obtain copies from the U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001. 
 (2) The
following Government guidelines are recommended for developing and implementing health and safety operating procedures and practices for both personnel and facilities: 

(i) Biosafety in Microbiological and Biomedical Laboratories, CDC. This publication is available at
http://www.cdc.gov/biosafety/publications/index.htm. 
 (ii) Prudent Practices for Safety in Laboratories (1995), National Research
Council, National Academy Press, 500 Fifth Street, NW., Lockbox 285, Washington, DC 20055 (ISBN 0-309-05229- 7). This publication is available at http://www.nap.edu/catalog/4911 .html. 

(b) Further, the Contractor shall take or cause to be taken additional safety measures as the Contracting Officer, in conjunction with the
Contracting Officer’s Technical Representative or other appropriate officials, determines to be reasonably necessary. If compliance with these additional safety measures results in an increase or decrease in the cost or time required for
performance of any part of work under this contract, the Contracting Officer will make an equitable adjustment in accordance with the applicable “Changes” clause set forth in this contract. 

  
 1 

 ATTACHMENT 5 

 

 (c) The Contractor shall maintain an accurate record of, and promptly report to the
Contracting Officer, all accidents or incidents resulting in the exposure of persons to toxic substances, hazardous materials or hazardous operations; the injury or death of any person; or damage to property incidental to work performed under the
contract and all violations for which the Contractor has been cited by any federal, State or local regulatory/enforcement agency. The report shall include a copy of the notice of violation and the findings of any inquiry or inspection, and an
analysis addressing the impact these violations may have on the work remaining to be performed. The report shall also state the required action(s), if any, to be taken to correct any violation(s) noted by the federal, State or local
regulatory/enforcement agency and the time frame allowed by the agency to accomplish the necessary corrective action. 
 (d) If the
Contractor fails or refuses to comply with the federal, State or local regulatory/enforcement agency’s directive(s) regarding any violation(s) and prescribed corrective action(s), the Contracting Officer may issue an order stopping all or part
of the work until satisfactory corrective action (as approved by the federal, State or local regulatory/enforcement agencies) has been taken and documented to the Contracting Officer. No part of the time lost due to any stop work order shall be
subject to a claim for extension of time or costs or damages by the Contractor. 
 (e) The Contractor shall insert the substance of this
clause in each subcontract involving toxic substances, hazardous materials, or hazardous operations. The Contractor is responsible for the compliance of its subcontractors with the provisions of this clause. 

(End of clause) 

  
 2 

 ATTACHMENT 6 

 
  

CLASSIFICATION (When filled in) 

																																					
	
CONTRACT PERFORMANCE REPORT

FORMAT 1 - WORK BREAKDOWN STRUCTURE
  
	 	DOLLARS IN
                                        
  
	 	Form Approved

OMB No. 0704-0188
  

	
The public reporting burden for this collection of information is estimated to average 3.1 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including
suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to
comply with a collection of information if it does not display a currently valid OMB control number.
 PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE
ORGANIZATION. SUBMIT COMPLETED FORMS IN ACCORDANCE WITH CONTRACTUAL REQUIREMENTS.

	1.   CONTRACTOR	 	2.   CONTRACT	 	3.   PROGRAM	 	4.   REPORT PERIOD
	a.   NAME	 	a.   NAME	 	a.   NAME	 	a.   FROM (YYYYMMDD)
	b.   LOCATION (Address and ZIP Code)	 	b.   NUMBER	 	b.   PHASE	 	 	 	 	 	 
	 	 		  		 		 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 	 	 	 	 	 	 	 	b.   TO (YYYYMMDD)
	 	 		  		 		 	 	 	c.   TYPE	 	d.   SHARE RATIO	 	c.   EVMS ACCEPTANCE	 		 		 	 
	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	NO	  	 	 	YES (YYYYMMDD)	 	 	 	 	 	 
	5.   CONTRACT DATA
	a.   QUANTITY	 	b.   NEGOTIATED COST	 	c.   EST. COST AUTHORIZED UNPRICED WORK	 	d.   TARGET PROFIT/ FEE	 	e.   TARGET PRICE	 	f.   ESTIMATED PRICE	 	g.   CONTRACT

CEILING
	 	h.   EST. CONTRACT

CEILING
	 	i.   DATE OF OTB/OTS

(YYYYMMDD)

	6.   ESTIMATED COST AT COMPLETION	 	7.   AUTHORIZED CONTRACTOR REPRESENTATIVE
	 	 	 MANAGEMENT
ESTIMATE
 AT COMPLETION

(1)
	 	CONTRACT BUDGET

BASE
 (2)
	 	VARIANCE

(3)
	 	a.   NAME (Last, First, Middle Initial)	 	b. TITLE
	a.   BEST CASE	 	 	 	 	 	 	 	c.   SIGNATURE	 		  		  		 		 		 	 	 	d.   DATE SIGNED (YYYYMMDD)
	b.   WORST CASE	 	 	 	 	 	 	 		 		 		  		  		 		 		 	 	 		 		 	 
	c.   MOST LIKELY	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	8.   PERFORMANCE DATA
	
ITEM
 (1)
	  	CURRENT PERIOD	 	CUMULATIVE TO DATE	 	REPROGRAMMING

ADJUSTMENTS
	 	AT COMPLETION
	  	BUDGETED COST	 	ACTUAL	 	 VARIANCE
	 	 BUDGETED COST
	 	ACTUAL	 	 VARIANCE
	 	 	 	 	 	 	 
	  	WORK
SCHEDULED
(2)
	 	WORK
PERFORMED
(3)
	 	COST WORK
PERFORMED
(4)
	 	SCHEDULE

(5)
	 	COST
 (6)
	 	WORK
SCHEDULED
(7)
	 	WORK
PERFORMED
(8)
	 	COST WORK
PERFORMED
(9)
	 	SCHEDULE

(10)
	  	COST
 (11)
	 	COST
VARIANCE
(12a)
	 	SCHEDULE
VARIANCE
(12b)
	 	BUDGET
 (13)
	 	BUDGETED

(14)
	 	ESTIMATED

(15)
	 	VARIANCE

(16)

	a.   WORK BREAKDOWN STRUCTURE ELEMENT	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	b.   COST OF MONEY	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	c.   GENERAL & ADMINISTRATIVE	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	d.   UNDISTRIBUTED BUDGET	  	 	 	 	 	 	 	 	 	 
	e.   SUBTOTAL (Performance Measurement Baseline)	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00
	f.   MANAGEMENT RESERVE	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	g.   TOTAL	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	 	 	 
	9.   RECONCILIATION TO CONTRACT BUDGET BASE	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	a.   VARIANCE ADJUSTMENT	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 
	b.   TOTAL CONTRACT VARIANCE	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	  	0.00	 	 	 	 	 	 	 	 	 	 	 	 

							
	    DD FORM 2734/1, APR 2005	 		  	PREVIOUS EDITION IS OBSOLETE.	  	LOCAL REPRODUCTION AUTHORIZED.

  
  

CLASSIFICATION (When filled in) 

 ATTACHMENT 6 

 
  

CLASSIFICATION 

(When filled in) 

																																					
	
CONTRACT PERFORMANCE REPORT

FORMAT 2 - ORGANIZATIONAL CATEGORIES
  
	 	DOLLARS IN
                                        
  
	 	Form Approved

OMB No. 0704-0188
  

	The public reporting burden for this collection of information is
estimated to average .6 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments
regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE
ORGANIZATION. SUBMIT COMPLETED FORMS IN ACCORDANCE WITH CONTRACTUAL REQUIREMENTS.
	1.   CONTRACTOR	 	2.   CONTRACT	 	3.   PROGRAM	 	4.   REPORT PERIOD
	a.   NAME	 	a.   NAME	 	a.   NAME	 	a.   FROM (YYYYMMDD)
	b.   LOCATION (Address and ZIP Code)	 	b.   NUMBER	 	b.   PHASE	 	 	 	 	 	 
	 	 		  		 		 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	  	 	 	 	 	 	 	 	 	b.   TO (YYYYMMDD)
	 	 		  		 		 	 	 	c.   TYPE	 	d.   SHARE RATIO	 	c.   EVMS ACCEPTANCE	 		 		 	 
	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	NO	  	 	 	YES (YYYYMMDD)	 	 	 	 	 	 
	5.   PERFORMANCE DATA
	
ITEM
 (1)
	  	CURRENT PERIOD	 	CUMULATIVE TO DATE	 	REPROGRAMMING

ADJUSTMENTS
	 	AT COMPLETION
	  	BUDGETED COST	 	ACTUAL	 	 VARIANCE
	 	 BUDGETED COST
	 	ACTUAL	 	 VARIANCE
	 	 	 	 	 	 	 
	  	WORK
SCHEDULED
(2)
	 	WORK
PERFORMED
(3)
	 	COST WORK
PERFORMED
(4)
	 	SCHEDULE

(5)
	 	COST
 (6)
	 	WORK
SCHEDULED
(7)
	 	WORK
PERFORMED
(8)
	 	COST WORK
PERFORMED
(9)
	 	SCHEDULE

(10)
	  	COST
 (11)
	 	COST
VARIANCE
(12a)
	 	SCHEDULE
VARIANCE
(12b)
	 	BUDGET
 (13)
	 	BUDGETED

(14)
	 	ESTIMATED

(15)
	 	VARIANCE

(16)

	a.   ORGANIZATIONAL CATEGORY	  	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	b.   COST OF MONEY	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	c.   GENERAL & ADMINISTRATIVE	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	d.   UNDISTRIBUTED BUDGET	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	e.   SUBTOTAL (Performance Measurement
Baseline)	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00
	f.   MANAGEMENT RESERVE	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 
	g.   TOTAL	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	0.00	  	0.00	 	0.00	 	0.00	 	0.00	 	0.00	 	 	 	 

							
	    DD FORM 2734/2, APR 2005	 	..	  		  	

  
  

CLASSIFICATION (When filled in) 

 ATTACHMENT 6 

 
  

CLASSIFICATION (When filled in) 

																																					
	
CONTRACT PERFORMANCE REPORT

FORMAT 3 - BASELINE
  
	  	 DOLLARS IN
                                        

  
	  	Form Approved

OMB No. 0704-0188
  

	The public reporting burden for this collection of information is
estimated to average 6.3 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments
regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE
ORGANIZATION. SUBMIT COMPLETED FORMS IN ACCORDANCE WITH CONTRACTUAL REQUIREMENTS.
	1.   CONTRACTOR	  	2.   CONTRACT	  	3.   PROGRAM	  	4.   REPORT PERIOD
	a.   NAME	  	a.   NAME	  	a.   NAME	  	a.   FROM (YYYYMMDD)
	b.   LOCATION (Address and ZIP Code)	  	b.   NUMBER	  	b.   PHASE	  	 	  	 	  	 
	 	 		  		  		  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	b.   TO (YYYYMMDD)
	 	 		  		  		  	 	  	c.   TYPE	  	d.   SHARE RATIO	  	c.   EVMS ACCEPTANCE	  		  		  	 
	 	 	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	NO	  	 	  	YES (YYYYMMDD)	  	 	  	 	  	 
	5.   CONTRACT DATA
	a.   ORIGINAL NEGOTIATED COST	  	b.   NEGOTIATED CONTRACT CHANGES	  	 c.   CURRENT
NEGOTIATED COST
       (a. + b.)

                  0.00
	  	d.   ESTIMATED COST OF AUTHORIZED UNPRICED WORK	  	 e.   CONTRACT
BUDGET BASE (c. + d.)

                  0.00
	  	 f.   TOTAL
ALLOCATED BUDGET
  
  
	  	 g.
  DIFFERENCE (e. - f.)

                  0.00

	 h.   CONTRACT START DATE

(YYYYMMDD)
	  	i. CONTRACT DEFINITIZATION DATE (YYYYMMDD)	  	j. PLANNED COMPLETION DATE

(YYYYMMDD)
	  	k. CONTRACT COMPLETION DATE
(YYYYMMDD)
	  	l. ESTIMATED COMPLETION DATE

(YYYYMMDD)

	6.   PERFORMANCE DATA

																															
	
ITEM
 (1)
	  	BCWS CUMULA- TIVE TO DATE	  	BCWS FOR REPORT PERIOD	  	BUDGETED COST FOR WORK SCHEDULED (BCWS) (Non-Cumulative)	  	UNDIS- TRIBUTED BUDGET	  	
TOTAL

BUDGET

	  	  	  	SIX MONTH FORECAST (Enter names of months)	  	ENTER SPECIFIED PERIODS	  	 	  	 
	 	  	
(2)
	  	(3)	  	
    +1    

(4)
	  	
    +2    

(5)
	  	
    +3    

(6)
	  	
    +4    

(7)
	  	
    +5    

(8)
	  	
    +6    

(9)
	  	(10)	  	(11)	  	(12)	  	(13)	  	(14)	  	(15)	  	(16)
	 a.   PERFORMANCE MEASUREMENT BASELINE

(Beginning of Period)
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	0.00
	b.   BASELINE CHANGES AUTHORIZED DURING REPORT PERIOD	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 c.   PERFORMANCE MEASUREMENT BASELINE

(End of Period)
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	0.00
	 7.   MANAGEMENT RESERVE
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 8.   TOTAL
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	0.00

							
	    DD FORM 2734/3, APR 2005	 	PREVIOUS EDITION IS OBSOLETE. LOCAL REPRODUCTION AUTHORIZED.

  
  

CLASSIFICATION (When filled in) 

 ATTACHMENT 6 

 
  

CLASSIFICATION (When filled in) 
  

																																					
	
CONTRACT PERFORMANCE REPORT

FORMAT 4 - STAFFING
  
	  	DOLLARS IN              
                           
 

	The public reporting burden for this collection of information is
estimated to average 5.0 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments
regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE
ORGANIZATION. SUBMIT COMPLETED FORMS IN ACCORDANCE WITH CONTRACTUAL REQUIREMENTS.
	1.   CONTRACTOR	  	2.   CONTRACT	  	3.   PROGRAM	  	4.   REPORT PERIOD
	a.   NAME	  	a.   NAME	  	a.   NAME	  	a.   FROM (YYYYMMDD)
	b.   LOCATION (Address and ZIP Code)	  	b.   NUMBER	  	b.   PHASE	  	 	  	 	  	 
	 	 		  		  		  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	b.   TO (YYYYMMDD)
	 	 		  		  		  	 	  	c.   TYPE	  	d.   SHARE RATIO	  	c.   EVMS ACCEPTANCE	  		  		  	 
	 	 	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	NO	  	 	  	YES (YYYYMMDD)	  	 	  	 	  	 
	5.   PERFORMANCE DATA (All figures in whole
numbers)

																													
	 	  	ACTUAL CURRENT PERIOD	  	ACTUAL END OF CURRENT PERIOD ((Cumulative)	  	            FORECAST
(Non-Cumulative)	  	AT COMPLETION
	ORGANIZATIONAL CATEGORY	  	  	  	SIX MONTH FORECAST BY MONTH (Enter names of months)	  	ENTER SPECIFIED PERIODS	  
	
(1)
	  	(2)	  	(3)	  	
+1
 (4)
	  	
+2
 (5)
	  	
+3
 (6)
	  	
+4
 (7)
	  	
+5
 (8)
	  	
+6
 (9)
	  	(10)	  	(11)	  	(12)	  	(13)	  	(14)	  	(15)
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	6.   TOTAL DIRECT	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0	  	0
	    DD FORM 2734/4, APR 2005	  	PREVIOUS EDITION IS OBSOLETE. LOCAL REPRODUCTION AUTHORIZED.

   

CLASSIFICATION (When filled in) 

 ATTACHMENT 6 
  

                       
                           

CLASSIFICATION (When filled in) 
  

															
	 CONTRACT PERFORMANCE REPORT

FORMAT 5 – EXPLANATIONS AND PROBLEM ANALYSES
	 	
Form Approved
 OMB No.
0704-0188

	The public reporting burden for this collection of information is estimated to
average 36.0 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this
burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any
other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION. SUBMIT
COMPLETED FORMS IN ACCORDANCE WITH CONTRACTUAL REQUIREMENTS.
	1. CONTRACTOR	 	2. CONTRACT	 	3. PROGRAM	 	4. REPORT PERIOD
	a. NAME	 	 	 	a. NAME	 	a. NAME	 	a. FROM (YYYYMMDD)
	b. LOCATION (Address and ZIP Code)	 	b. NUMBER	 	b. PHASE	 	 
	 	 	 	 	c. TYPE	 	d. SHARE RATIO	 	c. EVMS ACCEPTANCE	 	b. TO (YYYYMMDD)
	 	 	 	 	 	 	 ̈ NO  ̈ YES
(YYYY/MM/DD)	 	 	 	 
	5. EVALUATION
	
    Discussion should include but is not limited to:

 
     Summary Analysis:

 
             Summary of Overall
Contract Variances
  

            Differences between EAC’s (Blocks 6.a., 6.b., 6.c., or Block 8.15)

 
             Changes in
Undistributed Budget
  

            Changes in Management Reserve

 
             Significant
timephasing shifts in Baseline (BCWS) (Format 3)
  

            Significant timephasing shifts or overall changes in Forecasted Staffing (Format 4)

 
             Discussion of Over
Target Baseline and/or Over Target Schedule incorporation
  

    Analysis of Significant Variances (identify and describe each):

 
             Type and Magnitude
of Variance
  

            Explanation of Significant Reasons

 
             Effect on
Immediate Task
  

            Effect on Total Contract

 
             Correction Actions
Taken or Planned

  

							
	DD FORM 2734/5, APR 2005	 		 	PREVIOUS EDITION IS OBSOLETE. LOCAL REPRODUCTION AUTHORIZED.
		 	  
	 	
		 	 CLASSIFICATION (When filled in)
	 	

 ATTACHMENT 7 
  

																			
	FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT	 	Project Task:	 	Contract No.:	 	Date of Report:	 	  

0990-0134
0990-0131

	  

Note:     Complete this Form in Accordance with Accompanying Instructions.

 
	 	Reporting Period:	 	Contractor Name and Address:
	 Expenditure Category

 
	 	Percentage of
Effort/Hours	 	Cumulative
Incurred Cost
at End of Prior
Period	 	Incurred
Cost-Current
Period	 	Cumulative
Cost to Date
(D + E)	 	Estimated
Cost to
Complete	 	Estimated Cost at
Completion 
(F + G)	 	Negotiated
Contract Amount	 	Variance (Over
or Under) 
(I - H)
	 	Negotiated	 	Actual	 	 	 	 	 	 	 
	A	 	B	 	C	 	D	 	E	 	F	 	G	 	H	 	I	 	J
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  
 1 

 ATTACHMENT 8 

INSTRUCTIONS FOR COMPLETING 

“FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT” 

GENERAL INFORMATION 
 Purpose. This Quarterly
Financial Report is designed to: (1) provide a management tool for use by be BARDA in monitoring the application of financial and personnel resources to the BARDA contracts; (2) provide contractors with financial and personnel management
data which is usable in their management processes; (3) promptly indicate potential areas of contract underruns or overruns by making possible comparisons of actual performance and projections with prior estimates on individual elements of cost
and personnel; and (4) obtain contractor’s analyses of cause and effect of significant variations between actual and prior estimates of financial and personnel performance. 

REPORTING REQUIREMENTS 
 Scope. The specific cost
and personnel elements to be reported shall be established by mutual agreement prior to award. The Government may require the contractor to provide detailed documentation to support any element(s) on one or more financial reports. 

Number of Copies and Mailing Address. An original and two (2) copies of the report(s) shall be sent to the contracting officer at the address
shown on the face page of the contract, no later than 30 working days after the end of the period reported. However, the contract may provide for one of the copies to be sent directly to the Contracting Officer’s Technical Representative. 

REPORTING STATISTICS 
 A modification which extends the
period of performance of an existing contract will not require reporting on a separate quarterly report, except where it is determined by the contracting officer that separate reporting is necessary. Furthermore, when incrementally funded contracts
are involved, each separate allotment is not considered a separate contract entity (only a funding action). Therefore, the statistics under incrementally funded contracts should be reported cumulatively from the inception of the contract through
completion. 
 Definitions and Instructions for Completing the Quarterly Report. For the purpose of establishing expenditure categories in Column A,
the following definitions and instructions will be utilized. Each contract will specify the categories to be reported. 
  

	(1)	Key Personnel. Include key personnel regardless of annual salary rates. All such individuals should be listed by names and job titles on a separate line including those whose salary is not directly charged to the
contract but whose effort is directly associated with the contract. The listing must be kept up to date. 

 Personnel—Other. List
as one amount unless otherwise required by the contract. 

  
 1 

 Attachment 8 
  

 Fringe Benefits. Include allowances and services provided by the contractor to employees as
compensation in addition to regular salaries and wages. If a fringe benefit rate(s) has been established, identify the base, rate, and amount billed for each category. If a rate has not been established, the various fringe benefit costs may be
required to be shown separately. Fringe benefits which are included in the indirect cost rate should not be shown here. 
 Accountable Personal Property.
Include nonexpendable personal property with an acquisition cost of $1,000 or more and with an expected useful life of two or more years, and sensitive items regardless of cost. Form HHS 565, “Report of Accountable Property,” must
accompany the contractor’s public voucher (SF 1034/SF 1035) or this report if not previously submitted. See “Contractor’s Guide for Control of Government Property.” 

Supplies. Include the cost of supplies and material and equipment charged directly to the contract, but excludes the cost of nonexpendable equipment as
defined in (4) above. 
 Inpatient Care. Include costs associated with a subject while occupying a bed in a patient care setting. It normally
includes both routine and ancillary costs. 
 Outpatient Care. Include costs associated with a subject while not occupying a bed. It normally
includes ancillary costs only. 
 Travel. Include all direct costs of travel, including transportation, subsistence and miscellaneous expenses.
Travel for staff and consultants shall be shown separately. Identify foreign and domestic travel separately. If required by the contract, the following information shall be submitted: (i) Name of traveler and purpose of trip; (ii) Place of
departure, destination and return, including time and dates; and (iii) Total cost of trip. 
 Consultant Fee. Include fees paid to
consultant(s). Identify each consultant with effort expended, billing rate, and amount billed. 
 Premium Pay. Include the amount of salaries and
wages over and above the basic rate of pay. 
 Subcontracts. List each subcontract by name and amount billed. 

Other Costs. Include any expenditure categories for which the Government does not require individual line item reporting. It may include some of the
above categories. 
 Overhead/Indirect Costs. Identify the cost base, indirect cost rate, and amount billed for each indirect cost category. 

General and Administrative Expense. Cite the rate and the base. In the case of nonprofit organizations, this item will usually be included in the
indirect cost. 
 Fee. Cite the fee earned, if any. 

Total Costs to the Government. 
 PREPARATION
INSTRUCTIONS 
 These instructions are keyed to the Columns on the Quarterly Report. 

  
 2 

 Attachment 8 
  

 Column A—Expenditure Category. Enter the expenditure categories required by the contract. 

Column B—Percentage of Effort/Hours Negotiated. Enter the percentage of effort or number of hours agreed to during contract negotiations for each
labor category listed in Column A. 
 Column C—Percentage of Effort/Hours-Actual. Enter the cumulative percentage of effort or number of hours
worked by each employee or group of employees listed in Column A. 
 Column D—Cumulative Incurred Cost at End of Prior Period. Enter the
cumulative incurred costs up to the end of the prior reporting period. This column will be blank at the time of the submission of the initial report. 

Column E—Incurred Cost-Current Period. Enter the costs which were incurred during the current period. 

Column F—Cumulative Incurred Cost to Date. Enter the combined total of Columns D and E. 

Column G—Estimated Cost to Complete. Make entries only when the contractor estimates that a particular expenditure category will vary from the
amount negotiated. Realistic estimates are essential. 
 Column H—Estimated Costs at Completion. Complete only if an entry is made in Column G.

 Column I—Negotiated Contract Amount. Enter in this column the costs agreed to during contract negotiations for all expenditure categories
listed in Column A. 
 Column J—Variance (Over or Under). Complete only if an entry is made in Column H. When entries have been made in Column
H, this column should show the difference between the estimated costs at completion (Column H) and negotiated costs (Column I). When a line item varies by plus or minus 10 percent, i.e., the percentage arrived at by dividing Column J by Column I, an
explanation of the variance should be submitted. In the case of an overrun (net negative variance), this submission shall not be deemed as notice under the Limitation of Cost (Funds) Clause of the contract. 

Modifications. List any modification in the amount negotiated for an item since the preceding report in the appropriate cost category. 

Expenditures Not Negotiated. List any expenditure for an item for which no amount was negotiated (e.g., at the discretion of the contractor in
performance of its contract) in the appropriate cost category and complete all columns except for I. Column J will of course show a 100 percent variance and will be explained along with those identified under J above. 

  
 3 

 ATTACHMENT 9 - Milestone Table - Major Deliverables 

 

									
	 Area
	  	 WBS
	  	 Short Description
	  	 Milestone
	  	 Estimated

Completion

Timeframe

(Calendar days)

	PM	  	1.1.1.1	  	[**]	  	Development Plan	  	42 days after contract award
		  	1.1.1.2	  	[**]	  	Development Plan	  	42 days after contract award
		  	1.1.1.3	  	[**]	  	Development Plan	  	42 days after contract award
		  	1.1.1.4	  	[**]	  	Security Plan	  	42 days after contract award
		  	1.1.1.5	  	[**]	  	Management Plan	  	42 days after contract award
		  	1.1.3.1	  	[**]	  	Management Plan	  	42 days after contract award
		  	1.1.4.1	  	[**]	  	EVM Performance Measurement Baseline	  	120 days after contract award
					
	PreClin	  	1.2.2.1	  	[**]	  	[**]	  	[**]
		  	1.2.2.2	  	[**]	  	[**]	  	[**]
		  	1.2.2.3	  	[**]	  	[**]	  	[**]
		  	1.2.2.4	  	[**]	  	[**]	  	[**]
		  	1.2.2.5	  	[**]	  	[**]	  	[**]
		  	1.2.2.6	  	[**]	  	[**]	  	[**]
		  	1.2.2.7	  	[**]	  	[**]	  	[**]
		  	1.2.2.8	  	[**]	  	[**]	  	[**]
		  	1.2.2.9	  	[**]	  	[**]	  	[**]
		  	1.3.3.1	  	[**]	  	[**]	  	[**]
					
	Clinical	  	1.4.2.1	  	[**]	  	[**]	  	[**]
		  	1.4.2.2	  	[**]	  	[**]	  	[**]
		  	1.4.3.1	  	[**]	  	[**]	  	[**]
		  	1.4.4.1	  	[**]	  	[**]	  	[**]
		  	1.4.5.1	  	[**]	  	[**]	  	[**]

  
 1 

									
	 Area
	  	 WBS
	  	 Short Description
	  	 Milestone
	  	 Estimated

Completion

Timeframe

(Calendar days)

		  	1.4.5.2	  	[**]	  	[**]	  	[**]
					
	Reg	  	1.5.1.4	  	[**]	  	[**]	  	[**]
		  	1.5.1.5	  	[**]	  	[**]	  	[**]
		  	1.5.1.6	  	[**]	  	[**]	  	[**]
		  	1.5.1.8	  	[**]	  	[**]	  	[**]
					
	CMC	  	1.6.1	  	[**]	  	[**]	  	[**]
		  	1.6.2.1	  	[**]	  	[**]	  	[**]
		  	1.6.2.2	  	[**]	  	[**]	  	[**]
		  	1.6.2.3	  	[**]	  	[**]	  	[**]
		  	1.6.3.1	  	[**]	  	[**]	  	[**]
		  	1.6.3.2	  	[**]	  	[**]	  	[**]
		  	1.6.4	  	[**]	  	[**]	  	[**]
		  	1.6.5.1	  	[**]	  	[**]	  	[**]
		  	1.6.5.2	  	[**]	  	[**]	  	[**]
		  	1.6.5.3	  	[**]	  	[**]	  	[**]
		  	1.6.5.4	  	[**]	  	[**]	  	[**]

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]